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Abstract 
Astrocytes play a role in the central nervous system (CNS) inflammatory 
response. In many immune cell types cellular inflammation and metabolism are 
linked, a phenomenon termed ‘immunometabolism’. This has led to attempts to 
reduce chronic inflammation through manipulating cellular metabolism. Proteins 
of interest for this approach include transcription factor nuclear factor-kappa B 
(NF-κB) and mitochondrial protein ‘translocator protein (18 kDa)’ (TSPO). TSPO 
is of particular interest as a therapy for CNS disease as many TSPO ligands can 
access the CNS and have been demonstrated to have anti-inflammatory effects. 
However, immunometabolism has not been well described in astrocytes, and the 
function of TSPO is currently disputed. In this thesis, mouse primary astrocytes 
were used to characterise immunometabolic responses following treatment with 
the pro-inflammatory stimulus lipopolysaccharide (LPS). An initial increase in 
glycolytic metabolism was measured, prior to a shift towards oxidative 
phosphorylation and away from glucose metabolism, in part mediated by a 
decrease in glucose transporter GLUT1 expression. Pharmacological inhibition 
of NF-κB signalling demonstrated that this pathway is important in mediating the 
cellular metabolic response to inflammation in astrocytes, and may play a role in 
maintaining basal metabolic function in these cells. Pharmacological or genetic 
modulation of TSPO signalling in human astroglioma (U373) cells and/or mouse 
primary astrocytes demonstrated that while TSPO suppressed fatty acid 
oxidation and promoted glycolytic metabolism, this did not appear to acutely alter 
the inflammatory response of these cells after LPS treatment; however, the longer 
term effects remain to be explored. Together these data demonstrate that 
inflammation and metabolism are intrinsically linked in astrocytes and TSPO 
plays an important role in regulating metabolism in these cells. 
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EV Empty vector 
FABP Fatty acid binding protein 
FACS Fluorescence activated cell sorting 
FAD Flavin adenine dinucleotide 
FADH2 Flavin adenine dinucleotide (reduced) 
FAO Fatty acid oxidation 
FAS Fatty acid synthase 
FBS Foetal bovine serum 
FCCP Carbonyl cyanide-4-trifluromethoxyphenylhydrazone 
FSC Forward scatter 
g Gram 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFAP Glial fibrillary acidic protein 
GDP Guanosine diphosphate 
GLAST Glutamate aspartate transporter 
GLT Glutamate transporter 
GLUT Glucose transporter 
GM Genetically modified 
GTP Guanosine triphosphate 
HBSS Hanks Balanced Salt Solution 
HCl Hydrochloric acid 
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFD High fat diet 
HFHS High fat, high sugar 
HIF-1α Hypoxia inducible factor 1 alpha 
iATP  Intracellular adenosine triphosphate 
IBA-1 Ionized calcium binding adaptor molecule 1 
IC50 Half maximal inhibitory concentration 
IFN-γ Interferon gamma 
IκB I kappa B 
IKK I kappa B kinase 
IL Interleukin 
IL-R Interleukin receptor 
IMM Inner mitochondrial membrane 
JAK Janus kinase 
JNK c-Jun N-terminal kinases 
K+ Potassium ion 
Kir4.1 Potassium inwardly rectifying channel 4.1 
kDa Kilo Daltons 
LDH Lactate dehydrogenase 
LPS Lipopolysaccharide 
MAPK Mitogen-activated protein kinase 
MBP-1 Myc promoter-binding protein 1 
MCP Monocyte chemoattractant protein 
MD-2 Lymphocyte antigen 96 
Mfn Mitofusin 
mL Millilitre 
mM Millimolar 
MPTP Mitochondrial permeability transition pore 
mRNA Messenger RNA 
mTOR Mammalian target of rapamycin 
MyD88 Myeloid differentiation factor 88 
Na3VO4 Sodium orthovanadate 
NaCl Sodium chloride 
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NAD+ Nicotinamide adenine dinucleotide (oxidised) 
NADH Nicotinamide adenine dinucleotide (reduced) 
NADPH Nicotinamide adenine dinucleotide phosphate (reduced) 
NaF Sodium fluoride 
NaOH Sodium hydroxide 
NaPPi Sodium pyrophosphate tetrabasic decahydrate 
NEMO NF-κB regulatory subunit; IKKγ 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
nM Nanomolar 
nm Nanometer 
NOX NADPH oxidase 
O2 Oxygen 
O2•- Superoxide 
OCR Oxygen consumption rate 
Oligo Oligomycin 
OMM Outer mitochondrial membrane 
OPA-1 Optic atrophy 1 
OXPHOS Oxidative phosphorylation 
PAMP Pathogen-associated molecular pattern 
PBR Peripheral benzodiazepine receptor; see TSPO 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PET Positron emission tomography 
PFK2 Phospho-fructokinase 2 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
PI3K Phosphoinositide-3-kinase 
PKB Protein kinase B 
PKC Protein kinase C 
PKM2 Pyruvate kinase isozyme M2 
PLL Poly-L-lysine 
PMSF Phenylmethylsulfonyl fluoride 
PPAR Peroxisome proliferator-activated receptor 
PPP Pentose phosphate pathway 
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PRR Pattern recognition receptor 
R/A Rotenone with antimycin A 
RET Reverse electron transport 
RHD Rel homology domain 
RIPA Radioimmunoprecipitation assay 
ROS Reactive oxygen species 
RXR Retinoic X receptor 
SDS Sodium dodecyl sulphate 
SEM Standard error from the mean 
siRNA Small interefering RNA 
Sp Specificity protein 
Srepb Sterol regulatory element binding protein 
SSC Side scatter 
STAT Signal transducers and activators of transcription 
TBK1 TANK binding kinase 1 
TBS-T Tris buffered saline with tween 20 
TCA Tricarboxylic acid 
TEMED Tetramethylethylenediamine 
TIR Toll/IL-1-receptor domain 
TLR Toll-like receptor 
TMRE Tetramethylrhodamine ethyl ester 
TNF Tumour necrosis factor 
TSPO Translocator protein 18 kDa 
UCP Uncoupling protein 
VDAC Voltage dependent anion channel 
 
  
 Chapter 1. Introduction 
Many neurodegenerative diseases, including Alzheimer’s (Kinney et al., 2018), 
multiple sclerosis (Matthews, 2019) and Parkinson’s disease (Caggiu et al., 2019) 
are caused by inappropriate and perpetuated immune responses within the 
central nervous system (CNS). Recent developments in the study of the immune 
response have revealed that an intrinsic part of inflammation is a change in 
cellular metabolism (O'Neill et al., 2016). It has therefore been suggested that 
one way of controlling inflammation to help treat disease is through modulating 
cellular metabolism (Rhoads et al., 2017).  
 
In the CNS the immune response is in part controlled by a non-neuronal cell type 
called astrocytes. However, there is currently very little known about the 
metabolic response to inflammation in astrocytes. This chapter aims to introduce 
the concept of immunometabolism and consolidate the current knowledge of 
immunometabolism and its regulation in astrocytes. This will be with particular 
regard to the nuclear factor kappaB (NF-κB) pathway, although other 
inflammatory signalling pathways have been shown to play important roles in 
immunometabolic regulation (Hotamisligil, 2017; Robb et al., 2019). The 
translocator protein 18 kDa (TSPO) will also be introduced as a potential novel 
regulator of immunometabolism. 
 
1.1 Astrocytes as regulators of CNS function 
There are multiple classes of non-neuronal cells in the brain, collectively termed 
glia. One class of glia are the astrocytes. These are large stellate cells which 
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reside within the CNS and are ramified and highly plastic, both in function and 
morphology. Astrocytes were first classified by Santiago Ramon y Cajal and 
named by Michael von Lenhossek in 1891 (Parpura & Verkhratsky, 2012). Once 
assumed to be a homogenous class of cell, evidence is emerging that there are 
subtypes of astrocytes, with specialised roles dependent on receptor expression, 
location, and interactions with other specialised cells within the brain (Allen, 
2014).   
 
1.1.1 Maintenance of the extracellular environment 
Astrocytes are important for the maintenance of the CNS microenvironment and 
are key regulators of neuronal physiology and behaviour (Buskila et al., 2019). 
The position of astrocytes adjacent to blood vessels allows them to be responsive 
to peripheral cues, such as circulating nutrient, hormone and cytokine levels 
(Daneman & Prat, 2015). This positioning allows them to play a role in regulating 
access to the CNS. Astrocyte end feet contact capillaries, and tight junctions 
between end feet form a barrier called the glia limitans which prevents passage 
of large molecules into the CNS (Alvarez et al., 2013). Many substrates, such as 
glucose and fatty acids, access the brain by being taken up through specific 
transporters on astrocyte end feet. This allows astrocytes to regulate provision of 
nutrients and metabolites to the CNS (Alvarez et al., 2013). Thus astrocytes are 
an important component of the blood brain barrier (BBB), the selective, 
semipermeable interface which separates the brain from circulating blood 
(Daneman & Prat, 2015).  
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1.1.2 Maintenance of neuronal function 
Astrocyte end feet are in close proximity to neuronal synaptic clefts, forming a 
key component of the tripartite synapse. Due to their size and structure, 
astrocytes can interact with thousands of synapses simultaneously, allowing 
them to integrate information from across the CNS (Allen, 2014; Bushong et al., 
2002). This is in addition to contacting peripheral blood vessels, so allowing a 
single astrocyte to respond to information from both the periphery and within the 
CNS, and rapidly provide nutrients and substrate to neurons as needed to fuel 
their activity (Foo et al., 2011). Astrocytes are thought to ensheath roughly 60%–
90% of synaptic clefts in the CNS (Farhy-Tselnicker & Allen, 2018; Nedergaard 
& Verkhratsky, 2012). As astrocytes are morphologically plastic the interactions 
between astrocyte end feet and synapses are dynamic, and synapses can be 
ensheathed and unsheathed as needed (Farhy-Tselnicker & Allen, 2018). This is 
thought to occur through the receptor tyrosine kinase family eph and ligand 
ephrin. Astrocytes express multiple members of these families, including ephrin-
A1, -A3, -B2, and eph-A4 (Yang et al., 2018). These cell adhesion molecules 
drive the rearrangement of the astrocyte cytoskeleton (Carmona et al., 2009; 
Pasquale, 2008). As this interaction is bidirectional, astrocytes can also influence 
neuronal dendritic spine formation and axon guidance through this mechanism. 
For example, loss of EphrinA3 from glial cells reduces phosphorylation of EphA4 
and disrupts dendritic spine morphology in the mouse hippocampus (Carmona et 
al., 2009).  
 
Astrocytes express neurotransmitter transporters and receptors, making them 
capable of detecting, clearing and directly responding to alterations in 
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neurotransmitter levels (Verkhratsky et al., 2019). In particular, astrocytes 
regulate clearance of the excitatory neurotransmitter glutamate (Murphy-Royal et 
al., 2017). Glutamate is taken into astrocytes through glutamate transporters 
such as glutamate transporter 1 (GLT-1) and glutamate aspartate transporter 1 
(GLAST) making these cells important for preventing excitotoxicity (Mahmoud et 
al., 2019). Indeed, ablation of astrocytes in mice results in neurodegeneration 
and death due to overstimulation by excitatory neurotransmitters when they are 
not removed from the synapse (Allen, 2014; Jäkel & Dimou, 2017). This 
demonstrates that astrocytes are essential for the proper development and 
maintenance of normal CNS function (Allen, 2014; Jäkel & Dimou, 2017). 
 
In addition to clearing neurotransmitters from the synapse, astrocytes release 
compounds which can directly modulate both glial and neuronal signalling. These 
are collectively called gliotransmitters. Major gliotransmitters released by 
astrocytes include glutamate and adenosine triphosphate (ATP), among others 
(Covelo & Araque, 2018; Harada et al., 2016). Gliotransmitter release can be 
regulated by intracellular Ca2+ signalling (Harada et al., 2016), which stimulates 
vesicular exocytosis. Additionally, gliotransmitter release can be regulated by 
activity of astrocyte transporters such as GLT-1 and GLAST, and hemichannels 
such as connexin 43 (Cx43) (Harada et al., 2016), which allow bidirectional 
movement of molecules and ions between cells and into the extracellular space 
(Cotrina et al., 1998; Xu et al., 2019). 
 
Astrocytes also regulate neuronal firing through maintaining the ion concentration 
in the CNS extracellular environment. An action potential is propagated by loss 
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of neuronal membrane polarisation (Øyehaug et al., 2012). Polarisation is 
maintained by potassium ions (K+). K+ can be taken up into astrocytes through K+ 
channels, such as the inwardly rectifying Kir4.1 channel and pumps such as 
Na+/K+ ATPases (Nwaobi et al., 2016). Low levels of extracellular K+ decrease 
the membrane potential, increasing polarisation across the membrane (Øyehaug 
et al., 2012). This decreases neuronal excitability, demonstrating that astrocytes 
can contribute to the regulation of neuronal firing.  
 
Astrocytic regulation of neuronal firing results in astrocytes orchestrating 
physiological changes in the whole organism (Liddelow & Barres, 2017). 
However, inflammation alters astrocyte behaviour. This can result in changes in 
the CNS environment, which then affects physiology beyond the CNS. These 
changes to the CNS environment can promote neurodegeneration if 
inappropriately regulated. Therefore, we need to fully understand the astrocytic 
response to inflammation in order to develop appropriate interventions aimed at 
minimising the detrimental changes caused by inflammation. 
 
1.2 Inflammation 
Inflammation is the response to mechanical, chemical and/or biological damage, 
or deviations from homeostasis. Its role is to help resolve and restore the 
organism back to its basal state. This is orchestrated by immune effector cells, 
such as macrophages and lymphocytes (in the periphery) and astrocytes and 
microglia (in the CNS), which mediate the complex multifaceted response (Chen 
et al., 2017). Cellular inflammation is broadly constituted of two phases. The initial 
‘pro-inflammatory’ phase is characterised by immune cell proliferation and 
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release of cytotoxic agents. These include pro-inflammatory cytokines such as 
interleukin 1β (IL-1β) and tumour necrosis factor α (TNF-α), and chemokines, a 
group of small chemoattractive cytokines. This phase is designed to destroy 
infectious factors such as bacteria and viruses (Chen et al., 2017). Bacteria and 
viruses are detected by pattern recognition receptors (PRRs) found on immune 
effector cells which activate downstream pathways leading to the initiation of the 
pro-inflammatory phase. PRR signalling will be discussed in more depth later in 
the chapter. A secondary ‘anti-inflammatory’ phase is aimed at resolving 
inflammation and promoting tissue repair through the release of 
immunomodulatory agents such as interleukin 10 (IL-10) (Headland & Norling, 
2015). The second phase can be initiated by the increasing concentration of 
cytotoxic chemicals, including cytokines such as TNF-α released in the first 
phase. 
 
1.2.1 Chronic inflammation in disease 
Chronic inflammation is extended activation of the pro-inflammatory response. 
This can be caused either through failure of the immune response to remove the 
inflammatory stimulus or repeated persistent exposure to the stimulus (Pahwa & 
Jialal, 2019). This prolongs exposure of cells to cytokines, although often at 
relatively low concentrations, often leading to cell death and the development of 
disease specific to the tissue(s) affected (Newcombe et al., 2018). The effect of 
chronic inflammation in the CNS is of concern because of the current aging 
population. There is substantial evidence that chronic low grade inflammation 
contributes to the pathology of neurodegenerative diseases, including 
Parkinson’s disease (Whitton, 2007), multiple sclerosis (Matthews, 2019), and 
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dementias including Alzheimer’s disease (Kinney et al., 2018). For example, 
during Alzheimer’s disease beta-amyloid protein accumulates in the extracellular 
matrix, forming ‘plaques’, resulting cellular stress and leading to activation and 
perpetuation of the immune response. This immune response recruits both 
astrocytes and microglia, resulting in chronic inflammation (Johnson et al., 2020; 
Kinney et al., 2018). Accumulation of pro-inflammatory cytokines, such as IL-1β 
and IL-6, as a result of this unresolved immune response, can activate signalling 
pathways leading to the hyperphosphorylation of tau, a microtubule binding 
protein (Kinney et al., 2018). Hyperphosphorylated tau forms ‘tangles’ within 
neurons, disrupting normal neuronal function. Further to this, the prolonged 
presence of pro-inflammatory cytokines suppresses the expression of anti-
apoptotic proteins, promoting apoptosis of neurons (Kinney et al., 2018). This 
leads to neurodegeneration and advancement of Alzheimer’s disease. 
 
Neurodegeneration describes the loss of functional neurons, leading to 
impairment in motor and/or cerebral function and often resulting in premature 
death. This class of disease is highly prevalent: around 50 million people 
worldwide are currently living with a diagnosis of dementia (World Health 
Organisation, 2019). Beyond the debilitating symptoms mainly characterised by 
loss of memory and deteriorating physical ability, these diseases place a high 
burden of care on families. This results in high societal and financial costs, which 
are estimated to be an average 1.1% of the global GDP (Gross domestic product: 
US $818 billion) (World Health Organisation, 2019). Predictions currently 
estimate that there will be 82 million people living with dementia by 2030, 
emphasising the growing scale of the problem (World Health Organisation, 2019). 
These data only consider the impact of dementias, and not the other rarer forms 
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of neurodegeneration. However, they make clear the scale of the current burden 
of disease. Therefore, understanding CNS inflammation and developing methods 
to treat it are important. 
 
1.2.2 Inflammation in the CNS 
Despite the importance of this field of study, inflammation in the CNS is currently 
less well characterised than inflammation in the rest of the body. When intact, the 
BBB largely prevents passage of pathogens into the cerebrospinal fluid. 
However, while there is evidence of leukocyte and macrophage infiltration into 
the brain during disease (Schmitt et al., 2012; Zattoni et al., 2011), in the non-
diseased state the BBB also restricts movement of peripheral immune cells into 
the brain (Sofroniew, 2015). Typically, immune cell infiltration does not generally 
occur in sufficient numbers to orchestrate the scale of immune response seen in 
the CNS during disease. Therefore, CNS inflammation is thought to be mediated 
by glia, including astrocytes, which are immune competent cells (Engelhardt, 
2008; Wilson et al., 2010). An immune competent cell is defined as a cell capable 
of initiating an immune response when appropriately stimulated by an antigen. 
The immune response initiated by astrocytes includes recruiting and activating 
other immune cell types through expression and release of chemokines; 
presentation of antigens using class II major histocompatibility complex 
molecules; and removal of damaged structures and pathogens through 
phagocytosis (Preigo & Valiente, 2019; Wilson et al., 2010; Tremblay et al., 
2019). The role of astrocytes in the immune response within the CNS is discussed 
in further detail below. 
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1.2.3 Astrocytes in CNS inflammation 
During inflammation astrocytes undergo morphological and functional 
adaptations called reactive astrogliosis. Astrogliosis is defined by functional and 
structural changes to astrocytes, including upregulation of the cytoskeletal 
intermediate filament protein glial fibrillary acidic protein (GFAP) and a transition 
to a highly ramified structure. This is caused by activation of intracellular 
signalling pathways. Signalling pathways activated during astrogliosis include 
NF-κB, mitogen activated protein kinases (MAPKs) and Janus kinase (JAK) - 
signal transducers and activators of transcription (STATs). Activation of these 
signalling pathways vastly alters cellular activity, including the regulation of gene 
expression (Zamanian et al., 2012). 
 
The glia limitans places astrocytes in a unique position to regulate the CNS 
response to peripheral inflammation as there is evidence that astrocytes can 
regulate inflammation whilst the glia limitans is intact. Astrocytes express PRRs 
on their end feet both on the glia limitans extending into the periphery, and within 
the CNS. Activation of these PRRs induces inflammatory pathways in vivo when 
subjected to stressors, including metabolic stress or infection (Colombo & Farina, 
2016; Zamanian et al., 2012).  This leads to cytokine release by astrocytes within 
the CNS in response to inflammatory stimuli (Sofroniew, 2013). Astrocytes also 
regulate the migration of monocytes and leukocytes across the BBB whilst the 
glia limitans remains intact, mediated at least in part through expression of 
monocyte chemoattractant protein-1 (MCP-1). This chemokine attracts immune 
cells towards the glia limitans, and reduces tight junction formation between the 
cells of the glia limitans, impacting the permeability of the BBB (Stamatovic et al., 
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2005; Yao & Tsirka, 2014). Immune cells attracted by MCP-1 can then bind to 
adhesion proteins and migrate across the glia limitans (Weiss et al., 1998). In 
response to extensive inflammation and tissue damage astrocytes proliferate to 
form glial scars to maintain the glia limitans and limit further injury of healthy tissue 
(Adams & Gallo, 2018).  
 
Other regulatory roles that astrocytes play within the CNS are perturbed during 
inflammation. For example, during CNS inflammation, synaptic glutamate is 
increased (Matute et al., 2006). This may be exacerbated by impaired glutamate 
clearance by astrocytes as a result of downregulation of glutamate transporter 
expression after exposure to pro-inflammatory cytokines such as TNF-α and 
interleukin 1β (IL-1β) (Matute et al., 2006; Olmos & Lladó, 2014; Tilleux & 
Hermans, 2007). During inflammation astrocytes also release more 
gliotransmitters. In amyloid plaque forming mouse models of Alzheimer’s disease 
the opening of the astrocyte hemichannel Cx43 is increased. This results in 
increased glutamate and ATP release from astrocytes (Yi et al., 2016). This is 
supported by in vitro evidence demonstrating that pro-inflammatory stimulation 
with bacterial cell wall protein lipopolysaccharide (LPS) or bradykinin also 
increases glutamate and ATP release from rodent astrocytes, driven through 
hemichannel opening (Chávez et al., 2019; Liu et al., 2009; Xu et al., 2019). 
Together these data show that during inflammation changes in astrocytes can 
directly impact neuronal behaviour in part through gliotransmitter release and 
changes in neurotransmitter reuptake, which can exacerbate excitotoxicity and 
cell death (Matute et al., 2006). 
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During inflammation and neurodegenerative diseases astrocyte control over ion 
homeostasis is also disrupted. For example, in mouse models of multiple 
sclerosis and Alzheimer’s disease, or after treatment with the inflammatory 
cytokine IL-1β, the expression of the potassium channel Kir4.1 is downregulated 
in vivo, reducing K+ uptake by astrocytes (Nwaobi et al., 2016). Genetically 
induced overexpression of Kir4.1 in astrocytes in mouse models of Huntington’s 
disease reduced associated neurodegeneration (Tong et al., 2014). Together 
these data suggest that perturbations in K+ uptake increase neuronal cell death. 
Astrocyte synapse ensheathment is heightened during inflammation. During 
astrogliosis ephrin-B2 and Eph-A4 expression are increased, possibly to 
encourage axon regrowth and increase astrocyte involvement in neuronal 
signalling (Bundesen et al., 2003; Frugier et al., 2012). However, this can 
increase formation of glial scars (Pasquale, 2008; Yang et al., 2018). Loss of 
these key cell adhesion molecules prevents astrogliosis, suggesting a role of 
astrocyte-neuron interactions in CNS inflammation. 
 
Together, the data described in this section suggest that inflammation induces 
changes to astrocyte function, as summarised in fig. 1.2.3, resulting in changes 
to the CNS microenvironment. This in turn impacts neuronal survival and 
behaviour. 
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Figure 1.2.3: A simplified schematic demonstrating alteration in 
astrocyte function during inflammation. Glutamate transporter (GLT-1) 
expression is reduced, reducing glutamate clearance and cycling. Connexin 
43 (Cx43) expression is increased, increasing release of gliotransmitters ATP 
and glutamate into the synapse. Expression of the K+ inwardly rectifying 
channel (Kir4.1) is decreased, reducing K+ uptake and reducing neuronal 
membrane polarisation, promoting neuronal excitability. Adhesion molecules 
ephrin/eph are upregulated, encouraging synapse formation and plasticity but 
also promoting glial scar formation. 
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1.2.4 Regulation of inflammation 
The initiation of inflammation is mediated by multiple receptors, collectively 
termed PRRs, which detect activators called pathogen-associated molecular 
patterns (PAMPs; e.g. Lipopolysaccharide [LPS]) or damage-associated 
molecular patterns (DAMPs; e.g. DNA) (Tang et al., 2012). A well-known class of 
PRRs are toll-like receptors (TLRs). When stimulated these receptors activate 
downstream signalling pathways, such as NF-κB and mitogen-activated protein 
kinase (MAPK) signalling, which interact with each other to give a tightly 
controlled response (Chen et al., 2017). The signalling pathways used and 
resultant response differs from cell type to cell type depending on the role the cell 
plays in the whole-body inflammatory response, and also depending on the type 
of inflammatory stimulus (Escoll & Buchrieser, 2018; Kim & Harty, 2014; Mosser 
& Edwards, 2008; Pennock et al., 2013; Vergadi et al., 2017; Wager & Wormley, 
2014). This allows an appropriate proportional response to inflammatory stimuli, 
in both scale and duration, to ensure the long-term health of the organism. 
However, this process can become dysfunctional due to the failure of individual 
or multiple pathways. In turn, this may exacerbate inflammation and can result in 
failure of the response to resolve, leading to the development of chronic 
inflammation (Cope, 2002). 
 
The following sections will introduce NF-κB as an inflammatory regulator and 
discuss its role in astrocyte function, specifically regarding control of both cellular 
and systemic metabolism. 
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1.2.5 Nuclear Factor-kappa B regulation of inflammation 
In mammals the NF-κB family is composed of 5 proteins: p65 (RelA), RelB, c-Rel, 
p105/p50 (NF-κB1) and p100/p52 (NF-κB2) (Lawrence, 2009; Oeckinghaus & 
Ghosh, 2009; Perkins, 2007). These proteins can form homodimers and 
heterodimers which regulate cellular function by acting as transcription factors. 
These proteins all contain a Rel homology domain (RHD) which is bound by IκB 
(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor) to 
sequester the molecules in the cytoplasm, preventing them from promoting the 
unregulated transcription of target genes. NF-κB signalling can be activated by 
two distinct pathways: canonical or non-canonical activation. During the 
canonical or classical pathway IκB is phosphorylated by heterodimers of IκB 
kinase (IKK), IKKα and IKKβ with an IKKγ regulatory subunit (NEMO). This leads 
to ubiquitination and proteasomal degradation of IκB, releasing NF-κB; commonly 
p65-p50 heterodimers. NF-κB signalling can also be initiated through the non-
canonical or alternative pathway. This is regulated by IKKα homodimers which 
liberate primarily p52-RelB NF-κB dimers through ubiquitination and proteasomal 
processing of p100 into p52 (fig. 1.2.5.1). 
 
Once activated, NF-κB dimers from both pathways translocate into the nucleus. 
Here, they can bind to promotors to regulate gene transcription. It is important to 
note that active NF-κB dimers can also localise within the mitochondria when the 
tumour suppressor p53 is absent (Tornatore et al., 2012). Localisation to the 
mitochondria results in inhibition of mitochondrial genes, including those coding 
for components of the electron transport chain (ETC). This will be described in 
more detail later in this chapter. 
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Whilst both the canonical and non-canonical NF-κB pathways are activated by 
pro-inflammatory stimuli, they are activated by different cell surface receptors. 
The non-canonical pathway is activated by a subset of tumour necrosis factor 
(TNF) receptors through highly specific stimuli, including CD40 ligand and B-cell 
activating factor (Sun, 2017). By contrast, the canonical pathway has a broader 
range of activating stimuli, including the TNF receptor family, but also TLRs and 
interleukin receptors (IL-Rs) (Liu et al., 2017c).  
 
Activity of the canonical NF-κB pathway can be regulated by the pro-inflammatory 
factor LPS (Liu et al., 2017c). This is an endotoxin from the bacterial cell wall 
which acts as a PAMP and elicits a strong inflammatory response in most cell 
types. LPS stimulates multiple cell surface receptors, including Toll Like Receptor 
4 (TLR4). TLR4 signalling is summarised in fig 1.2.5.2 and can activate both 
canonical and non-canonical NF-κB signalling. Proteins CD-14 and MD-2 act as 
co-receptors to TLR-4. On activation, myeloid differentiation factor 88 (MyD88) is 
recruited to the Toll/IL-1-receptor domain (TIR) of the receptor to activate IKK and 
MAPK signalling cascades, c-Jun N-terminal kinases (JNK), extracellular signal 
regulated kinase (ERK), and p38. This leads to the activation of transcription 
factors activator protein-1 (AP-1) and NF-κB (Hayden & Ghosh, 2008). 
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Figure 1.2.5.1: A simplified schematic of nuclear factor κB (NF-κB) 
activation signalling pathways. The canonical signalling pathway is 
activated by stimulation of receptors such as interleukin receptor (IL-R) or 
tumour necrosis factor receptor (TNF-R). This leads to phosphorylation of IκB 
heterodimers (IKKα and IKKβ) bound to the regulatory subunit IKKγ (NEMO), 
which in turn phosphorylate IκB, allowing heterodimers of NF-κB p65-p50 to 
be liberated and translocated into the nucleus. The non-canonical signalling 
pathway is activated by CD40 ligand, leading to phosphorylation of IKKα 
homodimers. This results in phosphorylation, processing and ubiquitination of 
p100 NF-κB into p52, allowing translocation of RelB-p52 heterodimers into the 
nucleus. Both of these pathways can be activated by toll like receptor 4 (TLR4) 
and result in changes to gene transcription. 
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Figure 1.2.5.2: A simplified representation of signalling pathways 
downstream of Toll Like Receptor 4 (TLR4). When TLR4 is activated, it 
dimerises and recruits the co-receptors CD-14 and MD-2. This leads to 
recruitment of MyD88, which in turn activates intracellular signalling cascades, 
resulting in transcription of target genes. 
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1.2.6 Astrocytic NF-κB signalling in the regulation of neuronal 
function 
NF-κB signalling is activated in astrocytes during inflammation. Proteomic 
profiling of the astrocytic response to pro-inflammatory cytokines and LPS 
suggests that these stimuli differentially activate the canonical and non-canonical 
NF-κB signalling pathways, with LPS initially activating the non-canonical 
pathway, measured by immunoblot detection of p52 after 1 hour, although it is 
unclear through which mechanism (Dozio & Sanchez, 2018). This study showed 
no activation of the canonical NF-κB pathway by LPS after 1 hour, 8 hour or 24 
hour exposure. However, other studies have shown translocation of p65 to the 
nucleus and/or phosphorylation of p65 after treatment with LPS in astrocytes, 
with some studies showing activation persisting after 24 hours (Zhou et al., 2015). 
This suggests that LPS does activate the canonical NF-κB signalling pathway in 
astrocytes. Activation of NF-κB leads to genome-wide changes to protein 
expression, regulating proteins involved in inflammation such as TNF-α and 
interleukins (IL) including IL-6 and IL-10. It can also lead to activation of the 
NLRP-3 inflammasome leading to release of IL-1β. Additionally, NF-κB drives 
transcription of molecules associated with cell growth and survival in astrocytes 
(Pahl, 1999), and the structural protein vimentin (Zheng et al., 2005); thus, 
potentially linking changes in inflammatory signalling and morphology in 
astrocytes. 
 
Preventing inflammation in astrocytes through inhibition of NF-κB signalling can 
alter the pathophysiological response to disease. For example, inhibition of NF-
κB activity in GFAP expressing astrocytes promotes functional recovery of spinal 
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cord injury in mice, resulting in reduced glial scarring and increased locomotor 
activity (Brambilla et al., 2005). There is also evidence that loss of NF-κB 
signalling from astrocytes reduces astrogliosis in mouse models of diet-induced 
obesity, resulting in reduced disease pathology (Buckman et al., 2014; Douglass 
et al., 2017; Zhang et al., 2017b). Together these data show that NF-κB signalling 
plays a role in regulating astrogliosis in response to nutrient excess. This 
implicates NF-κB as an immunometabolic modulator in astrocytes. 
 
1.2.7 The energetic cost of inflammation 
Inflammation is an energetically costly process requiring an increase in the 
production of ATP, the ‘molecular currency’ of the cell, to fuel the rapid structural 
and functional changes involved (Romanyukha et al., 2006; Vander Heiden et al., 
2009). ATP stores energy liberated from fuel sources, allowing it to be transported 
in a stable form to a site of use where it can be converted back to adenosine 
diphosphate (ADP) to release the stored energy (Bonora et al., 2012). 
Inflammation necessitates a rapid and large supply of intermediate molecules for 
the synthesis of fatty acids, nucleotides and proteins (Gaber et al., 2017). This 
facilitates the increased cell replication often associated with inflammation (Gaber 
et al., 2017). Additionally the cells require more amino acids and oxidative agents 
for the synthesis of immunomodulatory molecules (Gaber et al., 2017). To allow 
these changes, the cell must use more energy and/or alter the source of energy, 
necessitating the reprogramming of metabolic behaviour of the cell during 
inflammation. 
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1.3 Immunometabolism: Fuelling inflammation 
To provide the additional energy needed a metabolic shift is often observed in 
immune cells during inflammation. Peripheral immune cells of myeloid and 
lymphoid lineage are dependent on the activity of a variety of metabolic pathways 
(O'Neill et al., 2016). Inflammatory stimuli are reported to drive metabolic 
changes, promoting the activity of the essential metabolic pathways (O'Neill et 
al., 2016; Russell et al., 2019). As is outlined further below, this metabolic change 
is often characterised as an increase in glucose metabolism through glycolysis, 
and a decrease in mitochondrial fatty acid metabolism. This bi-directional 
relationship between immune and metabolic function has become known as 
‘immunometabolism’.  
 
Immunometabolism is emerging as a therapeutic target for disease. This was first 
considered after the observation that treatment of rheumatoid diseases with 
salicylates improved patient glucose tolerance (Williamson, 1901). This has led 
to anti-inflammatory drugs being investigated to treat metabolic diseases 
including Type-2 diabetes and obesity (Goldfine et al., 2010; Goldfine et al., 2008; 
Lee et al., 2018). Additionally pharmaceuticals targeting cellular metabolism (e.g. 
Metformin) are being repurposed for conditions including cancers (Singer et al., 
2018), Alzheimer’s disease (Campbell et al., 2018; Koenig et al., 2017), and 
autoimmune diseases such as multiple sclerosis and lupus (Norata et al., 2015). 
 
Despite the therapeutic potential of this approach there is less understanding of 
whether the same immunometabolic changes are also seen in the central 
nervous system (CNS), most notably in astrocytes. A deeper understanding of 
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immunometabolism and the regulation of immunometabolism in astrocytes may 
allow a more targeted approach to drug development. Although many 
inflammatory pathways can regulate metabolism, NF-κB signalling will be the 
main pathway reviewed in this body of work, although others will be mentioned if 
they are of particular relevance in the context presented. 
 
1.3.1 Glycolysis in immunometabolism 
Glycolysis is a series of reactions that occur in the cytoplasm of the cell to break 
down glucose for ATP generation. Although glycolysis is a less efficient means 
of generating ATP than another metabolic pathway called oxidative 
phosphorylation (OXPHOS), it can generate ATP much more rapidly, making it 
more useful during an acute response to inflammatory stimulation (Pfeiffer et al., 
2001). Glycolysis also forms pyruvate and the reducing agents NADH and FADH2 
which are transported to the mitochondria and used in the tricarboxylic acid (TCA) 
cycle and in OXPHOS to generate a further 36 ATP molecules (fig 1.3.1.11). Any 
pyruvate which is not transported into the mitochondria is converted into lactate 
to regenerate NAD+, allowing glycolysis to continue. Although the pathway is 
always the same, glycolysis can be classified as anaerobic or aerobic (fig 
1.3.1.12). 
 
During limited periods of restricted oxygen availability, for example during 
exercise, cells can use anaerobic glycolysis as an energy source. This is 
facilitated by the conversion of pyruvate to lactate to regenerate the NAD+ used. 
This allows the cell to maintain ATP production during short periods of oxygen 
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deprivation. However, it cannot be used for long as NAD+ is not regenerated 
rapidly enough to maintain glycolysis through lactate production alone.  
 
Alternatively, cells can use aerobic glycolysis. This is often used during cell 
proliferation when there is plenty of oxygen available. For example, T cells divert 
85% of the product of glycolysis into lactate rather than into the TCA cycle (Fox 
et al., 2005), but importantly the presence of oxygen allows regeneration of NAD+ 
from NADH using the ETC, allowing continued glycolysis. This also generates 
two more ATP than anaerobic glycolysis and is much faster than OXPHOS. 
Aerobic glycolysis is facilitated by the transcription factor hypoxia inducible factor 
1α (HIF-1α) induction, which leads to enhanced expression of lactate 
dehydrogenase (LDH). This increases conversion of pyruvate to lactate. 
Interestingly, lactate can act as an immune cell modulator itself, decreasing pro-
inflammatory cytokine release and reducing glycolytic flux (Ratter et al., 2018). 
 
HIF-1α is a transcription factor, which among other functions, promotes gene 
transcription mediating a shift in cellular metabolism towards use of glycolysis 
over mitochondrial metabolism (Cimmino et al., 2019; Ziello et al., 2007). This 
helps to maintain oxygen homeostasis and during hypoxia promotes cell survival. 
HIF-1α can be activated directly through PRR and inflammatory signalling 
pathways that stabilise HIF-1α, preventing degradation, or indirectly through low 
oxygen levels (Devraj et al., 2017). During hypoxia, the oxygen dependent prolyl 
hydroxylases, which lead to ubiquitination and degradation of HIF-1α, are 
inactivated. Both mechanisms result in increased HIF-1α activity (Devraj et al., 
2017). 
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Figure 1.3.1.11 A simplified schematic of the steps in glycolysis, 
including products and enzymes involved. Glycolysis is the metabolism of 
glucose into pyruvate catalysed by a series of enzymes. This generates 
reduced nicotinamide adenine dinucleotide (NAD+; Reduced, NADH) and 
adenosine triphosphate (ATP). The resulting pyruvate can be transported into 
the mitochondria for use in the tricarboxylic acid (TCA) cycle. Alternatively 
pyruvate can be further reduced into lactate to replenish the pool of available 
NAD+. After initial phosphorylation by hexokinase, the resultant glucose-6-
phosphate can be introduced into the pentose phosphate pathway, a 
derivative pathway of glycolysis which generates nicotinamide adenine 
dinucleotide phosphate (NADPH) for nucleotide synthesis. Intermediates from 
both the pentose phosphate pathway and glycolysis can be used to synthesise 
amino acids. 
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Figure 1.3.1.12 The difference between aerobic glycolysis, aerobic 
mitochondrial metabolism and anaerobic glycolysis. Aerobic glycolysis is 
the metabolism of glucose into lactate, resulting in the reduction of 
nicotinamide adenine dinucleotide (NAD+; Reduced, NADH), and a small 
amount of adenosine triphosphate (ATP). A small percentage of the pyruvate 
produced is trafficked into the mitochondria for metabolism by the tricarboxylic 
acid cycle (TCA). Oxidative phosphorylation (OXPHOS) uses the reducing 
agents generated by aerobic glycolysis and the TCA cycle to generate ATP, 
and restore the reducing agents to their oxidised states. This allows aerobic 
glycolysis and the TCA cycle to continue. Anaerobic glycolysis is the 
metabolism of glucose into lactate in oxygen restricted environments. The lack 
of oxygen means NADH cannot be oxidised by the electron transport chain 
during OXPHOS. Over time the pool of NAD+ is depleted, halting glycolysis. 
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Although the metabolic response to inflammation varies between cell types, the 
initial pro-inflammatory phase is typically associated with an increase in glycolytic 
rate (O'Neill et al., 2016). Inhibition of glycolysis with the non-metabolisable 
glucose homolog 2-deoxyglucose (2-DG) prevents pro-inflammatory activation of 
monocytes and macrophages and suppresses NF-κB signalling in fibroblasts 
indicating that glycolysis is essential for inflammation in many cell types (Hamilton 
et al., 1986; Kawauchi et al., 2008b; Lee et al., 2019; Liu et al., 2016; Michl et al., 
1976; Tannahill et al., 2013). This is probably due to the need for rapid — as 
opposed to efficient — ATP production during the initial pro-inflammatory phase. 
 
There is evidence that glycolysis is also upregulated to provide substrates for the 
rapid increase in biomass seen during inflammation (Vander Heiden et al., 2009). 
In addition to being used as a substrate for the TCA cycle, pyruvate derived from 
glycolysis can be converted into the amino acids alanine, valine or leucine. Other 
glycolytic intermediates can also be converted into amino acids: 
phosphoenolpyruvate is a substrate for phenylalanine, tyrosine and tryptophan 
synthesis, while 3-phosphoglycerate is converted into serine and further 
synthesised into cysteine and glycine (Nelson & Cox, 2017). Additionally, the 
glycolytic intermediate glucose-6-phosphate fuels the pentose phosphate 
pathway (PPP; fig. 1.3.1.11) which is a derivative metabolic pathway of 
glycolysis. The PPP intermediate ribose 5-phosphate is used to synthesise the 
amino acid histidine. PPP also synthesises nucleotides and the reducing agent 
NADPH which protects the cell from oxidative stress (Kuehne et al., 2015). The 
amino acids produced via these various metabolic pathways can then be used to 
enable the rapid protein synthesis required during inflammation. 
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1.3.1.1 Regulation of glycolysis in inflamed peripheral immune cells by NF-κB 
signalling 
To allow the increase in glycolytic rate needed for inflammation, the expression 
of many glycolytic genes is upregulated in response to an inflammatory stimulus 
in many cell types (Remels et al., 2015). In dendritic cells c-Myc promotes 
transcription and expression of glycolytic genes, whereas in macrophages and T-
cells an increase in aerobic glycolysis can be driven by HIF-1α (Liu et al., 2016; 
Rodríguez-Prados et al., 2010; Shi et al., 2019; Shi et al., 2011; Tannahill et al., 
2013; Wang et al., 2011; Wang et al., 2017). HIF-1α promotes transcription of 
genes encoding glycolytic enzymes, including phospho-fructokinase 2 (PFK2) 
which appears to be essential for macrophage response to inflammation 
(Rodríguez-Prados et al., 2010). Expression of both of these transcription factors 
is upregulated by NF-κB signalling, demonstrating a role for NF-κB in regulating 
the glycolytic response to inflammation. 
 
HIF-1α is also regulated by degradation. HIF-1α is stabilised by TCA intermediate 
succinate and dimeric pyruvate kinase isozyme M2 (PKM2), the enzyme which 
catalyses the synthesis of pyruvate (Tannahill et al., 2013; Yang et al., 2014). NF-
κB can also promote transcription and expression of PKM2, thus promoting 
aerobic glycolysis through HIF-1α (Azoitei et al., 2016; Han et al., 2015). Inhibition 
of dimeric PKM2, the main regulator of aerobic glycolysis, impairs inflammasome 
activation and inflammation in these cells (Palsson-McDermott et al., 2015; Xie 
et al., 2016). 
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The major enzymatic regulator of glycolytic rate is hexokinase II, which introduces 
glucose into the glycolytic pathway (Roberts & Miyamoto, 2015). This enzyme is 
both transcriptionally and post-transcriptionally regulated. While hexokinase II 
can be upregulated by HIF-1α, it is under the direct transcriptional control of p65 
NF-κB (Kim et al., 2007b; Londhe et al., 2018; Yeung et al., 2008). However, 
hexokinase II activity is also inhibited by its product, glucose-6-phosphate, 
therefore reduced use of glycolytic products will result in accumulation of glucose-
6-phosphate, resulting in the inhibition of hexokinase II activity (Roberts & 
Miyamoto, 2015). 
 
Another limiting factor for hexokinase II activity is the availability of ATP to provide 
both the phosphate group and the energy to allow phosphorylation of glucose into 
glucose-6-phosphate. Localisation of hexokinase II to the mitochondria, through 
binding to the voltage dependent anion channel (VDAC) promotes coupling 
between mitochondrial metabolism and glycolysis (Arzoine et al., 2009; 
BeltrandelRio & Wilson, 1992; John et al., 2011; Perevoshchikova et al., 2010; 
Roberts & Miyamoto, 2015). This physical proximity enables increased 
movement of ATP from the inside the mitochondria to hexokinase II, through 
VDAC, allowing increased phosphorylation of glucose, increasing glycolytic flux. 
 
In dendritic cells hexokinase II targeting to the mitochondria is, in part, modulated 
by phosphoinositide-3-kinase (PI3K)/Protein kinase B (PKB/Akt), TANK binding 
kinase 1 (TBK1), and IKK signalling (Everts et al., 2014; Huynh et al., 2015; 
Krawczyk et al., 2010). As described earlier, these signalling pathways are 
activated by TLR4, and regulate NF-κB signalling (fig. 1.2.5.2). Activation of 
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these kinases promotes hexokinase II association with the mitochondria, 
increasing glycolytic flux during the inflammatory response (Calmettes et al., 
2013; Everts et al., 2014; Majewski et al., 2004; Sun et al., 2008).  
 
PI3K/Akt also regulates T-cell glycolysis during inflammation (Frauwirth et al., 
2002). However, unlike in macrophages where PI3K/Akt increases hexokinase II, 
increased glycolysis in T-cells driven by PI3K/Akt is driven by promotion of 
glucose transporter 1 (GLUT1) localisation to the plasma membrane of the cell 
(Frauwirth et al., 2002). GLUT1 is a uniporter which facilitates movement of 
glucose into the cell. This provides increased substrate for glycolysis, so 
increasing glycolytic rate. When glucose demand is low GLUT1 can be stored 
within endosomes inside the cell, ready to be inserted into the cell membrane 
when glucose demand is increased (Antonescu et al., 2014). This PI3K/Akt 
regulation of GLUT1 in T-cells is mediated through the mTOR (mammalian target 
of rapamycin) pathway (Fang, 2015; Makinoshima et al., 2015). 
 
GLUT1 expression is also transcriptionally regulated by mTOR signalling, 
through activation of c-Myc (Michalek et al., 2011). Overexpression of GLUT 
transporters increases cytokine production in T-cells (Michalek et al., 2011), 
whereas glucose limitation and loss of GLUT1 in T-cells prevents inflammation 
and cell division (Blagih et al., 2015; Macintyre et al., 2014; Siska et al., 2016; 
Wang et al., 2011). This suggests that GLUT1 expression can regulate 
inflammation in T-cells. Therefore, c-Myc appears to be essential for T-cell 
metabolic reprogramming, promoting GLUT expression and hexokinase II 
expression among other glycolytic genes (Wang et al., 2011). 
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NF-κB signalling can also increase expression of GLUT transporters during 
inflammation (Maedera et al., 2019; Zhang et al., 2017a). Loss of p65 significantly 
decreases glycolytic metabolism through reduced GLUT3 expression in 
fibroblasts (Kawauchi et al., 2008b). This implies that GLUT3 expression is driven 
by p65 signalling, as has been previously reported (Moriyama et al., 2018; Zha 
et al., 2015). Furthermore, loss of the tumour suppressor p53 in fibroblasts 
increases both NF-κB signalling and glycolytic metabolism (Kawauchi et al., 
2008b). In agreement with this work, Mauro et al. suggests that p53 represses 
GLUT3 expression to restrict inflammatory reprogramming of the cell (Kawauchi 
et al., 2008b; Mauro et al., 2011). 
 
Together these studies indicate that substrate availability is the rate-limiting step 
of glycolysis in both T-cells and fibroblasts. Hexokinase II regulates glucose 
uptake and substrate availability in part by metabolising glucose into glycogen, 
for storage, or glucose-6-phosphate (Roberts & Miyamoto, 2015). This maintains 
the glucose gradient promoting facilitated diffusion of glucose into the cell. 
Nevertheless, expression of GLUT transporters in the membrane appears to be 
more important during inflammation than hexokinase II activity in T-cells and 
fibroblasts (Kawauchi et al., 2008b; Mauro et al., 2011). GLUT1 mediated glucose 
uptake is also a regulator of inflammation in macrophages, as overexpression of 
GLUT1 promotes inflammation in these cells (Freemerman et al., 2014). 
However, in macrophages GLUT expression is less critical than hexokinase II 
activity for regulating glycolysis during inflammation, demonstrating signalling 
differences between these cell types (Van den Bossche et al., 2017).  
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Beyond fuelling inflammation, glycolytic enzymes also play an important role in 
immunity directly (Seki & Gaultier, 2017). For example, during inflammation 
hexokinase II targeted to the mitochondria protects against apoptosis (Miyamoto 
et al., 2008; Pastorino et al., 2002). Other glycolytic enzymes suppress 
inflammation, such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
which binds interferon γ (IFN-γ) and TNF-α messenger RNA (mRNA), 
suppressing translation. However, during intense glycolytic increases, such as 
those seen during inflammation, GAPDH becomes unbound from the transcripts, 
allowing their translation and synthesis (Chang et al., 2013; Millet et al., 2016). 
Additionally, a truncated form of α-enolase, called myc promoter-binding protein 
1 (MBP-1), represses c-Myc transcription, which (as discussed above) regulates 
GLUT1 transcription (Chaudhary & Miller, 1995; Ray & Miller, 1991). Together 
these data demonstrate that glycolytic enzymes and intermediates are essential 
for producing and regulating an inflammatory response in many cell types. 
However, the regulation of the response is complex and cell-type specific. 
 
1.3.1.2 Canonical NF-κB signalling in basal regulation of glycolysis 
In the absence of an inflammatory stimulus, canonical NF-κB signalling is still an 
important regulator of cellular metabolism. A seminal paper published by Mauro 
et al. demonstrated a role of NF-κB signalling in basal metabolism and during 
disease. Using IKKβ inhibitor SC-514 and p65 knockout fibroblasts, the group 
showed that basal NF-κB signalling is essential to prevent cellular metabolic 
reprogramming to aerobic glycolysis (Mauro et al., 2011). 
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There is some suggestion that the differential metabolic functions of NF-κB during 
basal and inflammatory states are mediated through p53 preventing NF-κB from 
translocating to the mitochondria, and so promoting oxidative phosphorylation 
(fig. 1.3.1.2) (Johnson et al., 2011). NF-κB signalling in mouse fibroblasts 
promotes p53 expression, increasing OXPHOS, particularly during glucose 
starvation (Schwartzenberg-Bar-Yoseph et al., 2004). There is additional 
evidence that in fibroblasts loss of p53 prevents NF-κB from promoting 
transcription of genes encoding ETC proteins, despite phosphorylation and DNA 
binding of the NF-κB p65 subunit (Kawauchi et al., 2008a). Furthermore, p53 also 
inhibits glycolysis and glucose uptake through repression of GLUT transporter 
expression by repressing p65 signalling (Kawauchi et al., 2008b; 
Schwartzenberg-Bar-Yoseph et al., 2004). This may suggest that p53 and NF-κB 
exist in a negative feedback loop to restrain glycolysis and glucose addiction at 
the cellular level during inflammation. Together, these data suggest that p53-NF-
κB signalling orchestrates normal metabolic function. 
 
Other components of NF-κB signalling may restrain aerobic glycolysis when an 
inflammatory stimulus is not present. The NF-κB regulator IKKβ can 
phosphorylate 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB3), 
acting to inhibit the action of this enzyme which synthesises allosteric activators 
of aerobic glycolysis (Reid et al., 2016). This decreases aerobic glycolysis and 
increases pyruvate input into the TCA cycle (Reid et al., 2016). This additional 
data further supports the theory that basal NF-κB signalling maintains normal 
cellular metabolism. 
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Figure 1.3.1.2: Presence of p53 determines NF-κB translocation to the 
mitochondria or nucleus. After phosphorylation, active NF-κB can be 
located to the mitochondria through the membrane channel mortalin. If p53 is 
present this is inhibited, and the active NF-κB instead translocated to the 
nucleus, where it promotes transcription of target genes. 
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1.3.1.3 Glycolysis and inflammation in astrocytes 
Glucose is the main fuel consumed by the brain. Data suggests that astrocyte 
glucose metabolism is entirely via aerobic glycolysis, particularly when supporting 
neuronal signalling (Bélanger et al., 2011a; Fernández-Moncada et al., 2018; 
Pellerin & Magistretti, 1994; Vardjan et al., 2018; Yellen, 2018). Glucose is 
metabolised by glycolysis into pyruvate and further oxidised into lactate, which is 
thought to be released as fuel for the neurons it supplies, rather than being 
transported into the astrocytic mitochondria for use in the TCA cycle. This is 
termed the Astrocyte-Neuron Lactate Shuttle, however this is currently a 
contentious theory (Mason, 2017).  Glucose taken up by astrocytes can also be 
stored as glycogen within the cell if it is not required immediately for energy 
metabolism (Bak et al., 2018; Falkowska et al., 2015). 
 
Some evidence already exists linking inflammation with changes in glycolytic 
metabolism in astrocytes. In vitro studies in mouse primary astrocytes 
demonstrate that treatment with pro-inflammatory cytokines increases glucose 
uptake and depletes intracellular glycogen stores (Bélanger et al., 2011b; Gavillet 
et al., 2008). This suggests an increase in astrocyte glucose use as a fuel during 
inflammation. This was coupled with increased flux through the TCA cycle and 
PPP (Bélanger et al., 2011b; Gavillet et al., 2008). The increase in TCA cycle use 
suggests that some pyruvate is being used to generate reducing agents for 
OXPHOS as opposed to lactate production for immediate energy gains. In a 
related study, Meares et al. showed that decreasing substrate availability to 
astrocytes in vitro, by limiting glucose and pyruvate availability, reduces IFN-γ 
induced inflammatory responses (Meares et al., 2013). This implies that 
glycolysis is essential for inflammation in astrocytes. Exposure to nitric oxide, 
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which can be an inflammatory factor at high concentrations (Sharma et al., 2007), 
also enhances glycolytic pathways in astrocytes, including activity of HIF-1α 
(Almeida et al., 2004; Brix et al., 2012). Together these data suggest that 
astrocytes rely on glycolysis to support protein synthesis and achieve full 
inflammatory activation, but to our knowledge this important question and the 
mechanisms driving it have never been directly examined. 
 
1.3.2 Mitochondria in energy metabolism 
Mitochondria are organelles which play an integral role in ATP generation. These 
organelles are bound with two membranes, an outer mitochondrial membrane 
(OMM) and an inner mitochondrial membrane (IMM). The IMM contains the 
mitochondrial matrix, where metabolic processes occur. Substrates for energy 
generation, including pyruvate, lactate, acyl-coA (derived from fatty acids), and 
amino acids, are transported into the mitochondrial matrix by either passive 
diffusion or active transport, dependent on substrate type (Becker & Wagner, 
2018; McCommis & Finck, 2015; Palmieri & Monné, 2016). 
 
Once inside the mitochondrial matrix these substrates are converted into acetyl-
coA and metabolised through the tricarboxylic acid (TCA) cycle (fig. 1.3.3). This 
generates reducing agents and substrates for the electron transfer chain (ETC; 
fig. 1.3.3). The dual membranes of the mitochondria are essential for 
mitochondrial function. The space between the two membranes is called the 
intermembrane space, and the IMM is highly folded into structures called cristae, 
increasing its surface area. During electron transport protons are pumped into the 
cristae of the intermembrane space, leading to high concentrations of protons 
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and establishing a proton gradient. This membrane polarisation is integral for 
oxidative phosphorylation (OXPHOS) and other metabolic functions, as will be 
discussed further later in this chapter. 
 
1.3.3 TCA cycle in immunometabolism 
The TCA cycle uses a sequence of enzymatic reactions to generate reducing 
agents for OXPHOS. This is fuelled by acetyl-coA which is converted into CoA-
SH to replenish levels of the critical TCA substrate citrate, allowing initiation of a 
new rotation. In addition to providing substrates for OXPHOS the TCA cycle 
provides precursors for biosynthetic pathways. Intermediates from the TCA cycle 
can be used to synthesise new amino acids, which are then used for protein 
synthesis, as is shown in fig 1.3.3 (Berg et al., 2002; Ryan & O'Neill, 2017). The 
TCA cycle also contributes to fatty acid synthesis through citrate which can be 
exported from the mitochondria by ATP citrate lyase (ACLY) and converted into 
acetyl co-A, for use in fatty acid synthesis (Berg et al., 2002; Infantino et al., 2013; 
Vittoria et al., 2019; Williams & O'Neill, 2018). 
 
ACLY is an important component of the inflammatory response. ACLY 
expression is driven through NF-κB and signal transducers and activators of 
transcription (STAT) signalling (Infantino et al., 2013). In dendritic cells the 
transcription factor sterol regulatory element binding protein (Srebp) regulates 
ACLY, and citrate driven lipid synthesis is essential for the full pro-inflammatory 
immune response (Assmann et al., 2017). There is data showing that in mice on 
a high fat diet inhibition of ACLY prevents the development of glucose intolerance 
and obesity, and suppresses inflammatory gene expression (Samsoondar et al., 
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2017). Together these data demonstrate that in immune cells inflammatory 
signalling pathways, including NF-κB play a role in regulating TCA cycle activity, 
and, in common with glycolysis, inflammatory and metabolic pathways are 
integrated at the level of the TCA cycle. 
 
In peripheral immune cells activity of the TCA cycle is instrumental in 
inflammation. During fungal infection dendritic cells have altered ratios of TCA 
cycle intermediates which influence the pro-inflammatory response (Márquez et 
al., 2019). For example, pyruvate dehydrogenase — the enzyme which converts 
pyruvate into acetyl-coA for use in the TCA cycle — increases expression of IL-
10 and IL-23A in dendritic cells (Márquez et al., 2019). Similarly TCA cycle 
intermediates accumulate in activated bone-marrow derived macrophages after 
LPS insult, despite decreased mitochondrial activity (Tannahill et al., 2013). This 
suggests increased TCA cycle activity during a pro-inflammatory response. 
 
In macrophages, succinate oxidation is instrumental in promoting inflammation 
(Mills et al., 2016). Succinate accumulates after LPS insult and stabilises HIF-1α 
to promote macrophage inflammasome activation and HIF-1α driven transcription 
(Koivunen et al., 2007; Mills et al., 2016; Palsson-McDermott et al., 2015; Selak 
et al., 2005; Tannahill et al., 2013). The TCA cycle is also essential for T cell 
activation (Wang et al., 2011). Together these studies demonstrate the 
importance of the TCA cycle in regulating the function of immune responsive 
cells. Whilst there is evidence that the TCA cycle is increased in astrocytes during 
inflammation (Bélanger et al., 2011b; Gavillet et al., 2008), it has not been 
demonstrated whether this is essential for the inflammatory response. 
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1.3.4 Oxidative phosphorylation in immunometabolism 
OXPHOS is a well characterised process, recently reviewed by Zhao et al. (Zhao 
et al., 2019). Briefly, OXPHOS generates ATP from ADP by capturing the energy 
generated by proton movement through ATP synthase (Complex V; fig. 1.3.4). 
Use of this pathway increases metabolic efficiency. As mentioned earlier, the 
ETC pumps protons across the inner mitochondrial membrane and into the 
intermembrane space using the energy generated through electron transport. 
Electrons are provided for this from the reducing agents NADH and FADH2 
derived from the TCA cycle, FAO and glycolysis. This polarises the inner 
mitochondrial membrane and creates a proton gradient. Protons flow down this 
gradient back into the mitochondrial matrix through ATP synthase. This flow of 
protons provides the energy needed to phosphorylate ADP into ATP. The spare 
electrons are accepted by oxygen and hydrogen to form water. Therefore, 
OXPHOS is only possible in the presence of oxygen. 
 
The ETC produces highly damaging reactive oxygen species (ROS). ROS are 
used as an important bactericidal molecule during the inflammatory response. 
Inhibition of ATP production by the ETC whilst there is availability of reducing 
agents and a proton gradient increases production of superoxide (O2•-), a species 
of ROS (Murphy, 2008). This is formed by incomplete reduction of oxygen. 
Complex I generates ROS when fully reduced by NADH (Kudin et al., 2004). 
Therefore the NAD+/NADH ratio determines the rate of ROS production, with 
increased NADH increasing the production of ROS (Adam-Vizi & Chinopoulos, 
2006; Murphy, 2008).   
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In the brain, succinate promotes ROS production by reducing Complex II (Cino & 
Del Maestro, 1989; Votyakova & Reynolds, 2001). When the mitochondrial 
membrane is polarised, this leads to reverse electron transport (RET) from 
Complex II to Complex I. This increases reduction of Complex I, increasing O2•- 
production.  Astrocytes are capable of producing ROS during the inflammatory 
response (Lopez-Fabuel et al., 2016; Sheng et al., 2013). Treatment of astrocytes 
with LPS impairs the NAD+/NADH ratio and increases succinate production, 
promoting ROS production (Tannahill et al., 2013). Lopez-Fabiel et al. suggested 
that this is due to increased free and inactive Complex I in astrocytes, preventing 
onward electron transport and encouraging ROS production (Lopez-Fabuel et al., 
2016). This suggests that astrocytes can produce high amounts of ROS during 
inflammation without affecting OXPHOS rate. This would allow astrocytes to 
maintain OXPHOS during the pro-inflammatory response. 
 
There is extensive evidence that ROS can activate both canonical and non-
canonical NF-κB signalling in astrocytes (Morgan & Liu, 2011). This leads to 
induction of compensatory expression of genes which are protective against 
ROS, in addition to genes which propagate ROS production (Morgan & Liu, 
2011). This encourages cell survival in an oxidative environment whilst allowing 
continued production of bactericidal ROS. 
 
It must be noted that ROS is not solely produced by the ETC. ROS are also 
produced at other sites by oxidase enzymes, including in peroxisomes and 
phagosomes (Snezhkina et al., 2019). ROS is most notably synthesised by the 
NADPH oxidase (NOX) family. Astrocytes have been reported to express NOX2, 
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NOX4 and NOX5, expression of which are increased after controlled cortical 
impact, or exposure to LPS or pro-inflammatory cytokines (Cooney et al., 2013; 
Sheng et al., 2013). NF-κB itself upregulates expression of NOX (Anrathar et al., 
2006; González-Reyes et al., 2017). Therefore, when considering ROS in the 
regulation of the immunometabolic response, whilst the ETC plays a role in ROS 
production, other sources cannot be overlooked.  
 
Despite the important role of ROS in inflammation, there is evidence that 
excessive ROS production is a significant contributing factor to neurotoxicity and 
neurodegeneration (Angelova & Abramov, 2018). Uncoupling proteins (UCPs) 
uncouple OXPHOS from ATP production, allowing free movement of protons 
through ATP synthase with no need for oxygen (Bouillaud et al., 2016). This 
allows the proton gradient to collapse. This can have a protective role, decreasing 
ROS production by increasing the NAD+/NADH ratio and depolarising the 
mitochondrial membrane. 
 
As previously mentioned, NF-κB signalling can inhibit OXPHOS through inhibiting 
transcription of ETC proteins coded for by mitochondrial DNA (fig. 1.3.1.2) 
(Albensi, 2019). NF-κB is transported into the mitochondria by binding to the 
mitochondrial transport protein mortalin (Flachbartová & Kovacech, 2013). 
However, in the presence of p53, which is upregulated by NF-κB signalling, the 
interaction between mortalin and NF-κB is disrupted, preventing NF-κB mediated 
inhibition of OXPHOS (Tornatore et al., 2012). Therefore, NF-κB can regulate 
OXPHOS during inflammation. 
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In astrocytes there is evidence that OXPHOS is maintained during inflammation. 
In aging mice, increased inflammatory markers and NF-κB signalling in astrocytes 
correlates with elevated metabolic oxygen consumption (Jiang & Cadenas, 
2014). This suggests that astrocytes are using oxidative metabolism during 
inflammation. Also, p53 expression is increased during pro-inflammatory 
simulation in rat astrocytes in vitro and gerbil astrocytes in vivo (Caito et al., 2014; 
Panickar et al., 2009; Tounai et al., 2007). This suggests that OXPHOS may be 
maintained during inflammation through NF-κB-p53 signalling. However, this has 
never been directly examined, to our knowledge. 
 
1.3.5 Mitochondrial dynamics in immunometabolism 
Mitochondria form complex and dynamic networks within the cell. Two separate 
mitochondria can fuse together to form a single structure, or fragment to form 
daughter mitochondria. Mitochondrial dynamics are essential for mitochondrial 
maintenance, ensuring mitochondrial DNA replication, regulation of calcium 
signalling and redistributing mitochondrial ROS (Vafai & Mootha, 2012).  
 
Mitochondrial dynamics also regulate OXPHOS rate, often in response to nutrient 
availability (Gomes et al., 2011; Rambold et al., 2011). Mitochondrial fusion 
promotes OXPHOS whilst mitochondrial fission limits OXPHOS (Rossignol et al., 
2004; Wai & Langer, 2016). These dynamics can be altered by inflammation. 
ROS, PI3K/Akt and MAPK signalling promote mitochondrial fission in some cell 
types (Rambold & Pearce, 2018; Wai & Langer, 2016). Furthermore, there is 
evidence that NF-κB signalling promotes mitochondrial fission in skeletal muscle 
cells (Nisr et al., 2019). This also appears to be the case in astrocytes, with 
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increased mitochondrial fission observed after treatment with LPS and IFN-γ 
(Motori et al., 2013). Treatment with the pro-inflammatory stimulus manganese 
reduces expression of mitofusin 2 (Mfn2), again suggesting reduced 
mitochondrial fusion and a shortening of mitochondria in astrocytes (Sarkar et al., 
2018). Hyperfusion of mitochondria in astrocytes has been shown to activate NF-
κB signalling (Zemirli et al., 2014). This suggests that NF-κB regulation of 
mitochondrial dynamics is bidirectional and designed to reduce hyperfusion of 
mitochondria. Fission allows mitochondria to move into the astrocytic processes 
(Genda et al., 2011; Jackson et al., 2014; Kolikova et al., 2006; Reyes & Parpura, 
2008). This allows local energy generation and regulation of Ca2+ dynamics, 
which plays an important role in regulating astrocyte behaviour (Göbel et al., 
2018; Jackson & Robinson, 2015).  
 
Although the previous data demonstrates that NF-κB signalling promotes 
mitochondrial fission, loss of NEMO or IKKβ does not affect mitochondrial 
dynamics in mouse fibroblasts. Conversely, loss of IKKα which activates the non-
canonical NF-κB pathway in these cells reduced expression of Optic atrophy 1 
(OPA1), a protein which promotes mitochondrial fusion, and increased 
mitochondrial fragmentation (Laforge et al., 2016). This is supported by evidence 
that mTOR/NF-κB signalling increases OPA1 and fusion in cardiomyocytes in 
response to insulin (Parra et al., 2014). Together these data suggest that 
canonical NF-κB promotes mitochondrial fission whilst non-canonical NF-κB 
promotes mitochondrial fusion. 
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1.3.6 Fatty acid oxidation in immunometabolism 
Fats can also be used as a source of energy. Fatty acid oxidation (FAO), also 
known as β-oxidation, is the shortening of acyl-coA structures derived from fatty 
acids. This generates acetyl-coA which can be further metabolised by the TCA 
cycle. FAO occurs within bi-lipid bound structures, including peroxisomes and 
mitochondria. Four reactions make up the FAO cycle, with each cycle removing 
two carbon atoms from fatty acyl residues in the form of acetyl-CoA, generating 
NADH and FADH2 (fig 1.3.6). The NADH and FADH2 produced by FAO are used 
as reducing agents to drive OXPHOS. FAO is primarily regulated by availability 
of acyl-coA within the mitochondrion or peroxisome. Carnitine palmitoyl 
transferase I (CPT-1; see section 1.2.3.2 below) facilitates the transport of acyl-
coA into the structure (mitochondrion or peroxisome; fig. 1.3.6.1) and thus acts 
as the rate-limiting step in FAO. 
 
Astrocytes use FAO to obtain energy. Indeed, fatty acids appear to be the 
preferential fuel source for fuelling the TCA cycle (over glucose) in some 
astrocytes (Taïb et al., 2013). Glucose dephosphorylates the metabolic regulator 
AMP activated protein kinase (AMPK) in hypothalamic neurons and astrocytes, 
reducing oxidation of the saturated long chain fatty acid palmitate (Taïb et al., 
2013). However, this is not the case in cortical astrocytes, where AMPK 
phosphorylation and fatty acid oxidation are maintained in the presence of 
glucose. This suggests that cortical astrocytes are using FAO to fuel the TCA 
cycle preferentially to glycolysis. Together this suggests brain region specific 
heterogeneity in astrocyte metabolism. 
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Figure 1.3.6: A simplified schematic of the steps in fatty acid oxidation, 
including products and enzymes involved. FAO uses acyl-coA derived 
from fatty acids to generate acetyl-coA and reducing agents flavin adenine 
dinucleotide (reduced, FADH2) and nicotinamide adenine dinucleotide 
(reduced, NADH). Acetyl-coA is used as a substrate for the tricarboxylic acid 
(TCA) cycle, and the reducing agents generated are used in oxidative 
phosphorylation (OXPHOS). Each turn of the FAO cycle reduces the length 
of the acyl-coA by one carbon. 
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1.3.6.1 Carnitine palmitoyl transferase I (CPT-1) 
The main regulator of FAO is CPT-1A. CPT-1A is an enzyme which sits on the 
outer mitochondrial membrane and catalyses the reaction transferring an acyl 
group from coenzyme A to carnitine, allowing the acyl-carnitine to be transported 
into the intermembrane space through VDAC (Lee et al., 2011). CPT-1A is 
exclusively expressed in astrocytes in the CNS, and inhibition of CPT-1A activity 
in brain tissue almost completely prevents FAO (Jernberg et al., 2017). This 
suggests that in the CNS FAO is predominantly used by astrocytes to generate 
energy. 
 
The main mechanism of regulation of CPT-1 activity is inhibition by malonyl co-A 
which is generated by acetyl-coA carboxylase 2 (ACC2) from acetyl-coA. AMPK 
is a major inhibitor of ACC2 activity (Herzig & Shaw, 2018). Activation of this 
kinase allows it to in turn phosphorylate downstream targets, including ACC2 to 
increase ATP production and decrease energy expenditure (Long & Zierath, 
2006). As well as regulation by malonyl-coA, CPT-1A can be regulated at the 
transcriptional level with AMPK activation increasing the expression of CPT-1A 
(Kim et al., 2011; Krämer et al., 2007). Thus, through these combined modes of 
action, AMPK promotes acyl-CoA oxidation in the mitochondria.  
 
Modulation of FAO has different effects on the inflammatory response depending 
on the cell type. In macrophages, limiting FAO through CPT-1A inhibition 
increases inflammation (Namgaladze et al., 2014). However, in lymphocytes and 
epithelial cells inhibition of FAO reduces expression of inflammatory markers 
(Calle et al., 2019; Mørkholt et al., 2017). This suggests that in these cells FAO 
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is maintained during inflammation. It is important to note here that despite 
increasing energy production through FAO and glycolysis, activation of AMPK 
does not facilitate the pro-inflammatory response. Indeed, AMPK activation can 
lead to suppression of NF-κB phosphorylation, HIF-1α stabilisation and cytokine 
signalling, while pharmacological activation of AMPK in astrocytes replicated the 
anti-inflammatory effect of reduced glucose and/or pyruvate availability (Faubert 
et al., 2013; Meares et al., 2013; Salminen et al., 2011). Therefore, during 
inflammation AMPK is often inactive with the pro-inflammatory stimulus LPS 
dephosphorylating AMPK (Fan et al., 2018b). This means AMPK cannot be 
driving metabolic pathways in astrocytes during inflammation, so CPT-1A must 
be regulated through a different mechanism, if it is regulated at all during 
inflammation in astrocytes. To date, the effect of CPT-1A activity and expression 
on inflammation in astrocytes has not been explored, so I cannot comment on 
how FAO is regulated during inflammation in astrocytes. 
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Figure 1.3.6.1: The role and regulation of carnitine palmitoyl transferase 
1A (CPT-1A). CPT-1A catalyses the transfer of the acyl group from coA onto 
carnitine. This allows the transfer of the acyl group into the mitochondrion 
through the voltage dependent anion channel (VDAC). This provides acyl 
groups as a substrate for fatty acid oxidation (FAO). Activity of CPT-1A is 
inhibited by malonyl coA which is synthesised by acetyl-coA carboxylase 2 
(ACC2). AMP activated protein kinase (AMPK) inhibits the production of 
malonyl coA by ACC2, resulting in increased CPT-1A activity. 
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1.4 Translocator protein 18 kDa (TSPO) 
As discussed above, metabolism is a critical driver of the different stages of 
inflammation in most cell types examined thus far. There is currently significant 
interest in exploiting this intrinsic link between inflammation and metabolism to 
manage chronic inflammation and associated diseases (Norata et al., 2015). One 
protein that is emerging as a potential therapeutic target in inflammation, 
particularly within the brain, is translocator protein 18 kDa (TSPO). Expression of 
TSPO is increased in the CNS in response to brain tumours and Alzheimer’s 
disease (Bhoola et al., 2018; Lagarde et al., 2018). This has led to TSPO ligands 
being utilised to detect CNS inflammation in humans using Positron Emission 
Tomography (PET) (Dupont et al., 2017; Werry et al., 2019). 
 
TSPO is upregulated in astrocytes during inflammation (Lavisse et al., 2012). In 
vitro studies showing upregulation of TSPO in rodent microglia in response to 
pro-inflammatory stimuli led to the initial assumption that the increased CNS 
expression seen via PET imaging with TSPO ligands was predominantly 
microglial in origin. However, in vitro studies suggest that TSPO is not regulated 
in human macrophages or microglia (Narayan et al., 2017; Owen et al., 2017b). 
This indicates that in the human brain other cells in the CNS upregulate TSPO in 
response to inflammation. Indeed, Lavisse et al. provided evidence that in mice 
upregulation of TSPO in reactive astrocytes is at least in part responsible for the 
responses seen in PET imaging in response to CNS inflammation, using 
overexpression of the cytokine ciliary neurotrophic factor, which induces gliosis 
specifically in astrocytes (Lavisse et al., 2012). This may suggest that in humans 
TSPO is upregulated in astrocytes during CNS disease. 
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1.4.1 Expression of TSPO 
In humans the Tspo gene is located on the 22q13.31 chromosome and is 
composed of 891 nucleotides (Chang et al., 1992; Riond et al., 1991). The gene 
is arranged in four exons, with a large intron between the first and second exon 
(Casalotti et al., 1992; Lin et al., 1993). Only the third exon is completely 
translated, with partial translation of the other three exons, resulting in the gene 
encoding 169 amino acids (fig. 1.4.1.1; Casalotti et al., 1992; Lin et al., 1993). 
This gene is transcribed and translated into a protein composed of 5 
transmembrane α-helices with a steroid binding site termed the Cholesterol 
Recognition/Interaction Amino Acid Consensus (CRAC) motif on the c-terminus 
(fig. 1.4.2) (Guo et al., 2015; Korkhov et al., 2010; Li et al., 2015). Mechanisms 
behind the regulation of TSPO translation are still unclear. The Tspo gene is 
highly conserved between species, and prokaryotes express an ortholog of the 
protein known as tryptophan-rich sensory protein gene (tspO) (Chapalain et al., 
2009; Yeliseev & Kaplan, 1995; Yeliseev et al., 1997). 
 
Within the eukaryotic cell TSPO is expressed on the OMM, with the majority of 
literature reporting this as the only cellular location of TSPO (Anholt et al., 1986; 
Basile & Skolnick, 1986; Bribes et al., 2004). However it has also been reported 
on the Golgi apparatus, plasma membrane, lysosomes, peroxisomes, and the 
nuclear envelope of cancerous cells (Hardwick et al., 1999; O'Beirne et al., 1990; 
Oke et al., 1992). Notably, the TSPO paralog TSPO2 is reported in mature 
erythrocytes, which are devoid of intracellular organelles including mitochondria 
and nuclei (Marginedas-Freixa et al., 2016). A recent paper suggests that TSPO 
is strictly expressed on the OMM, whilst an isoform of TSPO termed PBR-S, 
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which is a truncated form of TSPO1 and not the same as TSPO2, is also localised 
to non-mitochondrial sites (Liu et al., 2017a). 
 
In humans, genetic variants of TSPO have been reported (Owen et al., 2012). 
The most common polymorphisms are A147T and R162H (Owen et al., 2012). 
These polymorphisms have been observed in 30% of the Caucasian population 
and 25% of the African American (Owen et al., 2012), although reported at much 
lower rates in other human populations. Human polymorphisms have been 
associated with disrupted pregnenolone production and increased prevalence of 
neuropsychiatric disorders (Colasanti et al., 2013; Costa et al., 2009; Nakamura 
et al., 2006). In the TSPO protein containing A147T polymorphism the area 
surrounding the CRAC motif is altered, which may result in a lower affinity for 
cholesterol, hence the phenotypes observed associated with the polymorphism 
(Li et al., 2015; Milenkovic et al., 2018). Similarly, the R162H polymorphism 
results in an amino acid substitution within the CRAC domain, induction of which 
leads to decreased circulating corticosteroids (Owen et al., 2017a). This suggests 
that common polymorphisms within the TSPO gene alter steroidogenesis. 
 
TSPO is expressed constitutively in many tissues (Gavish et al., 1999). These 
tissues include the liver, kidney, brain, and steroidogenic tissues such as the 
adrenal gland and gonads. It has since been reported to be found in other tissues 
such as the spleen, lung, muscle, bone marrow, adipose tissue, and white blood 
cells including macrophages (Giatzakis & Papadopoulos, 2004). In healthy brain 
tissue TSPO is expressed at low levels in glial cells, including astrocytes and 
microglia, which are brain resident macrophages, and upregulated in response 
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to disease and inflammation (Gavish et al., 1999; Karlstetter et al., 2014; Lavisse 
et al., 2012; Owen et al., 2017b). Expression in human tissues is similar to that in 
murine tissues, suggesting that mouse-derived cells are a suitable model for 
studying this protein (Batarseh & Papadopoulos, 2010).  
 
1.4.1.1 Regulation of TSPO 
As mentioned previously, TSPO is upregulated during inflammation (Lee et al., 
2016). This occurs through protein kinase C (PKC) mediated activation of MAPK 
signalling (fig. 1.4.1.1). Loss of PKCε and ERK1/2 from the mouse steroidogenic 
cell line MA-10, and fibroblasts results in suppression of TSPO expression, 
whereas overexpression of MAPK signalling pathway components in these cells 
increases TSPO expression (Batarseh et al., 2008; Batarseh et al., 2010). 
 
This control of TSPO expression by MAPK signalling is mediated through the 
action of multiple transcription factors. For example, nuclear accumulation of the 
specificity protein 1 (Sp1), STAT3 and AP-1 transcription factors increase Tspo 
mRNA expression in fibroblasts, a mouse microglia cell line (BV-2) and MA-10 
steroidogenic cells (Batarseh et al., 2010; Giatzakis et al., 2007; Giatzakis & 
Papadopoulos, 2004; Rashid et al., 2018; Shimoyama et al., 2019). Silencing of 
these transcription factors using RNA interference prevents increased TSPO 
expression after LPS stimulation of BV-2 microglia (Rashid et al., 2018). 
Interestingly, there is evidence that PKC can also activate NF-κB signalling, 
suggesting a role for NF-κB in the regulation of TSPO expression (Garg et al., 
2012; Satoh et al., 2004). However, the TSPO promotor is still active when NF-
κB is inhibited (Batarseh et al., 2010). This suggests that whilst TSPO expression 
79 
 
may be increased by NF-κB signalling, the activity of NF-κB is not essential for 
TSPO expression; therefore, NF-κB is not considered to be a major regulator of 
TSPO expression (Batarseh et al., 2010). Regarding the current available 
evidence, the gene (Tspo) is thought to be primarily regulated by the PKCε-
ERK1/2-AP1/Stat3 signalling transduction pathway (fig. 1.4.1.1) (Batarseh et al., 
2008; Batarseh et al., 2010; Batarseh & Papadopoulos, 2010). 
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Figure 1.4.1.1: Summary of the regulation and roles of translocator 
protein 18 kDa (TSPO). TSPO expression has been implicated in multiple 
mechanisms. Expression of TSPO is regulated at the transcriptional level by 
activator protein 1 (AP-1), specificity protein 1 (Sp1), and signal transducer 
and activator of transcription 3 (STAT3). These are regulated by mitogen 
activated protein kinases (MAPKs), activated by protein kinase C (PKC). 
Nuclear factor κB (NF-κB), which is regulated by PKC may also regulate 
TSPO expression. When active, the promoter drives the synthesis of an 11.68 
kb transcript (Exons depicted by boxes, introns by lines; adapted from 
Ensembl, 2020), of which the regions indicated in solid colour are transcribed 
into an 169 amino acid product. 
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1.4.2 Synthetic TSPO ligands  
Activity of TSPO can be regulated by ligands binding to the protein. Endogenous 
ligands of TSPO include tetrapyrroles and acyl-coA binding protein (Guidotti et 
al., 1983; Li et al., 2015; Veenman et al., 2016). Functions of these ligands 
include REDOX and metabolic regulation, although the extent through which this 
is mediated through TSPO in eukaryotes is currently unknown (Tonon et al., 
2019; Veenman et al., 2016; Zhao et al., 2016). 
 
Several synthetic ligands against TSPO have been developed for use in humans 
(Michelle et al., 2006). Some of the early ligands developed included PK11195, 
Ro5-4864 and XBD-173 (emapunil, AC-5261). Since then more specific ligands 
have been developed. These have been classified as either agonists or 
antagonists of TSPO based on their ability to displace PK11195 in radioligand 
binding assays and their impact on cholesterol transport (Campiani et al., 1996; 
Katz et al., 1992; Papadopoulos et al., 1990). PK11195 is classified as a TSPO 
antagonist due to initial reports that PK11195 decreases steroidogenesis in MA-
10 steroidogenic cells (Papadopoulos et al., 1990). However, emerging evidence 
suggests that the effect of PK11195 on steroidogenesis is inconsistent, with some 
studies showing no change or increased steroidogenesis after PK11195 
treatment (Selvaraj & Tu, 2016). 
 
Ro5-4864 is classified as a TSPO agonist due to its ability to displace PK11195 
and the finding that it consistently increases steroidogenesis (Le Fur et al., 1983; 
Selvaraj & Tu, 2016). The ligand XBD-173 is also classified as a TSPO agonist 
due to increased steroidogenesis after treatment (Selvaraj & Tu, 2016). While 
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these synthetic ligands bind TSPO and clearly influence its purported function(s), 
caution needs to be used with respect to utilising the terms ‘agonist’ and 
‘antagonist’, as TSPO is not a receptor. The terms ‘activator’ and ‘inhibitor’ may 
be more appropriate, but classification of these ligands remains challenging due 
to the currently poor definition of TSPO function. 
 
TSPO ligands change the structure of TSPO. For example, PK11195 binds to 
multiple amino acids on separate cytoplasmic loops, resulting in a conformational 
change which obscures the channel formed by the 5 transmembrane alpha-
helices (fig. 1.4.2; green squares) (Iatmanen-Harbi et al., 2019; Jaremko et al., 
2014). This is thought to prevent transport of cholesterol into the mitochondria. 
Proposed ‘agonists’ probably modulate the activity of TSPO through a different 
mechanism as they increase steroidogenesis, but this is as yet unknown.  
 
Recent studies have shown that PK11195 and Ro5-4864 bind to different amino 
acids in the TSPO structure (fig. 1.4.2) (Farges et al., 1994; Jaremko et al., 2014; 
Liu et al., 2014b). This may suggest that Ro5-4864 causes a unique 
conformational change which promotes cholesterol transport. Interestingly, ligand 
displacement assays suggest that XBD-173 binds to a site more similar to 
PK11195 than Ro5-4864 (Zhang et al., 2007). However, as XBD-173 has 
reported agonistic functions it must also promote channel opening, suggesting 
that while XBD-173 and PK11195 bind to similar sites on TSPO they cause 
different conformational changes (Biswas et al., 2018; Zhang et al., 2007). 
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As with many drugs, TSPO ligands have been shown to have off-target effects, 
with data from BV-2 microglial cells demonstrating that TSPO ligands can 
modulate metabolism in these cells in the absence of  TSPO (Bader et al., 2019). 
At micromolar concentrations, the TSPO ligand PK11195 inhibits ATP synthesis 
by isolated F1F0ATPase, directly mimicking inhibition of F1F0ATPase by 
benzodiazepine Bz-423 (Cleary et al., 2007). This may result in some of the off-
target effects of PK11195 and other TSPO ligands. This is something that must 
be considered when interpreting any ligand-based data as it is apparent that 
TSPO and the ATPase have some homologous domains (Cleary et al., 2007). 
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Figure 1.4.2: A simplified structure of translocator protein 18 kDa (TSPO) 
showing the amino acids involved in binding TSPO ligands. Differences 
in ligand binding indicated by arrows. 
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1.4.3 Functions of TSPO 
In 1977, Braestrup and Squires identified TSPO in the kidney as an alternative 
binding site for the benzodiazepine diazepam (Braestrup & Squires, 1977). It was 
initially named peripheral benzodiazepine receptor (PBR) to distinguish it from 
the central benzodiazepine receptor found on the plasma membrane of some 
neurons (Braestrup et al., 1979; Braestrup & Squires, 1977; Tallman et al., 1978). 
In 2006 it was proposed that PBR should be renamed ‘translocator protein 
(18kDa)’ (TSPO) due to its apparent involvement in the translocation of 
cholesterol across the outer mitochondrial membrane (Papadopoulos et al., 
2006). After initial attempts to create a TSPO knockout mouse line failed it was 
assumed that loss of TSPO was embryonic lethal, but a viable global 
homozygous TSPO knockout mouse line was created in 2014 (Papadopoulos et 
al., 1997; Tu et al., 2014). This proved that functional TSPO expression is not 
essential for survival (Tu et al., 2014) and is supported by findings that knockouts 
in vivo do not lead to an altered genetic profile, phenotype, or metabolic changes 
that are observed in vitro (Banati et al., 2014). 
 
1.4.3.1 Steroidogenesis 
TSPO transports cholesterol into the mitochondria for steroidogenesis. This has 
been shown in multiple studies from independent groups and in many cell types 
including in glial cells (Papadopoulos et al., 2018). TSPO ‘agonists’ increase 
pregnenolone production in mitochondria purified from the brain (Papadopoulos 
et al., 2018; Romeo et al., 1993). This is inhibited by PK11195, suggesting that 
TSPO activity increases neurosteroid production, whilst ‘antagonism’ of TSPO 
reduces neurosteroid production. 
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In recent years as more data has emerged, whether TSPO plays a role in 
steroidogenesis has become a contentious issue and data has been published 
suggesting that TSPO is not essential for cholesterol transport into the 
mitochondria (Fan et al., 2018a; Selvaraj & Stocco, 2018; Selvaraj et al., 2016). 
Despite this on-going debate, TSPO is still believed to play a role in cholesterol 
transport as it contains a cholesterol binding domain, and there is significant 
supporting evidence from multiple publications and research groups (Jaipuria et 
al., 2017; Jamin et al., 2005; Lejri et al., 2019; Li & Papadopoulos, 1998; Murail 
et al., 2008; Musman et al., 2017; Paradis et al., 2013). 
 
1.4.3.2 Inflammation 
TSPO ligands have been shown to be anti-inflammatory in many cell types 
(Horiguchi et al., 2019; Pozzo et al., 2019). However, the evidence for this in 
astrocytes is relatively sparse. TSPO ligands etifoxine, PK11195 and XBD-173 
decrease TLR1/2 and TLR4 induced production of pro-inflammatory cytokines IL-
6 and TNF-α in microglial cells (Lee et al., 2016). This was also demonstrated in 
astrocytes, although XBD-173 did not affect TLR4 stimulated TNF-α release from 
astrocytes. However, in this study TSPO ligands were used at 50 µM regardless 
of their affinity, bioactivity and specificity, so there may be off-target effects at 
these relatively high concentrations. In C6 glioma cells PK11195 reduces 
production of the inflammatory mediator cyclooxygenase 2 (COX2), although 
again this was used at 10 µM, a concentration which has been shown to cause 
off-target effects (Cleary et al., 2007; Santoro et al., 2016).  
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Anti-inflammatory actions of TSPO ligands have also been reported in vivo in 
disease models. In mice, whilst Ro5-4864 and PK11195 reduce microglial 
reactive gliosis, these TSPO ligands did not reduce astrogliosis after LPS-
induced inflammation (Veiga et al., 2007). Intraperitoneal injection of the TSPO 
ligand etofoxine is neuroprotective in mouse models of multiple sclerosis, and 
PK11195 and Ro5-4864 reduce astrogliosis in hyper-phosphorylated tau 
expressing mouse models of Alzheimer’s disease (Barron et al., 2013; Daugherty 
et al., 2013). These data suggest that in vivo TSPO ligands can reduce CNS 
disease severity, but it is unclear whether the primary mechanism is through 
microglia and/or astrocytes. Further to this, there is no data currently available 
from published literature exploring the effect of loss of TSPO on the in vivo 
response to infection. As such, there is clearly more to be understood about the 
role of TSPO in CNS inflammation. 
 
1.4.3.3 Regulation of reactive oxygen species production 
The neuroprotective role of TSPO modulation may in part be due to regulation of 
ROS. TSPO expression is implicated in increasing ROS production, with its 
evolutionary role thought to be mainly related to ROS regulation in part due to 
TSPO acting as an oxygen sensor in bacteria (Batarseh & Papadopoulos, 2010; 
Gatliff et al., 2014; Yeliseev et al., 1997). In addition, colonic cells overexpressing 
Tspo have increased mitochondrial stability and resilience to ROS damage, as 
do cells treated with pharmacological TSPO ‘agonists’ (Issop et al., 2016; Lejri et 
al., 2019). This effect is proposed to be regulated through increased TSPO 
expression as a ratio compared to VDAC1 (Gatliff et al., 2014; Issop et al., 2016). 
However, loss of TSPO from MA-10 steroidogenic cells and treatment with TSPO 
‘antagonists’ such as PK11195 also results in increased ROS production (Lejri et 
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al., 2019; Tu et al., 2016). Together these data suggest that TSPO plays a role in 
regulating ROS production; however, to what end is currently unclear as the data 
available appears to be contradictory. 
 
1.4.3.4 Ca2+ signalling and interaction with VDAC 
TSPO interacts with the VDAC, the principal Ca2+ channel in the OMM (Gatliff et 
al., 2014; Papadopoulos et al., 1994; Shoshan-Barmatz et al., 2019). Loss of 
TSPO results in elevated levels of mitochondrial Ca2+ (Gatliff et al., 2017). 
Furthermore, the interaction between VDAC and TSPO appears to reduce the 
ability of VDAC to transport cytosolic Ca2+ into the mitochondria, leading to an 
accumulation of Ca2+ in the cytosol (Gatliff et al., 2017). This accumulation of Ca2+ 
potentially influences multiple signalling pathways, affecting astrocyte behaviour 
(Bazargani & Attwell, 2016). For example, increases in cytosolic Ca2+ can drive 
release of gliotransmitters such as ATP and glutamate; changes to cellular 
morphology, leading to the upregulation of GFAP associated with astrocyte 
activation; and synapse remodelling (Shigotomi et al., 2019). 
 
The interaction between TSPO and VDAC may play a role in the other functions 
attributed to TSPO. Downregulation of VDAC1 in astroglioma cells using small 
interfering RNA (siRNA) decreases TSPO expression, resulting in reduced cell 
growth and tumour volume (Arif et al., 2016). However, this is not mediated 
through apoptosis, suggesting it is instead through a decrease in cell proliferation, 
which as previously discussed is a proposed role of TSPO (Arif et al., 2016). 
However, it has not been shown what effect TSPO binding has on this role of 
VDAC. 
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1.4.3.5 Cell maintenance and growth 
In addition to regulating cellular inflammation, TSPO also seems to play a role in 
maintaining cell health through the regulation of autophagy. Autophagy is the 
degradation and metabolism of pre-existing cellular structures to generate energy 
or new precursors for biosynthesis (Ravanan et al., 2017). This term is suffixed 
after the structure being degraded e.g. mitophagy is autophagy of the 
mitochondria, whereas lipophagy is autophagy of lipid droplets. Autophagy helps 
to maintain cell health through recycling and regenerating damaged cell 
structures, preventing the accumulation of cell death signals within the cell 
(Ravanan et al., 2017).  
 
In section 1.4.3.3 it was mentioned that TSPO overexpression increases ROS 
production in fibroblasts. Gatliff et al. showed that this overexpression of TSPO 
in fibroblasts also inhibits mitophagy due to excessive phosphorylation of VDAC1, 
resulting in reduced mitochondrial quality (Gatliff et al., 2014). Conversely, in 
tanycytes, pharmacological inhibition or loss of TSPO activates lipophagy (Kim 
et al., 2019). It is suggested that lipophagy is regulated through activation of 
AMPK, which in turn is activated by Ca2+ signalling (Kim et al., 2019). This 
provides evidence that expression of TSPO may restrict autophagy, possibly 
through interaction with VDAC. 
 
TSPO was thought to play a role in apoptosis through regulating the mitochondrial 
permeability transition pore (MPTP) opening (Obame et al., 2007). However, this 
has since been disputed, and the apparent role in apoptosis may instead be due 
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to the role of TSPO in autophagy allowing increased accumulation of pro-
apoptotic proteins (Hurst et al., 2017; Šileikytė et al., 2014). 
 
Data also suggests that TSPO regulates cell proliferation. In breast cancer cells 
TSPO ligands have been shown to decrease cell proliferation, and loss of TSPO 
decreases cell proliferation both in vitro and in vivo (Bader et al., 2019; Mukherjee 
& Das, 2012). Conversely, TSPO overexpression increases cell proliferation and 
motility (Liu et al., 2017b). However, in contrast to previous studies, loss of TSPO 
increased cell proliferation in glioblastoma cell lines and in vivo (Fu et al., 2019). 
This may be related to the difference in the role of TSPO in inflammation in 
astrocytes compared to other cell types. 
 
1.4.3.6 Cell energy metabolism 
There is increasing evidence that TSPO plays an important role in energy 
metabolism; however, its exact role remains unclear. The TSPO ‘antagonist’ 
PK11195 increases expression of metabolic genes including CPT-1A in zebra 
fish in vivo (Gut et al., 2013). This suggests that TSPO acts to decrease fatty acid 
metabolism. This is supported by data that indicate that loss of TSPO increases 
fatty acid oxidation and expression of CPT-1A in MA-10 steroidogenic cells (Tu 
et al., 2016). 
 
There is also published data indicating that TSPO acts to increase mitochondrial 
energy production and OXPHOS rate. Loss of TSPO in mouse microglia 
significantly decreases mitochondrial ATP production and oxygen consumption 
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(Banati et al., 2014). Similarly, TSPO ‘agonists’ including Ro5-4864 increase 
mitochondrial metabolism, mitochondrial membrane potential and glycolysis, 
resulting in increased ATP accumulation in SH-SY5Y cells (Grimm et al., 2019; 
Lejri et al., 2019). Overexpression of TSPO in Jurkat cells increases ETC gene 
expression, including ETC complex IV, which was abated by treatment with 100 
nM PK11195 (Liu et al., 2017b). This results in increased intracellular ATP 
accumulation (Liu et al., 2017b). However, another paper suggests that TSPO 
knockdown in BV-2 cells has no effect on mitochondrial respiration, although it 
has been reported to increase proton leak and decrease coupling efficiency 
(Bader et al., 2019). 
 
Taken together, these data indicate that TSPO plays important regulatory roles 
within the cell. However, the exact role it is playing is yet to be fully elucidated. 
Interestingly it appears to be playing a role in both inflammatory and metabolic 
regulation. Although the underlying mechanism(s) by which this occurs are 
unclear, given the strong evidence for metabolic rate being a critical regulator of 
inflammation it is likely that these are related.  
 
1.4.4 TSPO ligand safety and clinical use 
Due to the variety and importance of possible roles for TSPO, it has become a 
promising drug target for neuropsychiatric disorders, inflammatory conditions and 
cancer (Rupprecht et al., 2010). Some TSPO ligands are already approved for 
use in humans (Owen et al., 2014; Rupprecht et al., 2010; Sridharan et al., 2019): 
etifoxine has been approved as an anxiolytic; XBD-173 has been used in pre-
clinical human studies investigating anxiety and seizures; and radiolabelled 
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PK11195 has mainly been used for PET scanning (Choi & Kim, 2015; Hirvonen 
et al., 2010).  Indeed, the use of TSPO ligands in PET demonstrates their ability 
to cross the BBB, making them appropriate for potential treatment of CNS 
disease. 
 
More data is emerging demonstrating the potential clinical applications of TSPO 
ligands. With studies in mice suggesting that TSPO ligands may be useful for the 
treatment of Alzheimer’s disease, reducing β-amyloid plaques, and TSPO agonist 
etifoxine improving recovery from traumatic brain injury in mice, interest in TSPO 
as a drug target is increasing (Barron et al., 2013; Shehadeh et al., 2019). Novel 
ligands are currently being developed, which are more specific and able to bind 
TSPO regardless of the gene polymorphisms, which has been an issue with 
existing ligands (Alam et al., 2017). An in silico approach is currently being used 
to develop TSPO inhibitors aimed at decreasing cancerous cell proliferation 
(Bhargavi et al., 2017). TSPO ligands may be even more useful therapeutically 
once the function of TSPO has been fully elucidated. 
 
1.5 Summary of introduction 
The data discussed in sections 1.1-1.3 of this chapter demonstrate that 
astrocytes may undergo immunometabolic reprogramming. However, there are 
limited studies that have examined this directly. In many cell types the 
immunometabolic response is in part regulated by NF-κB signalling, and whilst 
NF-κB clearly plays a role in regulating metabolic responses during inflammation 
in astrocytes, to what extent NF-κB regulates the link between inflammation and 
metabolism in astrocytes needs further work. This work is of importance due to 
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the role of astrocytes and CNS inflammation in prevalent neurodegenerative 
diseases, such as Alzheimer’s disease. TSPO, which is upregulated during 
inflammation and neurodegenerative diseases, is emerging as a player in 
metabolic regulation. As TSPO is primarily regulated during inflammation this 
protein has been explored as a therapeutic target for inflammatory disease, 
particularly in the CNS, due to the availability of safe ligands which can cross the 
BBB.  
 
1.6 Aims of investigation 
 Characterise the metabolic responses to inflammation in astrocytes. 
 Establish the role of NF-κB signalling in immunometabolic responses in 
astrocytes. 
 Investigate a potential role of TSPO in astrocyte metabolism. 
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Chapter 2. Methods 
 
2.1 Materials 
2.1.1 Equipment 
Table 2.1.1 List of instruments and suppliers 
Instrument Company 
PHERAstar FS BMG LABTECH 
Seahorse XFe96 Analyser Agilent 
DM4000B-M widefield microscope Leica 
DMi8 confocal microscope Leica 
BD Accuri C6 Plus Flow Cytometer BD Biosciences 
SimpliAmp Thermocycler Applied Biosystems 
Mini-PROTEAN tetra vertical handcast 
protein electrophoresis systems 
Bio-Rad 
Wide mini-sub cell GT cell nucleic acid 
electrophoresis system 
Bio-Rad 
GelMax Imager UVP 
TC20 Automated cell counter Bio-Rad 
Odyssey CLx imaging system Li-Cor 
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2.1.2 Reagents 
Unless listed in table 2.2, all reagents were purchased from Sigma-Aldrich (part 
of Merck, UK) or ThermoFisher Scientific (UK).  
Table 2.1.2 List of reagents not sourced from ThermoFisher (UK) or Sigma-
Aldrich (UK) 
Chemical Supplier 
Acrylamide National diagnostics 
ATPLite two step kit Luminescence assay system Perkin Elmer 
Bio-Rad Protein Assay Dye Reagent BioRad 
Bovine Serum Albumin, Fatty Acid Free (FAF-BSA) Roche 
DuoSet ELISAs Bio-Techne 
FCCP Cambridge Bioscience 
Fluoroshield mounting medium Abcam 
Foetal Bovine Serum (FBS) Seralabs 
GelRed BIOTIUM 
Glycolytic Stress Test Agilent 
Glucose Uptake-Glo Promega 
Hanks Balanced Salt Solution (HBSS) Gibco 
L-Glutamate Gibco 
Mitotracker CMXRos Invitrogen 
Mito Stress Test Agilent 
Odyssey blocking buffer Li-Cor 
Penicillin-Streptomycin Gibco 
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Phosphate buffered saline Oxoid 
PK11195 Tocris 
Precision Plus Protein Dual Colour standards BioRad 
Primers IDT 
Protein G dynabeads Invitrogen 
Seahorse XF media Agilent 
Sucrose Melford 
Tetramethylrhodamine ethyl ester (TMRE) Cambridge Bioscience 
TPCA-1 Tocris 
Tris Melford labs 
Trypsin 0.05% Gibco 
Trypsin – phenol red free, 2.5% Gibco 
11966 DMEM (No Glucose) Gibco 
 
2.1.3 Animals and ethics 
All animal studies were conducted in accordance with the UK Animals in Scientific 
Procedures Act 1986 (ASPA) and study plans were approved by the institutional 
Animal Welfare and Ethical Review Body at the University of Exeter. Mouse pups 
(postnatal day 1-5) were used to produce cultures of primary astrocytes from the 
cortex; offspring of both sexes were used. Pups from breeding pairs of C57BL6/J 
mice (Charles River, UK) were used for non-genetically modified (GM) astrocytes. 
Pups from breeding pairs of heterozygous C57BL/6NTac Tspotm1b(EUCOMM)Wtsi 
(HMGU-EPD0803_2_H02-2-1; Infrafrontier, UK) mice were used for breeding. 
Homozygous TSPO knockout (TSPO-/-) mice were used to culture TSPO-
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deficient primary cortical astrocytes as described in section 2.2.2, with 
homozygous TSPO expressing littermates used as wildtype (TSPO+/+) controls. 
Mice were group housed on a 12:12 light-dark cycle at 22 ± 2 °C, with unlimited 
access to standard laboratory rodent diet (EURodent diet [5LF2], LabDiet, UK) 
and water. 
 
2.2 Methods 
2.2.1 Genotyping 
Genotypes of animals in the TSPO colony were determined using a polymerase 
chain reaction (PCR) and agarose gel electrophoresis. Tissue was biopsied from 
the tails of the pups immediately after euthanasia, or from the ear of living adult 
animals. Tissue was digested at 55 °C for 5 hours in PCR sample digestion buffer 
with non-ionic detergents (50 mM KCl, 10 mM Tris- HCl [pH 8.0], 2.5 mM MgCl2-
6H2O, 0.1 mg/mL gelatine, 0.45% v/v Nonidet P40, 0.45% v/v Tween-20, 1% v/v 
proteinase K) prior to heating at 95 °C for 10 minutes. PCR reaction mix was 
made as detailed in table 2.2.1.1 and PCR was run as detailed in table 2.2.1.2. 
A negative control reaction containing water instead of DNA digest was run with 
every PCR. 5 µL PCR product was run on agarose gel (1.5% w/v 1X TAE: 40 mM 
Tris Acetate [pH 6.8], 1 mM EDTA) with 0.05% GelRed (Biotum, UK; # 41003). 
GeneRuler 1 kb Plus DNA ladder (ThermoFisher, UK; # SM1333) was used to 
estimate size of bands. The presence of the higher band (~244 kb) only indicated 
a TSPO -/- mouse, the lower (~188 kb) band only indicated TSPO +/+ mouse and 
the presence of both bands indicated TSPO +/- mouse (fig. 2.2.1). TSPO +/- mice 
were not used for this study. 
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Table 2.2.1.1 Genotyping reaction composition 
Component  Volume (µL)  
2X DreamTaq green PCR master mix (Thermo, UK; # 
K1081)  
10  
DNA-Free water  6  
5’ arm primer 5’>3’ [AGCAGAAGTAGGAAGAAGGTG]        
(10 pmol/µL) 
1  
3’ arm primer 5’>3’ [GTCAACCCATCACTGCCTTCA]         
(10 pmol/µL) 
1  
LAR3 primer 5’>3’ [CAACGGGTTCTTCTGTTAGTCC]        
(10 pmol/µL) 
1  
DNA digest (50-100 ng) 1  
Total volume 20  
 
 
Table 2.2.1.2 Polymerase chain reaction cycling conditions 
Temp (°C)  Time  # cycles  
95  5 minutes  1  
94  30 seconds  
39  65  45 seconds 
72  45 seconds  
72  10 minutes  1  
4  Hold  1  
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Figure 2.2.1: An example electrophoresis gel of TSPO colony 
genotyping results. DNA was extracted from ear or tail biopsies using PCR 
sample digestion buffer with non-ionic detergents and proteinase K. After PCR 
amplification the PCR product was separated and visualised using a 1.5% 
agarose electrophoresis gel with 0.05% GelRed. Band at 244 kb denotes 
TSPO -/- (KO) animals, 188 kb denotes TSPO +/+ (WT) animals, and double 
bands denote TSPO +/- (Het) animals. 
100 
 
2.2.2 Primary astrocyte isolation and cell culture 
Mouse primary cortical astrocytes were isolated using the method described by 
Schildge et al. (Schildge et al., 2013). Briefly, pups (post-natal days 1-5) were 
decapitated in a regulated procedure and brains were removed from skulls. 
Forceps were used to blunt dissect brain to remove the cerebellum and 
hypothalamus. Cortical regions were chopped into smaller sections and digested 
in 0.5% w/v trypsin-EDTA in Hank’s Balanced Salt Solution (HBSS) for 30 
minutes at 37 °C with gentle agitation every 2-3 minutes. Trypsin was neutralised 
in supplemented Dulbecco’s Modified Eagle’s Media (DMEM; 25 mM glucose, 8 
mM L-glutamate, 10% v/v foetal bovine serum (FBS), 200 U/mL penicillin-
streptomycin) and cells were mechanically dislodged from cerebral membranes 
using repeated pipetting motions. 
 
For culturing isolated cells, plastics were coated with poly-L-lysine (PLL; 4 µg/mL) 
by 30 minute incubation at room temperature and washed with PBS prior to 
seeding cell suspensions. Non-GM mouse primary astrocyte cultures were 
seeded at 2-3 brains in T75 flasks. GM mouse primary astrocytes were seeded 
at 1 brain per T25 flask. As previously described (Vlachaki Walker et al., 2017), 
cultures were maintained in DMEM containing 25 mM glucose and supplemented 
with 10% v/v FBS (Seralabs), 200 U/mL penicillin-streptomycin and 8 mM L-
glutamine. Media was replaced every 2-3 days. Cultures were maintained in a 
humidified incubator at 37 °C with 5% CO2. Astrocytes were left to grow until 
100% confluent. 
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Once confluent, cells were dissociated with trypsin (0.05% w/v) from culture 
flasks. After neutralisation of trypsin with media, cell suspensions were 
centrifuged at 100 xg for 5 minutes at room temperature and excess trypsin was 
removed. After this step non-GM cells were seeded for experimentation as 
described below. Once confluent, GM cells were frozen in 10% dimethylsulfoxide 
(DMSO) and 90% supplemented DMEM at -80 °C and stored in liquid nitrogen 
until use. For experimentation, homozygous cells of the same genotype were 
defrosted and centrifuged at 100 xg for 5 minutes at room temperature. Excess 
DMSO containing media was removed. Cells were combined to 3 cultures per 
T75 and allowed to grow to 100% confluence prior to dissociation with trypsin 
(0.05% w/v), centrifugation at 100 xg for 5 minutes and removal of trypsin and 
seeding for experiments as described below.  
 
Prior to experimentation cells were seeded on PLL coated plasticware at an 
appropriate density as described for the experiment in the relevant section. The 
TC20 Automated Cell Counter (Bio-Rad, UK) was used to quantify cell numbers 
for seeding for experiments. 24 hours prior to experimentation cells were 
maintained in DMEM (Gibco) supplemented with 10% v/v FBS, 200 U/mL 
penicillin-streptomycin, 8 mM L-glutamine and 7.5 mM glucose. On the day of 
experimentation cells were cultured in serum free DMEM (Gibco) containing 2.5 
mM glucose. Immunocytochemistry was used to confirmed that mature cultures 
contained >99% GFAP-immunoreactive glial cells, as described in section 2.2.5 
(fig. 2.2.2).  
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Figure 2.2.2: Cultures taken from mouse brains were mainly GFAP 
expressing cells. Glial cells were seeded at a density of 1 x 105 cells per well 
on glass coverslips in 24 well plates prior to fixation with 4% paraformaldehyde 
and immunostaining.  A. GFAP (Cyan) and IBA-1 (Magenta) immunostaining 
of primary glial culture. 99.7% of nuclei (DAPI; blue) were associated with 
GFAP-immunoreactivity (n=12; 3 images per coverslip across 4 coverslips). 
B. Example images of no first layer (primary antibody) negative control. Scale 
bars = 50 µm. 
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2.2.3 Human astroglioma cell line (U373) culture 
Human astroglioma U373 cells were sourced from Sigma-Aldrich (UK). The U373 
TSPO deficient cells were created by Daisy Stewart (a professional training year 
student) under the supervision of Dr Rosie Bamford and Dr Asami Oguro-Ando 
using CRISPR-Cas9 technology to knock out the TSPO gene through 
introduction of double strand breaks in exon 2. Non-genetically modified cells 
were continuously cultured in T75 sterile flasks up to p30 in stock DMEM to 
maintain passage equivalent controls which were transfected with a control 
empty vector. Genetically modified TSPO KO U373 line and the paired empty 
vector (EV) control line were used indefinitely, but for experiments presented in 
this work were p50-60. Although the high passage number generated is not ideal, 
due to the nature of CRISPR-Cas9 genetic modification this could not be avoided. 
However, a stable total knockout generated by CRISPR-Cas9 was preferable to 
a transient and partial knock down generated by siRNA, which would be an 
alternative method. 
 
U373 cultures were maintained in DMEM containing 25 mM glucose and 
supplemented with 10% v/v FBS (Seralabs; UK), 200 U/mL penicillin-
streptomycin and 8 mM L-glutamine. Cells were passaged when at approximately 
70% confluence. During passage, cells were washed with 0.01 M PBS before 
being dissociated with trypsin (0.05% w/v) at 37 °C. Cells were centrifuged at 100 
xg for 5 minutes at room temperature and excess trypsin was removed. 25-30% 
of the cell suspension was seeded into new T75 flasks to maintain the culture. 
Cells were seeded on plasticware at an appropriate density 24 hours prior to 
experimentation. The TC20 Automated Cell Counter (Bio-Rad, UK) was used to 
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quantify cell numbers for seeding. Cells were maintained after seeding for 
experimentation in DMEM (Gibco) supplemented with 10% v/v FBS, 200 U/mL 
penicillin-streptomycin, 8 mM L-glutamine and 7.5 mM glucose. On the day of 
experimentation cells were cultured in serum free DMEM (Gibco) containing 2.5 
mM glucose. 
 
2.2.4 Cell treatments 
LPS (E. coli O26:B6) was conjugated to 0.17 mM fatty acid free bovine serum 
albumin [BSA (Roche, UK)] in 150 mM NaCl for 1 hour prior to treatment of cells. 
BSA was adjusted to pH 7.4 at 37 °C with 1 N NaOH. BSA conjugated LPS or 
BSA vehicle were diluted 1:10 into DMEM to give a final concentration of 1 µg/mL 
LPS and 0.017 mM BSA. Where used, TPCA-1 (1 µM; Tocris, UK; IKK-β inhibitor; 
IC50 17.9 nM) (Podolin et al., 2005) was diluted in 0.1% v/v DMSO vehicle 2 hours 
prior to additional treatments. 2-deoxyglucose (2-DG; 10 mM) diluted in ddH2O 
was applied 1 hour prior to additional treatments, when used. Where TSPO 
ligands were used, cells were pre-treated with PK11195 (25 nM; Tocris, UK; IC50 
2.2 – 5.65 nM) (Cleary et al., 2007; James et al., 2006; Kita et al., 2004) or XBD-
173 (25 µM; Sigma, UK; IC50 2.73-3.04 nM) (Kita et al., 2004) made up in 0.1% 
v/v DMSO vehicle for 1 hour prior to additional treatment. 
 
2.2.5 Immunocytochemistry and culture purity 
For immunocytochemical staining, mouse primary astrocytes were plated on 
sterile PLL coated 13 mm diameter glass coverslips at a density of 1 x 105 
cells/coverslip. After treatment, cells were fixed with 4% w/v paraformaldehyde 
for 30 minutes at 37 °C and permeabilised for staining by treatment with lysine 
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block (0.01 M PBS, 0.02% v/v Triton-X100, 2% w/v lysine) for 15 minutes at room 
temperature. Purity of the mouse primary astrocyte culture was confirmed using 
mouse anti-GFAP (1:1000; Millipore; UK; #MAB360) and goat anti-IBA1 (1:1000; 
Abcam; UK; #ab5076) immunoreactivity. Both primary and secondary antibodies 
were diluted in lysine block. Fixed and permeabilised cells were incubated with 
each primary antibody overnight (~18 hours) at 4 °C, sequentially. After 
incubation with GFAP primary antibody, coverslips were incubated with 
fluorescent secondary donkey anti-mouse Alexafluor488 (1:500; Invitrogen; UK; 
#A-21202) for 1 hour at room temperature. After incubation with IBA1 antibody 
overnight, fixed cells were incubated with fluorescent secondary donkey anti-goat 
Alexafluor594 (1:500; Invitrogen; UK; #A-11058) for 1 hour at room temperature. 
Both between and after antibody incubations, fixed cells were washed three times 
for 5 minutes with 0.01 M PBS to remove unbound antibody. Nuclei were stained 
with DAPI at room temperature for 5 minutes (0.01 mg/mL, 0.01 M PBS). 
Coverslips were briefly washed in H2O, mounted in Fluoroshield Mounting 
Medium (Abcam; UK) and allowed to dry prior to imaging using wide-field 
microscopy (DM4000B-M; 10x/0.30; Leica; UK).  FIJI Cell Counter plugin (Fiji Is 
Just ImageJ; (Schneider et al., 2012; Schindelin et al., 2012) was used to 
manually count nuclei associated with GFAP or IBA-1 staining. 
 
2.2.6 Mitochondrial network characterisation 
Mitochondrial networks were visualised using mitochondrial dye Mitotracker Red 
CMXRos (Invitrogen; UK). Cells were seeded on 13 mm diameter glass 
coverslips at a density of 1 x 105 cells/coverslip. Staining was carried out before 
treatment and fixation. Cells were stained with 100 nM Mitotracker Red CMXRos 
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in DMEM (serum free, 2.5 mM glucose) for 15 minutes at 37 °C. Cells were then 
washed with PBS and subjected to treatment conditions. After treatment, cells 
were fixed with 4% w/v paraformaldehyde for 30 minutes at 37 °C and 
permeabilised for staining by treatment with lysine block (0.01 M PBS, 0.02% v/v 
Triton-X100, 2% w/v lysine) for 15 minutes at room temperature. Nuclei were 
stained with DAPI (0.01 mg/mL, 0.01 M PBS) for 5 minutes at room temperature. 
Coverslips were briefly washed with H2O, mounted in Fluoroshield Mounting 
Medium (Abcam; UK) and allowed to dry prior to imaging. 
 
Cells were imaged individually by confocal microscopy (DMi8; Leica, UK) using 
the x64 oil immersion lens (1x magnification). The number and length of objects 
in the red channel of the processed images were quantified using a custom-
written MatLab program (modified from root script provided by Dr John Chilton; 
Appendix 1). Data from this processing was analysed using Prism (v5). 
 
2.2.7 Cell viability assay 
Cells were seeded at a density of 3.5 x 105 cells/well in 6 well plates. After 24 
hours of treatment (described above in section 2.2.4) cells were dissociated with 
0.05% w/v trypsin-EDTA and transferred to flow cytometry tubes where trypsin 
was neutralised with fluorescence activated cell sorting (FACS) buffer (2% v/v 
FBS in 0.01 M PBS). Cells were centrifuged at 100 xg for 5 minutes at room 
temperature and the supernatant was aspirated. Cells were resuspended in 
FACS buffer and stained with propidium iodide (2 µg/mL), which is taken into cells 
with disrupted membranes, for 10 minutes at 4°C. Uptake of dye was determined 
using flow cytometry (BD Accuri C6; BD Systems; UK). Data was collected with 
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the 488 nm wavelength laser with the 585/40 nm filter. Increased uptake 
representing dead or dying cells. The gating used to identify the number of alive 
vs dead cells is shown as part of the relevant figures. Cell sized objects were first 
defined using forward scatter (FSC) and side scatter (SSC), and any events too 
small to be cells were excluded from further analysis. A second region of interest 
on a second plot was defined using fluorescence, and events with high 
fluorescence relative to cell size as determined using the 488 nm laser combined 
with FSC were classified as dead cells. 
 
2.2.8 Protein isolation 
Cells were plated at a density of 4.5 x 105 cells per 60 mm diameter dish. After 
treatment cells were washed with 0.01 M PBS to remove excess BSA (if 
appropriate). Cells were lysed and protein isolated using modified RIPA buffer 
and mechanical scraping on ice (table 2.2.8). Lipids were removed with 
centrifugation at 1.3 x 104 xg at 4 °C for 20 minutes. 
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Table 2.2.8 Modified RIPA buffer 
Reagent Concentration (mM) 
Tris HCL pH 7.4 25 
NaF 50 
NaCl 100 
EDTA pH 8 1 
EGTA pH 8 5 
Triton 100x 1% 
NaPPi 10 
Sucrose 270 
2-Mercaptoethanol 0.1% 
Sodium orthovanadate 1 
Benzamidine 1 
Phenylmethylsulfonyl fluoride 0.1 
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2.2.9 Protein estimation 
Protein content was estimated using the Bradford method according to the 
manufacturer’s instructions (BioRad; UK). Briefly, between 1 and 3 µg of sample 
protein were loaded per well in triplicate wells. This was usually between 0.3 and 
1 µL of protein lysate from a 60 mm dish, or 10-30 µL of lysate from a seahorse 
plate well. Increasing protein concentrations in triplicate were used to create a 
standard curve of 0, 1, 2 and 3 µg BSA with the same volume of solution used to 
lyse cells as was present in the protein lysate loaded. 200 µL of Protein Assay 
Dye Reagent (20% v/v in water) was added per well and the plate was agitated 
for 5 minutes at 500 rpm in the PHERAstar FS (BMG LABTECH; UK) prior to 
measuring absorbance at 595 nm. 
 
2.2.10 Immunoblotting 
Lysates were diluted to 1 µg/µL in sample buffer (125 mM Tris/HCl [pH 6.8], 4% 
w/v sodium dodecyl sulphate, 20% v/v glycerol, bromophenol blue). Gels were 
hand cast within 5 days of immunoblotting (table 2.2.10.1). 10 µg protein was 
loaded per lane and proteins were separated on a 12% v/v resolving acrylamide 
gel with approximately 1 cm 4% v/v stacking acrylamide gel using SDS-PAGE 
(150 V, ~1 hour 20 minutes), and transferred to nitrocellulose membranes (0.45 
nm pore; 100 V, 1 hour 10 minutes). 5 µL Precision Plus Protein Dual Colour 
standards (BioRad; UK) were run on all gels and used to estimate protein size.  
 
For immunoblotting, membranes were blocked for 1 hour in Odyssey Blocking 
Buffer (TBS; Licor; UK). Primary antibodies against proteins of interest were 
made up in 2.5% w/v milk powder or 2.5% w/v BSA in 0.01 M Tris-buffered saline 
110 
 
with 0.1% v/v Tween-20 (TBS-T) as detailed in table 2.2.10.2 and incubated with 
the membranes overnight at 4 °C. The relative fluorescence of GAPDH was used 
as a loading control. Antibodies against GAPDH were incubated with membranes 
for 1 hour at room temperature (see table 2.2.10.2 for further details). Between 
antibody binding steps, blots were washed three times for 5 minutes with TBS-T. 
Bound antibody was detected with species specific fluorescent antibodies, 
incubated with membranes for 1 hour at room temperature (see table 2.2.10.2 
for further details). Protein was visualised using the Li-Cor Odyssey CLx imaging 
system. Fluorescence from detected protein was estimated with Image Studio 
software (V5.2; Li-cor; UK). Data was normalised to GAPDH expression and 
again as a fold change from the mean of control groups. Full representative blots 
are shown in Appendix 1. 
 
 
 
 
Table 2.2.10.1 Immunoblotting gel formulation 
2 x Gels   4% v/v acrylamide   12% v/v acrylamide 
H2O   2.8 mL   3.42 mL 
1.5 M Tris (lower buffer)     3.15 mL   
0.5 M Tris (upper buffer)   1.25 mL   
30% v/v Acrylamide   850 µL 4.48 mL   
10% w/v SDS   50 µL 110 µL 
20% w/v APS   50 µL 55.4 µL   
TEMED   5.35 µL   11 µL  
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2.2.11 Cell culture media cytokine concentrations 
Cells were plated at a density of 4.5 x 105 cells per 60 mm diameter dish. Media 
was collected from cells after treatment and cytokine concentrations determined 
using DuoSet ELISAs (BioTechne; UK) against mouse TNF-α, IL-6 and IL-10 as 
per the manufacturer’s instructions. Media taken from cells was undiluted for IL-
6 and IL-10 ELISA and diluted 1:2 for TNF-α ELISA. Cytokine concentrations 
were normalised to protein concentration, collected and estimated using the 
Bradford method (BioRad; UK) as described in sections 2.2.8 - 2.2.9.   
 
2.2.12 Metabolic analyses 
The metabolic rate of cells was determined by measuring extracellular 
acidification rate (ECAR) as a measure of glycolysis, and oxygen consumption 
rate (OCR) as a measure of mitochondrial function using the Seahorse Metabolic 
Bioanalyser XFe96 (Agilent; UK). The day before treatment cells were plated in 
96-well Agilent Seahorse Culture plates (Agilent; UK) at 4 x 104 cells per well in 
supplemented DMEM (10% v/v FBS, 200 U/mL penicillin-streptomycin, 8 mM L-
glutamine and 7.5 mM glucose). After treatment, and 1 hour prior to 
experimentation, media was replaced with Seahorse XF DMEM medium (pH 7.4; 
Agilent; UK) supplemented with either L-glutamine (2 mM; Glycolytic Stress Test) 
or L-glutamine (2 mM); glucose (2.5 mM); and sodium pyruvate (2.5 mM; Mito 
Stress Test). Cells were incubated for 1 hour at 37 °C in a humidified non-CO2 
incubator. Glycolysis and oxidative metabolism were determined using Glycolytic 
Stress Tests and Mito Stress Tests respectively, as per the manufacturer’s 
instructions (Agilent, UK). Fatty acid oxidative metabolism was measured using 
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a modified Mito Stress Test following instructions provided by the manufacturer 
(Agilent, UK). Drugs were diluted in media as appropriate for the assay used. 
 
2.2.12.1 Glycolytic Stress Test 
This assay measures the normal glycolytic rate of cells by introducing a surplus 
of glucose as a substrate. Glycolytic capacity is also measured in this assay by 
preventing oxidative phosphorylation through inhibiting ATP synthase with 
oligomycin, and so forcing the cells to use glycolysis as an alternative source of 
energy production. The difference between these two measures is the glycolytic 
reserve of the cell. Cells were treated sequentially with glucose (10 mM), 
oligomycin (1 µM), and 2-DG (50 mM). Glycolytic rate describes the highest 
ECAR measurement after addition of glucose (fig. 2.2.12.1). Glycolytic capacity 
describes the maximum ECAR measurement after addition of oligomycin (fig. 
2.2.12.1). Glycolytic reserve was calculated as the difference between glycolytic 
capacity and glycolytic rate (fig. 2.2.12.1). 
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Figure 2.2.12.1: Schematic of parameters used for metabolic 
calculations from the Glycolytic Stress Test. Extracellular acidification rate 
(ECAR) was the output measure of this assay. Dotted lines indicate points of 
drug/substrate injection. 2-DG (2-deoxyglucose). Blue line represents 
example data. 
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2.2.12.2 Mito Stress Test 
This assay measures the capability of cells to use OXPHOS through measuring 
OCR. Cells were treated sequentially with oligomycin (0.5 µM; Complex V 
inhibitor), carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP; 1 µM; 
OXPHOS uncoupler) and rotenone with antimycin A (R/A; 0.5 µM; Complex I and 
III inhibitors respectively). Basal respiration was calculated as OCR immediately 
prior to addition of oligomycin minus the lowest measurement after addition of 
R/A. ATP production was calculated as the difference between basal respiration 
and the lowest OCR measurement after addition of oligomycin. Proton leak was 
calculated as the difference between the lowest OCR measurement (after 
addition of oligomycin) and the lowest OCR measurement after addition of R/A. 
Maximal respiration was calculated as the maximum OCR measurement after 
FCCP addition, minus the lowest OCR measurement after R/A addition. Spare 
capacity was calculated as the difference between basal respiration and maximal 
respiration. Coupling efficiency was ATP production as a percentage of basal 
respiration (fig. 2.2.12.2). 
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Figure 2.2.12.2: Schematic of parameters used for metabolic 
calculations from the Mito Stress Test. Oxygen consumption rate (OCR) 
was the output measure of this assay. Dotted lines indicate points of drug 
injection. Blue line represents example data. 
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2.2.12.3 Baseline metabolism experiments  
On the day of the experiment, treatment media was made up (2.5 mM glucose, 
2.5 mM sodium pyruvate, 2 mM L-glutamine, in XF basal media) and pH was 
adjusted to 7.4 at 37 °C with NaOH and HCl. Cells were washed with 0.01 M PBS 
and 180 µL treatment media added per well. Cells were ‘de-gassed’ at 37 °C in a 
humidified non-CO2 incubator for 1 hour prior to the start of the experiment. A 
cartridge was loaded with the appropriate amounts of treatment for injection (if 
used) and loaded for calibration at the start of the 1 hour de-gas. No commercial 
kits were used in these experiments. 
 
2.2.12.4 Fatty acid oxidation Mito Stress Test  
This assay measures the ability of a cell to use fatty acids for respiration. Through 
depriving the cells of other metabolic substrates overnight and providing the cells 
with carnitine, the cells can use fatty acid oxidation and are prevented from using 
glucose and glucose stores to fuel OCR. Further to this, a control group is treated 
with etomoxir to inhibit transport of acyl-coA into the mitochondria by CPT-1 to 
give a negative control group. The respiration rate of this control group can be 
removed from the experimental group to give an OCR which is only driven by 
fatty acid oxidation (fig. 2.2.12.4). 
 
Cells were plated at 4 x 104 cells/well 48 hours prior to experimentation. 24 hours 
prior to experimentation media was replaced with substrate limited media (11966 
DMEM, 0.5 mM glucose, 1 mM glutamate, 0.5 mM carnitine and 1% FBS). 45 
minutes prior to experimentation the cell’s media was replaced with fatty acid 
oxidation media (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 
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mM NaH2PO4, 2.5 mM glucose, 0.5 mM carnitine and 5 mM HEPES; pH adjusted 
to 7.4 at 37 °C). 15 minutes prior to loading into the machine half of the cells were 
treated with CPT-1 inhibitor etomoxir (40 µM). Immediately prior to loading the 
plate into the machine, half of the etomoxir treated cells and half of the control 
cells were treated with palmitate (200 µM; 0.17 mM BSA). Cells were treated 
sequentially with oligomycin (0.5 µM), carbonyl cyanide-4 (trifluoromethoxy) 
phenylhydrazone (FCCP; 1 µM) and rotenone with antimycin A (R/A; 0.5 µM). 
Basal fatty acid oxidation was calculated as the difference between the [palmitate 
+ etomoxir] group and the [palmitate – etomoxir] group immediately prior to 
oligomycin injection (fig. 2.2.12.4). Maximal fatty acid oxidation was calculated 
as the difference between the [palmitate + etomoxir] group and the [palmitate – 
etomoxir] group at the highest OCR rate after FCCP treatment (fig. 2.2.12.4). 
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Figure 2.2.12.4: Schematic of parameters used for metabolic 
calculations from the Fatty Acid Oxidation Mito Stress Test. Oxygen 
consumption rate (OCR) was the output measure of this assay. Dotted lines 
indicate points of drug injection. Blue lines represent example data. Treatment 
groups were provided with palmitate conjugated to bovine serum albumin 
(Palm:BSA) as a substrate prior to the start of the assay.  
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2.2.13 Glucose uptake rate measurement 
Cellular glucose uptake was determined using Glucose Uptake-Glo kit (Promega) 
following the manufacturer’s instructions. Briefly, cells were plated at 4 x 104 
cells/well in 96-well plates. On the day of the experiment cells were treated as 
appropriate. After treatment cells were washed with 0.01 M PBS twice and PBS 
was removed. 10 µM 2-DG in 0.01 M PBS was added with omission of 2-DG used 
as a negative control. Reaction was stopped with stop buffer and neutralisation 
buffer prior to addition of detection reagent. Luminescence was measured after 
30 minutes incubation in detection reagent using the PHERAstar plate reader 
(BMG LABTECH; UK). Data are shown as fold change from the mean of 
contemporaneous control groups. 
 
2.2.14 Intracellular ATP measurements 
Intracellular ATP concentrations (iATP) were quantified using the ATPLite Two 
Step kit (PerkinElmer; UK) following the manufacturer’s instructions with 
modifications as previously described (Vlachaki Walker et al., 2017). Briefly, cells 
were seeded at 4 x 103 cells/well in a black 96-well plate. After treatment, cells 
were washed with 100 µL PBS. 40 µL DMEM was added to each well and cells 
were lysed with 40 µL mammalian lysis buffer and agitated at 500 rpm for 5 
minutes on the PHERAstar plate reader. 80 µL ATPLite luciferase reagent was 
added to each well and the plate was dark adapted and agitated at 500 rpm on 
the PHERAstar for 10 minutes prior to measurement of luminescence. Data are 
shown as fold change from the mean of contemporaneous control groups. 
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2.2.15 Mitochondrial membrane potential 
Mitochondrial membrane potential was determined using tetramethylrhodamine 
ethyl ester (TMRE) dye uptake. Cells were plated in 6-well plates at 3.5 x 105 
cells/well. After treatment (as appropriate), cells were dissociated using 0.05% 
w/v trypsin-EDTA. Cells were transferred to flow cytometry tubes, and trypsin was 
neutralised with FACS buffer (2% v/v FBS in 0.01M PBS). Cells were centrifuged 
at 100 xg for 5 minutes at room temperature and the supernatant was aspirated. 
Treatment for 15 minutes with the positive depolarisation control FCCP (10 µM; 
0.04% v/v DMSO vehicle in FACS buffer) at 37 °C prior to TMRE dye uptake was 
used as an indicator of mitochondrial depolarisation. Cells were resuspended and 
incubated with TMRE (100 nM) in 0.04% v/v DMSO vehicle and FACS buffer for 
30 minutes at 37 °C prior to centrifugation, aspiration of supernatant and 
resuspension in FACS buffer. Cellular fluorescence was determined using flow 
cytometry (BD Accuri C6; BD Systems; UK). Data was collected with the 488 nm 
wavelength laser with the 585/40 nm filter. Increased dye uptake correlates with 
increased mitochondrial polarisation. Example gating is shown in Appendix 5. 
Cell sized objects were first defined using FSC and SSC, and any events too 
small to be cells were excluded from further analysis. A second region of interest 
on a second plot was defined using fluorescence using the 488 nm laser. Cells 
treated with 0.04% v/v DMSO and no TMRE were used to define unstained cells. 
Region of interest M2 was determined as fluorescence intensity greater than the 
fluorescence intensity from the TMRE untreated control group. Mean 
fluorescence of events counted in M2 (Plot 2) was taken as fluorescence of 
treatment group. Data are shown as fold change from the contemporaneous 
mean of vehicle treated control groups. 
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2.2.16 Immunoprecipitation 
Cells were seeded at 3 x 106 cells/dish in 150 mm dishes and cultured for 24 
hours prior to collection. Media was aspirated and cells washed with PBS. Cells 
were lysed with 500 µL ice cold immunoprecipitation lysis buffer (table 2.2.16.1) 
and homogenised using a Dounce glass homogeniser (30 turns). Supernatant 
was centrifuged at 1,000 xg for 10 minutes at 4 °C. Supernatant was kept, and 
the protein content quantified using the Bradford method according to the 
manufacturer’s instructions (BioRad, UK) as described in section 2.2.9.  
Protein G dynabeads (Invitrogen, UK) were washed with 0.02% v/v PBS-Tween 
and incubated with 200 µL primary antibody (at the appropriate concentrations; 
table 2.2.16.2) in 0.02% v/v Tween-20 (0.02% PBS-T: 0.01 M PBS) for 1 hour at 
room temperature on a rotary mixer. Supernatant was discarded and the 
dynabeads were washed 3 times with 0.02% PBS-T and transferred to a new 
tube. Dynabeads were incubated with 400 µg protein diluted in 0.01% v/v n-
dodecyl-beta-maltoside (0.01% PBS-DBM: 0.01 M PBS) for 2 hours at 4 °C on a 
rotary mixer. Supernatant was removed to a fresh tube and 50 µL sample buffer 
(125 mM Tris/HCl [pH 6.8], 4% w/v sodium dodecyl sulphate, 20% v/v glycerol, 
bromophenol blue) added to the supernatant and incubated at 70 ºC for 5 
minutes. Dynabeads were washed 3 times with 0.01% PBS-DBM and transferred 
to a fresh tube. Bound protein was eluted from the dynabeads by incubation at 
70 °C for 5 minutes in 50 µL sample buffer (125 mM Tris/HCl [pH 6.8], 4% w/v 
sodium dodecyl sulphate, 20% v/v glycerol, bromophenol blue). Proteins in the 
samples were then identified using the immunoblotting method (described in 
section 2.2.10) to probe for presence of proteins of interest. 
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Table 2.2.16.1 Immunoprecipitation lysis buffer 
Compound Concentration (mM) 
Sucrose 320 
EGTA 1 
Tris-HCl (pH 7.8) 10 
Β-mercaptoethanol 0.1% 
Sodium orthovanadate 1 
Benzamidine 1 
Phenylmethylsulfonyl fluoride 0.1 
 
 
 
 
 
 
Table 2.2.16.2 Antibodies used for immunoprecipitation 
Antibody 
target 
Species Catalogue 
number 
Supplier Conc.  
TSPO Goat NB100-41398 Novus 1:200 (2 µg/mL) 
CPT-1A Mouse 66039-1-Ig ProteinTech 1:500 (4 µg/mL) 
N/A  Goat (IgG) I-5000 Vector 2 µg/mL 
N/A Mouse (IgG2A) X0943 Dako 4 µg/mL 
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2.3 Data presentation and statistics 
Data were processed using Microsoft Excel 2013. GraphPad Prism 8 was used 
to present data and for statistical analyses. For comparisons between two groups, 
unpaired t-tests were used. For multiple comparisons, one-way ANOVA with post 
hoc Tukey’s tests were used. For multiple comparisons between two independent 
variables, two-way ANOVA with post hoc Sidak’s tests were used. A minimum of 
3 independent replicates were used for each study. For studies using the 
Seahorse Metabolic Analyser 2-3 independent plates were used, and individual 
wells were used as separate experiments. Data are presented as mean ± 
standard error of the mean (SEM). Statistical significance was taken as p<0.05. 
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Chapter 3. Metabolic changes due to 
inflammation are essential for cytokine release 
in mouse primary astrocytes 
 
A modified version of this chapter is published as part of: 
The metabolic response to inflammation in astrocytes is regulated by 
nuclear factor-kappa B signalling. 
Josephine L. Robb, Nadia A. Hammad, Paul G. Weightman Potter, John K. 
Chilton, Craig Beall, Kate L.J. Ellacott. Glia. DOI:10.1002/glia.23835. 
 
3.1 Introduction 
In many immunocompetent cell types, including macrophages, dendritic cells and 
T-cells, it has been shown that during a pro-inflammatory response activity of the 
main metabolic pathways are altered, including glycolysis and oxidative 
phosphorylation (Dumitru et al., 2018; O'Neill et al., 2016; Thapa & Lee, 2019; 
Viola et al., 2019). These metabolic changes are intrinsic to the inflammatory 
response and have been defined as ‘immunometabolism’ (Jung et al., 2019; 
Loftus & Finlay, 2016). Immunometabolic changes can vary greatly in magnitude 
and timescale depending on cell type. Although immunometabolic changes have 
been explored in depth in peripheral immune cells, there is comparatively little 
data available investigating an intrinsic link between metabolism and 
inflammation in astrocytes. 
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In most cell types the initial response to pro-inflammatory stimulation requires an 
increase in glycolytic rate (Loftus & Finlay, 2016; O'Neill et al., 2016; Wang et al., 
2017). There is some data available suggesting that this is also the case in 
astrocytes. For example, in aging mice, increased nuclear NF-κB activity in 
astrocytes correlates with elevated aerobic metabolism (Jiang & Cadenas, 2014). 
Furthermore, in vitro studies in mouse primary astrocytes demonstrate that 
treatment with pro-inflammatory cytokines increases their glucose uptake, 
reduces intracellular glycogen stores, and increases flux through the tricarboxylic 
acid (TCA) cycle and pentose phosphate pathway (Bélanger et al., 2011b; 
Gavillet et al., 2008). Exposure to nitric oxide, which can be an inflammatory 
factor in high concentrations (Sharma et al., 2007), also enhances the activity of 
hypoxia inducible factor 1α (HIF1α) and the cellular energy sensor AMP-activated 
protein kinase (AMPK) (Almeida et al., 2004; Brix et al., 2012). These signalling 
pathways regulate glycolysis in astrocytes. This suggests that astrocytes rely on 
glucose metabolism during inflammation. In a related study, Meares et al. showed 
that decreasing substrate availability to astrocytes in vitro, by limiting glucose and 
pyruvate, reduces interferon-gamma (IFN-γ) induced inflammatory responses 
(Meares et al., 2013). The anti-inflammatory effect of reduced glucose and/or 
pyruvate availability was replicated by pharmacological activation of AMPK 
(Meares et al., 2013). Together these data suggest that there is a glycolytic 
component to the response to pro-inflammatory stimulation in astrocytes. 
However, the link between glycolysis and inflammation has not been directly 
studied. 
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In cells such as pro-inflammatory macrophages and dendritic cells the increase 
in glycolysis is coupled with a decrease in OXPHOS and changes in enzyme 
activity in the TCA cycle, leading to accumulation of TCA intermediates such as 
citrate and succinate (Kelly & O'Neill, 2015; Krawczyk et al., 2010). Intermediates 
generated by the TCA cycle are scavenged and used to synthesise new proteins 
and fats required for growth and inflammatory molecule production. In addition, 
accumulation of succinate drives the pro-inflammatory phenotype through 
inhibition of anti-inflammatory immunomodulators (Mills et al., 2016). The 
concomitant decrease in OXPHOS activity is essential for macrophages to enter 
a pro-inflammatory state as OXPHOS suppresses inflammation in macrophages 
through preventing modification of the electron transport chain for reactive 
oxygen species generation (Maranzana et al., 2013; Sag et al., 2008; Vats et al., 
2006). However, OXPHOS is not suppressed during inflammation in all 
immunomodulatory cell types. In T cells and alternatively activated macrophages 
OXPHOS is maintained during inflammation whereas in memory T cells 
OXPHOS is increased during an infection, promoting long term survival (Sena et 
al., 2013; van der Windt et al., 2012; Wang et al., 2011). The relative dependence 
on OXPHOS and the TCA cycle during inflammation is clearly different in different 
cell types. However, the role of mitochondrial energy production in astrocytes 
during inflammation has not been extensively explored. 
 
In vivo, astrocytes are highly glycolytic compared to neurons (Fernández-
Moncada et al., 2018; Pellerin & Magistretti, 1994; Vardjan et al., 2018; Yellen, 
2018). This increases lactate production by astrocytes, which can be used as a 
fuel by neurons and also reduces oxygen consumption by astrocytes. Whilst 
OXPHOS in astrocytes does not appear to be essential for astrocyte survival, 
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disruption reduces neuronal viability and astrocyte proliferation after traumatic 
brain injury (Fiebig et al., 2019; Supplie et al., 2017). Indeed, loss of mitochondria 
in astrocytes through prevention of mitochondrial DNA replication leads to 
neuronal death and spongiotic encephalopathy (Ignatenko et al., 2018). This 
suggests that mitochondrial metabolism/OXPHOS capability in astrocytes is 
essential for maintenance of the extracellular environment during times of stress. 
Supporting this, disruption of OXPHOS in astrocytes increases reactive gliosis in 
mice (Fiebig et al., 2019). This demonstrates that OXPHOS may play a role in 
resolving inflammation in astrocytes. In many cell types OXPHOS can be 
regulated through changes to mitochondrial networks, known as mitochondrial 
dynamics (Wai & Langer, 2016). OXPHOS is increased by mitochondrial fusion, 
and limited by mitochondrial fission. Motori et al. have demonstrated that 
mitochondrial networks become more fragmented in astrocytes during 
inflammation resulting from trauma (Motori et al., 2013). This suggests that 
OXPHOS is reduced in astrocytes during inflammation. 
  
Together these published data may suggest that, in common with other immune 
competent cells, astrocytes increase glycolysis and reduce OXPHOS during pro-
inflammatory stimulation. In many cell types it has been shown that preventing 
glycolysis reduces the ability of the cell to become inflamed (Abboud et al., 2018; 
Lee et al., 2019). This has led to the repurposing of some metabolic drugs as 
therapies for disease, including cancers (Singer et al., 2018), Alzheimer’s disease 
(Campbell et al., 2018; Koenig et al., 2017), and autoimmune diseases such as 
multiple sclerosis and lupus (Norata et al., 2015). If astrocytes have 
immunometobolic responses this may open opportunities for new therapies for 
neuroinflammatory conditions. 
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3.2 Hypothesis 
In this chapter I tested the overarching hypothesis that metabolic changes during 
inflammation are essential for cytokine release in astrocytes. I further 
hypothesised that glycolytic rate will be increased but OXPHOS will be reduced 
during pro-inflammatory stimulation. 
 
3.3 Results 
3.3.1 Lipopolysaccharide (LPS) stimulated NF-κB signalling in mouse 
primary astrocytes 
LPS was used as a pro-inflammatory stimulus in this model. This molecule 
activates toll like receptor 4 (TLR4) signalling, activating signalling pathways 
which include NF-κB signalling, an important pro-inflammatory transcription 
factor. To confirm LPS-induced NF-κB signalling in mouse primary astrocytes, 
cells were treated with LPS for 3 hours or 24 hours. NF-κB (p65) phosphorylation 
(Ser536) and total NF-κB expression were quantified using immunoblotting. 
Phosphorylation of Ser536 was used as a measure of NF-κB activity, as 
phosphorylation at this site has been demonstrated to be essential for canonical 
NF-κB signalling and nuclear translocation both in vitro and in vivo (Hu et al., 
2004; Jiang et al., 2003; Sakuri et al., 1999). NF-κB phosphorylation was 
increased 3 hours and 24 hours after LPS treatment compared to untreated 
controls (83% and 87.6% respectively, p<0.0001 at both time points (fig. 
3.3.1.1A-B).  Total expression of NF-κB was not altered by LPS treatment after 
3 hours or 24 hours (fig. 3.3.1.2A-B). 
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Figure 3.3.1.1: LPS increased phosphorylation of p65 NF-κB. Mouse 
primary astrocytes were seeded at a density of 4.5 x 105 cells per dish in 60 
mm dishes prior to treatment with lipopolysaccharide (LPS; 0.1 µg/mL) or 
vehicle. Cells were lysed and protein collected for immunoblotting. A-B. Anti-
phospho-NF-κB p65 (Ser536) immunoblot after 3 hours (A) or 24 hours (B) 
treatment with anti-GAPDH loading control. Top: Densitometric analysis of 
anti-phospho-NF-κB p65 (Ser536) fluorescence normalised to anti-GAPDH 
fluorescence and represented as fold change in fluorescence from the mean 
of vehicle treated controls (n=8). Unpaired t-test, **** p<0.0001. Data are 
presented as mean ± standard error of mean. Bottom: Representative 
immunoblot of phospho-NF-κB p65 (Ser536) with GAPDH loading control. 
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Figure 3.3.1.2: LPS did not regulate total expression of NF-κB. Mouse 
primary astrocytes were seeded at a density of 4.5 x 105 cells per dish in 60 
mm dishes prior to treatment with lipopolysaccharide (LPS; 0.1 µg/mL) or 
vehicle. Cells were lysed and protein collected for immunoblotting. A-B. Anti-
NF-κB p65 immunoblot after 3 hours (A) or 24 hours (B) treatment with anti-
GAPDH loading control. Top: Densitometric analysis of anti-NF-κB p65 
fluorescence normalised to anti-GAPDH fluorescence and represented as fold 
change in fluorescence from the mean of vehicle treated controls (n=8). 
Unpaired t-test. Data are presented as mean ± standard error of mean. 
Bottom: Representative immunoblot of NF-κB p65 with GAPDH loading 
control. 
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3.3.2 LPS increased cytokine secretion from mouse primary 
astrocytes 
TNF-α release was increased in comparison to vehicle-treated controls (0.017 
mM BSA) after 3 hours treatment with LPS (fig. 3.3.2A; p<0.0001). Neither IL-6 
(fig. 3.3.2C) nor IL-10 (fig. 3.3.2E) release were increased after 3 hours 
treatment with LPS. After 24 hours of LPS treatment release of TNF-α, IL-6 and 
IL-10 (p<0.01) were all increased compared to vehicle-treated controls (fig. 
3.3.2B, D & F; p<0.0001, p=0.0002, and p=0.0028 respectively). 
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Figure 3.3.2: LPS increased cytokine release from mouse primary 
astrocytes. Mouse primary astrocytes were seeded at a density of 4.5 x 105 
cells per dish in 60 mm dishes prior to treatment with lipopolysaccharide (LPS; 
0.1 µg/mL) or vehicle. Conditioned media was collected and used for 
estimation of extracellular cytokine concentrations using DuoSet ELISAs 
(BioTechne, UK).   A-B. Extracellular TNF-α concentration 3 hours (A) or 24 
hours (B) after LPS treatment (n=6). C-D. Extracellular IL-6 concentration 3 
hours (C) or 24 hours (D) after LPS treatment (n=6). E-F. Extracellular IL-10 
concentration 3 hours (E; n=4) or 24 hours (F; n=5) after LPS treatment. 
Unpaired t-test, ** p<0.01, *** p<0.001, **** p<0.0001. Data are expressed as 
mean ± standard error of the mean. 
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3.3.3 Lipopolysaccharide did not decrease viability of mouse primary 
astrocytes 
To ensure that cell viability was not decreased by the concentration of LPS used 
in this study, cell viability was measured using propridium iodide exclusion. Cell 
viability was not affected by treatment with LPS after 24 hours, with >90% cell 
viability, in both LPS and vehicle-treated control groups (fig 3.3.3). 
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Figure 3.3.3: LPS did not affect cell viability of mouse primary 
astrocytes. Propidium iodide staining and flow cytometry of cells 24 hours 
after treatment with lipopolysaccharide (LPS). Cells were seeded at a density 
of 3.5 x 105 cells per well in a 6 well plate. After treatment with LPS, cells were 
trypsinised and stained with 2 µg/mL propidium iodide prior to analysis with 
the BD Accuri C6 Plus flow cytometer. A. Percentage cell viability. One-way 
ANOVA with post hoc Tukey; * p<0.05; n=3. Data are presented as mean ± 
standard error of the mean. B-D. Gating used to define events. Plot 2 region 
of interest and P1 defined non-viable cells. Example data from 0 µg/mL (B), 
0.1 µg/mL (C), and 1 µg/mL (D) LPS treated cells. 
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3.3.4 LPS induced an acute increase in glycolytic rate in mouse 
primary astrocytes 
The acute metabolic consequences of LPS stimulation of mouse primary 
astrocytes were measured using the Seahorse Bioanalyzer XFe96. Following a 
baseline period, the cells were treated with LPS or vehicle (0.017 mM BSA). 
Oxygen consumption rate (OCR) (fig. 3.3.4.1A-B) and extracellular acidification 
rate (ECAR) (fig. 3.3.4.1C-D) were measured for 1 hour every 6 minutes. No 
change in OCR was observed after treatment with LPS compared to vehicle, 
indicating that oxidative phosphorylation (OXPHOS) was not altered after LPS 
treatment (fig. 3.3.4.1A-B). However, there was a 20% increase in ECAR 
indicating an increase in glycolytic rate (fig. 3.3.4.1C-D, p<0.0001). There was a 
25% increase in glucose uptake rate after 15 minutes treatment with LPS in 
comparison to vehicle treated controls, however this did not reach statistical 
significance (fig. 3.3.4.2; p=0.24).  
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Figure 3.3.4.1: LPS increased glycolysis in mouse primary astrocytes. 
Cells were seeded at a density of 4 x 104 cells per well in Seahorse XF96 cell 
culture microplates. Oxidative phosphorylation rate, represented as oxygen 
consumption rate (OCR) and glycolysis represented as extracellular 
acidification rate (ECAR) of the cells were measured using the Seahorse 
BioAnalyzer XFe96. A. OCR over time of cortical primary mouse astrocytes 
(CRTAS). Treatment point indicated by dotted line. Lipopolysaccharide (LPS; 
0.1 µg/mL) treatment compared with vehicle treated control (0.017 mM fatty 
acid free bovine serum albumin). B. Area under the curve (AUC) of OCR after 
treatment with LPS. C. ECAR over time of CRTAS after treatment with LPS. D. 
AUC of ECAR after treatment with LPS. Unpaired t-test, **** p<0.0001; n=18, 
from two independent plates. Data are expressed as mean ± standard error of 
the mean. 
139 
 
 
 
 
 
 
  
Figure 3.3.4.2: Glucose uptake rate was not significantly altered within 
15 minutes LPS treatment. Mouse primary astrocytes were seeded at a 
density of 4 x 104 cells per well in 96 well plates. Glucose uptake rate after 
treatment with lipopolysaccharide (LPS) was estimated using the Glucose 
Uptake-Glo kit (Promega, UK). Glucose uptake was represented as fold 
change in 2-deoxyglucose-6-phosphate (2DG6P) luminescence compared to 
the mean of vehicle treated controls after 15 minutes treatment with LPS. 
Unpaired t-test, p>0.05; n=5. Data are expressed as mean ± standard error of 
the mean. 
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3.3.5 Changes to glycolytic metabolism were maintained 3 hours after 
treatment with LPS in mouse primary astrocytes 
To further interrogate the changes in cellular metabolism related to inflammation, 
mouse primary astrocytes were treated with LPS for 3 hours and subjected to a 
Glycolytic Stress Test to assess glycolytic rate, capacity and reserve. After 3 
hours treatment with LPS, glycolytic rate and capacity were both significantly 
increased by 26% (p=0.0138) and 20% (p=0.025) respectively (fig. 3.3.5.1A-C). 
However, glucose uptake rate was not significantly increased in cells treated with 
LPS for 3 hours compared to vehicle-treated controls (fig. 3.3.5.2; p=0.46). The 
glycolytic reserve was unchanged between LPS treated astrocytes and vehicle 
treated controls (fig. 3.3.5.1D).  
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Figure 3.3.5.1: 3 hours LPS treatment increased glycolysis in mouse 
primary astrocytes. Cells were seeded at a density of 4 x 104 cells per well in 
Seahorse XF96 cell culture microplates. Glycolysis, represented as extracellular 
acidification rate (ECAR) of the cells was measured using the Seahorse 
BioAnalyzer XFe96 in conjunction with a Glycolytic Stress Test (Agilent, UK). A. 
ECAR of mouse primary cortical astrocytes during a Glycolytic Stress Test 3 
hours after treatment with LPS compared with vehicle treated control (0.017 mM 
fatty acid free bovine serum albumin; Glu = 10 mM glucose; Oligo = 1 µM 
oligomycin; 2-DG = 50 mM 2-deoxyglucose). B. Glycolytic rate: change in ECAR 
after treatment with glucose. C. Glycolytic capacity: change in ECAR after 
treatment with oligomycin. D. Glycolytic reserve: difference between glycolytic 
rate and glycolytic capacity. Unpaired t-test, * p<0.05; n=30, 2 independent 
plates. Data are expressed as mean ± standard error of the mean. 
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Figure 3.3.5.2: Glucose uptake rate in mouse primary astrocytes was not 
altered by 3 hours LPS treatment.  Mouse primary astrocytes were seeded 
at a density of 4 x 104 cells per well in 96 well plates. Glucose uptake rate 
after treatment with lipopolysaccharide (LPS) was estimated using the 
Glucose Uptake-Glo kit (Promega, UK). Glucose uptake was represented as 
fold change in 2-deoxyglucose-6-phosphate (2DG6P) luminescence from the 
mean of vehicle treated controls after 3 hours treatment with 
lipopolysaccharide (LPS). Unpaired t-test, p>0.05; n=6. Data are expressed 
as mean ± standard error of the mean. 
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3.3.6 Mitochondrial metabolism was not altered after 3 hours 
treatment with LPS 
Mouse primary astrocytes were exposed to LPS for 3 hours and studied using a 
Mito Stress Test, to assess OXPHOS (fig. 3.3.6A). There was no change in basal 
or maximal OXPHOS compared to vehicle treated controls (fig. 3.3.6B-C). This 
resulted in no change in spare mitochondrial capacity (fig. 3.3.6D). In addition to 
mitochondrial function being unchanged, 3 hours LPS treatment did not change 
mitochondrial efficiency, with no change in proton leak or oxygen associated ATP 
production (fig. 3.3.6E-G). 
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Figure 3.3.6: Mitochondrial metabolism was not altered by 3 hours of 
LPS treatment. Cells were seeded at a density of 4 x 104 cells per well in 
Seahorse XF96 cell culture microplates. Oxidative phosphorylation, 
represented as oxygen consumption rate (OCR) of the cells was measured 
using the Seahorse BioAnalyzer XFe96 in conjunction with a Mito Stress Test 
(Agilent, UK). A. OCR of mouse primary cortical astrocytes during a Mito 
Stress Test 3 hours after treatment with lipopolysaccharide (LPS; 0.1 µg/mL) 
compared with vehicle treated control (0.017 mM fatty acid free bovine serum 
albumin). Oligo = 0.5 µM oligomycin; FCCP = 1 µM; R/A = 0.5 µM 
rotenone/antimycin. B. Basal Respiration: difference in OCR prior to 
oligomycin injection and after rotenone/antimycin injection. C. Maximal 
respiration: difference in OCR after injection of FCCP and after 
rotenone/antimycin injection. D. Spare capacity: difference in OCR between 
basal respiration (B) and maximal respiration (C). E. Proton leak: difference in 
OCR after oligomycin injection and after rotenone/antimycin injection. F. ATP 
production: difference in OCR prior to oligomycin injection and after oligomycin 
injection. G. Coupling efficiency: percentage of basal respiration (B) used for 
ATP production (F). Unpaired t-test, p>0.05; n=42-44, 3 independent plates. 
Data are presented as mean ± standard error of the mean. 
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3.3.7 The glycolytic capacity of mouse primary astrocytes was greatly 
reduced after 24 hour treatment with LPS 
Mouse primary astrocytes were treated with LPS for 24 hours prior to study with 
a Glycolytic Stress Test. In contrast to the acute (3 hours) treatment, after 24 
hours LPS treatment there was no significant difference in glycolytic rate between 
LPS and vehicle treated groups (fig. 3.3.7.1A-B; p=0.29). However, glycolytic 
capacity was reduced by 47% in the LPS group in comparison to vehicle treated 
controls (fig. 3.3.7.1C; p=0.0002), resulting in a 97% decrease in glycolytic 
reserve (fig. 3.3.7.1D; p<0.0001). This reduced capacity could be partly due to 
the 37% reduction in the rate of glucose uptake seen in the 24 hour LPS-treated 
group, compared to a vehicle treated control (fig. 3.3.7.2; p=0.0091). These data 
show that after 24 hours of exposure to LPS, mouse primary astrocytes undergo 
pronounced changes in their cellular metabolism, characterised by a reduction in 
both the glucose uptake and glycolytic capacity of the cells. 
 
Due to the inherit instability of the assay used, variation in baseline between 
assays was high. To account for this, data were represented as a fold change 
from the mean of the contemporaneous controls. However, this resulted in the 
loss of the ability to compare between the controls. Additionally, as the assays 
were not run simultaneously, this comparison would not be appropriate due to 
various confounding factors including the circadian rhythms of the cells and 
variations in environmental conditions. Therefore I cannot comment on whether 
there was any change in glucose uptake by the control group between the 3 hour 
and 24 hour time points. To investigate this further a direct assay comparing 
these two time points would be required.  
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Figure 3.3.7.1: 24 hours LPS treatment suppressed glycolytic capacity 
in mouse primary astrocytes. Cells were seeded at a density of 4 x 104 cells 
per well in Seahorse XF96 cell culture microplates. Glycolysis, represented as 
extracellular acidification rate (ECAR) of the cells was measured using the 
Seahorse BioAnalyzer XFe96 in conjunction with a Glycolytic Stress Test 
(Agilent, UK). A. ECAR of mouse primary cortical astrocytes during a 
Glycolytic Stress Test 24 hours after treatment with LPS compared with 
vehicle treated control (0.017 mM fatty acid free bovine serum albumin; Glu = 
10 mM glucose; Oligo = 1 µM oligomycin; 2-DG = 50 mM 2-deoxyglucose). B. 
Glycolytic rate: change in ECAR after treatment with glucose compared to 
post-2-deoxyglucose treatment. C. Glycolytic capacity: change in ECAR after 
treatment with oligomycin compared to post-2-DG treatment. D. Glycolytic 
reserve: difference between glycolytic rate and glycolytic capacity. Unpaired 
t-test, **** p<0.0001, *** p<0.001; n=30, 2 independent plates. Data are 
expressed as mean ± standard error of the mean. 
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Figure 3.3.7.2: Glucose uptake was repressed by 24 hours LPS 
treatment. Mouse primary astrocytes were seeded at a density of 4 x 104 cells 
per well in 96 well plates. Glucose uptake rate after treatment with 
lipopolysaccharide (LPS) was estimated using the Glucose Uptake-Glo kit 
(Promega, UK). Glucose uptake was represented as fold change in 2-
deoxyglucose-6-phosphate (2DG6P) luminescence compared to the mean of 
vehicle treated controls after 24 hours treatment with lipopolysaccharide 
(LPS). Unpaired t-test, ** p<0.01; n=6. Data are expressed as mean ± 
standard error of the mean. 
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3.3.8 GLUT1 expression was reduced by 24 hour LPS treatment in 
mouse primary astrocytes 
GLUT1 is a glucose transporter expressed in astrocytes that has previously been 
reported to be regulated during inflammation (Wieman et al., 2007). To 
investigate potential causes of the reduced glycolytic capacity observed after 24 
hours LPS treatment, GLUT1 expression was quantified using immunoblotting. 
Bands of multiple molecular weights were detected around the 55 kDa mark, 
ranging from ~45-55 kDa in weight. All bands detected were quantified as 
GLUT1, and the variation in weight was likely due to varying levels of 
glycosylation and/or phosphorylation, as has previously been reported (Devraj et 
al., 2011; Kumagai et al., 1994). After 3 hours of LPS treatment astrocyte GLUT1 
expression was not altered compared to vehicle treated controls (fig. 3.3.8A; 
p=0.96). In line with the alterations in glycolytic rate and capacity seen after 24 
hours LPS treatment (fig. 3.3.7.1A-D) and in concordance with the glucose 
uptake data (fig. 3.3.7.2), 24 hour treatment with LPS significantly reduced 
astrocyte GLUT1 expression compared to vehicle treated controls (fig. 3.3.8B; 
p=0.0044). 
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Figure 3.3.8: GLUT1 expression was suppressed by 24 hours LPS 
treatment. Mouse primary astrocytes were seeded at a density of 4.5 x 105 
cells per dish in 60 mm dishes prior to treatment with lipopolysaccharide (LPS; 
0.1 µg/mL) or vehicle. Cells were lysed and protein collected for 
immunoblotting.  A-B. GLUT1 expression quantified by immunoblotting with 
anti-GLUT1 (Millipore) after 3 hours (A; n=7) or 24 hours (B; n=6) treatment 
with lipopolysaccharide (LPS; 0.1 µg/mL). Left: Representative blot. Right: 
Densitometric analysis normalised to GAPDH (Protein Tech) and as fold 
change compared to mean of vehicle treated controls. Unpaired t-test, ** 
p<0.01. Data are expressed as mean ± standard error of the mean. 
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3.3.9 Basal mitochondrial respiration in mouse primary astrocytes 
was increased after 24 hours LPS treatment 
The impact of chronic exposure to an inflammatory stimulus on mitochondrial 
metabolism was investigated. Mouse primary astrocytes were exposed to LPS 
for 24 hours prior to study with a Mito Stress Test. Basal mitochondrial respiration 
was increased by 53% in comparison to vehicle treated controls (fig. 3.3.9A & B; 
p<0.0001). Conversely, maximal mitochondrial respiration was reduced by 27% 
(fig. 3.3.9C; p=0.0003), resulting in a 79% reduction in spare capacity (fig. 
3.3.9D; p<0.00001). Proton leak was significantly increased by 54% (fig. 3.3.9E; 
p=0.0019). Mitochondrial ATP production was increased by 52% (fig. 3.3.9F; 
p<0.0001). The mitochondrial coupling efficiency was unchanged (fig. 3.3.9G). 
Together these data suggest after 24 hours of LPS treatment basal mitochondrial 
activity of mouse primary astrocytes is increased, despite reduced mitochondrial 
capacity. 
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Figure 3.3.9: Basal mitochondrial metabolism was increased by 24 hours 
LPS.  Cells were seeded at a density of 4 x 104 cells per well in Seahorse 
XF96 cell culture microplates. Oxidative phosphorylation, represented as 
oxygen consumption rate (OCR) of the cells was measured using the 
Seahorse BioAnalyzer XFe96 in conjunction with a Mito Stress Test (Agilent, 
UK). A. OCR of mouse primary cortical astrocytes during a Mito Stress Test 
24 hours after treatment with lipopolysaccharide (LPS; 0.1 µg/mL) compared 
with vehicle treated control (0.017 mM fatty acid free bovine serum albumin). 
Oligo = 0.5 µM oligomycin; FCCP = 1 µM; R/A = 0.5 µM rotenone/antimycin. 
B. Basal Respiration: difference in OCR prior to Oligo injection and after R/A 
injection. C. Maximal respiration: difference in OCR after injection of FCCP 
and after R/A injection. D. Spare capacity: difference in OCR between basal 
respiration (B) and maximal respiration (C). E. Proton leak: difference in OCR 
after Oligo injection and after R/A injection. F. ATP production: difference in 
OCR prior to Oligo injection and after Oligo injection. G. Coupling efficiency: 
percentage of basal respiration (B) used for ATP production (F). Unpaired t-
test, **** p<0.0001, *** p<0.001, ** p<0.01; n=42-44, 3 independent plates. 
Data are presented as mean ± standard error of the mean. 
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3.3.10 LPS did not alter mitochondrial potential 
As a complementary measure of mitochondrial activity, mitochondrial membrane 
potential was assessed using TMRE dye uptake. 15 minutes after treatment with 
LPS there was no change in mitochondrial membrane potential in LPS treated 
astrocytes compared to vehicle treated controls (fig. 3.3.10A; p=0.58), while the 
positive control, the mitochondrial oxidative phosphorylation uncoupler FCCP, 
significantly reduced TMRE uptake by 72% (fig. 3.3.10A; p<0.0001). Mouse 
primary astrocytes treated for 3 hours with LPS did not have different TMRE 
uptake compared to vehicle treated controls (fig. 3.3.10B), in contrast to the 
FCCP treated positive controls which showed a 70% reduction in TMRE uptake 
(fig. 3.3.10B; p<0.0001). There is no difference in TMRE dye uptake in cells 
treated with LPS for 24 hours compared to vehicle treated controls (fig. 3.3.10C) 
although FCCP positive controls reduced TMRE uptake by 67% (p<0.0001). This 
suggests that the integrity of the mitochondrial membrane was not immediately 
altered by LPS treatment, and rate of proton flow across the membrane was not 
altered. This corroborates the observed absence of change in coupling efficiency. 
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Figure 3.3.10: Mitochondrial membrane potential was not altered by 
LPS. TMRE dye uptake as a fold change from controls after 15 minutes (A; 
n=4), 3 hours (B; n=6), or 24 hours (C; n=6) treatment with lipopolysaccharide 
(LPS; 0.1 µg/mL). FCCP (10 µM) was used as a positive depolarisation 
control. Cells were seeded at a density of 3.5 x 105 cells per well in a 6 well 
plate. After treatment with LPS, cells were dissociated and incubated with 
FCCP prior to incubation with TMRE (100 nM) and analysis with the BD Accuri 
C6 Plus flow cytometer. One-way ANOVA with post hoc Tukey, **** p<0.0001. 
Data are presented as mean ± standard error of the mean. 
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3.3.11 The number of individual mitochondria were reduced after 3 
hours LPS treatment 
Although there was no measurable change in mitochondrial potential in the LPS-
treated astrocytes, some cell types alter their mitochondrial dynamics to regulate 
energy metabolism in response to LPS treatment (Nair et al., 2019; Park et al., 
2013). Mitochondrial network connectivity was assessed using immuno-
cytochemistry and confocal microscopy. No change was found in mitochondrial 
networks after 15 minutes (fig. 3.3.11.1) or 24 hours treatment (fig. 3.3.11.3) in 
LPS- compared to vehicle-treated controls. However, after 3 hours treatment with 
LPS there was a 39% reduction in the number of mitochondria (fig. 3.3.11.2C; 
p=0.0003), seemingly due to there being less mitochondria under 2 µm in length 
(fig. 3.3.11.2B). This may suggest increased mitochondrial fusion 3 hours after 
LPS treatment, or alternatively increased mitophagy of fragmented mitochondria.   
 
The total number of mitochondria in the control group was lower in after 24 hours 
compared to the earlier time points. This may be reflective of increased 
mitochondrial fusion, resulting in a reduced number of mitochondria without 
reducing mitochondrial biomass, due to changes in the cell cycle stage. It has 
previously been reported that the G1-S phase of the cell cycle results in 
mitochondrial fusion compared to the G0 phase which is characterised by 
mitochondrial fission and more punctate mitochondria (Antico Arciuch et al., 
2012). 
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Figure 3.3.11.1: Mitochondrial networks were not altered by 15 minutes 
LPS treatment. Cells were seeded at a density of 1 x 105 cells per well on 
glass coverslips in 24 well plates. Prior to treatment, cells were stained 
MitoTracker Red CMXRos (100 nM). After treatment cells were fixated with 
4% paraformaldehyde prior to DAPI staining and imaging. A. Representative 
images of the mitochondrial networks of mouse primary astrocytes treated 
with vehicle or lipopolysaccharide (LPS; 0.1 µg/mL) for 15 minutes, with 
example processed images for analysis. B. Mitochondrial length distribution 
(two-way ANOVA with post hoc Tukey). C. Number of mitochondria per cell 
(unpaired t-test). n=16; 4 independent coverslips with 4 cells per coverslip. 
Scale bar = 20 µm. Data are presented as mean ± standard error of the mean. 
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Figure 3.3.11.2: The number of mitochondria were decreased 3 hours 
after treatment with LPS. Cells were seeded at a density of 1 x 105 cells per 
well on glass coverslips in 24 well plates. Prior to treatment, cells were stained 
MitoTracker Red CMXRos (100 nM). After treatment cells were fixated with 
4% paraformaldehyde prior to DAPI staining and imaging. A. Representative 
images of the mitochondrial networks of mouse primary astrocytes treated 
with vehicle or lipopolysaccharide (LPS; 0.1 µg/mL) for 3 hours, with example 
processed images for analysis. B. Mitochondrial length distribution (two-way 
ANOVA with post hoc Sidak; **** p<0.0001). C. Number of mitochondria per 
cell (unpaired t-test; *** p<0.001). n=15; 3 independent coverslips with 5 cells 
per coverslip. Scale bar = 20 µm. Data are presented as mean ± standard 
error of the mean. 
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Figure 3.3.11.3: Mitochondrial networks were not altered by 24 hours 
LPS treatment. Cells were seeded at a density of 1 x 105 cells per well on 
glass coverslips in 24 well plates. Prior to treatment, cells were stained 
MitoTracker Red CMXRos (100 nM). After treatment cells were fixated with 
4% paraformaldehyde prior to DAPI staining and imaging. A. Representative 
images of the mitochondrial networks of mouse primary astrocytes treated 
with vehicle or lipopolysaccharide (LPS; 0.1 µg/mL) for 24 hours, with example 
processed images for analysis. B. Mitochondrial length distribution (two-way 
ANOVA with post hoc Tukey). C. Number of mitochondria per cell (unpaired t-
test). n=15; 3 independent coverslips with 5 cells per coverslip. Scale bar = 20 
µm. Data are presented as mean ± standard error of the mean. 
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3.3.12 Intracellular ATP was not altered by LPS 
ATP is the key unit of cellular energy. As oxidative phosphorylation is more 
efficient at generating ATP than glycolysis, any change in metabolic pathways 
used may affect intracellular ATP (iATP) content. iATP concentrations were not 
altered after 15 minutes of treatment with LPS in comparison to vehicle treated 
controls (fig. 3.3.12A; p=0.31) despite increased glycolytic rate. iATP 
concentrations were also unchanged 3 hours (fig. 3.3.12B; p=0.78) and 24 hours 
after treatment with LPS compared to vehicle treated controls (fig. 3.3.12C; 
p=0.48) despite the metabolic adaptations observed. This suggests that in the 
face of pro-inflammatory stimulation astrocytes can maintain their intracellular 
energy levels, at least in part, through altered substrate utilisation.  
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Figure 3.3.12: Intracellular ATP is not altered by LPS treatment. Fold 
change in intracellular ATP (iATP) in mouse primary astrocytes 15 minutes 
(A), 3 hours (B) and 24 hours (C) after lipopolysaccharide (LPS; 0.1 µg/mL) 
treatment compared to mean of vehicle treated controls. Mouse primary 
astrocytes were seeded at a density of 4 x 103 cells per well in black 96 well 
plates. iATP after treatment with lipopolysaccharide (LPS) was estimated 
using the ATPLite TwoStep kit (PerkinElmer, UK). Unpaired t-test, p>0.05; 
n=4. Data are presented as mean ± standard error of the mean. 
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3.3.13 2-deoxyglucose inhibited glycolysis but not mitochondrial 
metabolism in mouse primary astrocytes 
In many cell types which display an increase in glycolytic rate during pro-
inflammatory stimulation, access to glycolysis is essential for inflammation 
(Hamilton et al., 1986; Kawauchi et al., 2008b; Lee et al., 2019; Liu et al., 2016; 
Michl et al., 1976; Tannahill et al., 2013). To ensure Icould selectively inhibit 
glycolysis in these cells, mouse primary astrocytes were treated with the non-
metabolisable glucose analogue 2-deoxyglucose (2-DG; 10 mM), a glycolytic 
inhibitor, and their metabolism measured. Mouse primary astrocytes showed a 
36% reduction in glycolytic rate after addition of 2-DG (fig. 3.3.13A-B; p<0.0001). 
No significant change in OCR was measured, suggesting that astrocyte 
mitochondrial metabolism was unaffected by this intervention (fig. 3.3.13C-D). 
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Figure 3.3.13: 2-DG inhibited glycolysis in mouse primary astrocytes. 
Cells were seeded at a density of 4 x 104 cells per well in Seahorse XF96 cell 
culture microplates. Oxidative phosphorylation rate, represented as oxygen 
consumption rate (OCR) and glycolysis represented as extracellular 
acidification rate (ECAR) of the cells were measured using the Seahorse 
BioAnalyzer XFe96. A. ECAR of primary mouse astrocytes over time after 
treatment with 2-deoxyglucose (2-DG) as indicated by dotted line. B. Area 
under the curve (AUC) of ECAR after treatment with 2-DG. C. OCR of mouse 
primary astrocytes over time after treatment with 2-DG. D. AUC of OCR after 
treatment with 2-DG. One-way ANOVA with post hoc Tukey, **** p<0.0001; 
n=28-32, 2 independent plates. Data are expressed as mean ± standard error 
of the mean. 
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3.3.14 2-DG caused minimal cell death 
Astrocytes are a highly glycolytic cell type (Bélanger et al., 2011a; Fernández-
Moncada et al., 2018; Pellerin & Magistretti, 1994; Vardjan et al., 2018; Yellen, 
2018). Therefore, blocking glycolysis using 2-DG may result in cell death, which 
could have caused the results reported here. To assess this, cell viability after 2-
DG treatment was measured using propidium iodide exclusion. 24 hours 
treatment with 2-DG caused a 2% decrease in cell viability which, while 
statistically significant (fig. 3.3.14A; p<0.0001), was unlikely to explain the 
observed changes in metabolism (fig. 3.3.13), cytokine release (fig. 3.3.15), and 
NF-κB phosphorylation (fig. 3.3.16). 
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Figure 3.3.14: 2-DG caused cell death in mouse primary astrocytes. 
Propidium iodide staining and flow cytometry of cells 24 hours after treatment. 
Cells were seeded at a density of 3.5 x 105 cells per well in a 6 well plate. After 
treatment with LPS, cells were dissociated and stained with 2 µg/mL 
propidium iodide prior to analysis with the BD Accuri C6 Plus flow cytometer.  
A. 2 hour pre-treatment with 2-deoxyglucose (2-DG; 10 mM) ± 
lipopolysaccharide (LPS; 0.1 µg/mL; **** p<0.0001, ns p>0.05; n=4). One-way 
ANOVA with post hoc Tukey. Data are presented as mean ± standard error of 
the mean. B-E. Gating used to define events. Plot 2 region of interest and P1 
defined non-viable cells. Example collection plots with data from Ctrl (B), LPS 
(C), 2-DG (D) 2-DG+LPS treated cells. 
  
168 
 
3.3.15 Inhibition of the glycolytic response to LPS attenuated cytokine 
release from mouse primary astrocytes 
To investigate the importance of glycolytic metabolism for the inflammatory 
response in astrocytes, glycolysis was inhibited by 2 hours treatment with 2-DG 
(10 mM) prior to stimulation with LPS. 2-DG significantly reduced TNF-α and IL-
6 release at both 3 hours and 24 hours (fig. 3.3.15A-B; 3 hours p=0.03, 24 hours 
p=0.0118; fig. 3.3.15C-D, p<0.0001) and completely abolished IL-10 release at 
both time points (fig. 3.3.15E-F; p<0.0001).  
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Figure 3.3.15: 2-DG decreased cytokine release after LPS treatment. 
Mouse primary astrocytes were seeded at a density of 4.5 x 105 cells per dish 
in 60 mm dishes prior to treatment or vehicle. Conditioned media was 
collected and used for estimation of extracellular cytokine concentrations 
using DuoSet ELISAs (BioTechne, UK).  A-B. Extracellular TNF-α 
concentration 3 hours (A) or 24 hours (B) after lipopolysaccharide (LPS; 0.1 
µg/mL) treatment ± 2-deoxyglucose (2-DG; 10 mM) 2 hours pre-treatment 
(n=6). C-D.   Extracellular IL-6 concentration 3 hours (C) or 24 hours (D) after 
LPS treatment ± 2-DG 2 hours pre-treatment (n=6). E-F. Extracellular IL-10 
concentration 3 hours (E) or 24 hours (F) after LPS treatment ± 2-DG 2 hours 
pre-treatment (n=6). One-way ANOVA with post-hoc Tukey, ns p>0.05, * 
p<0.05, ** p<0.01, **** p<0.0001. Data are expressed as mean ± standard 
error of the mean. 
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3.3.16 Inhibition of glycolysis attenuated NF-κB phosphorylation after 
24 hours 
Although reduced cytokine release was measured, this may have been due to 
multiple factors including reduced substrate availability for synthesis of new 
molecules (Menk et al., 2018; Williams & O'Neill, 2018). To investigate whether 
intact glycolysis was required for initiation of NF-κB signalling, mouse primary 
astrocytes were pre-treated with 2-DG for 2 hours prior to treatment with LPS or 
vehicle. 2-DG pre-treatment abolished the LPS-induced increase in NF-κB 
phosphorylation (Ser536) at 24 hours post-treatment (fig. 3.3.16.1B; p<0.0001) 
but not 3 hours after LPS treatment (fig. 3.3.16.1A; p=0.80). Total expression of 
NF-κB was not affected by treatment with 2-DG at either time point (fig. 3.3.16.2).  
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Figure 3.3.16.1: 2-DG reduced LPS induced p65 NF-κB phosphorylation 
after 24 hours. Mouse primary astrocytes were seeded at a density of 4.5 x 
105 cells per dish in 60 mm dishes prior to treatment or vehicle. Cells were 
lysed and protein collected for immunoblotting.  A-B. Anti-phospho-NF-κB p65 
(Ser536) immunoblot after 2 hours pre-treatment with 2-deoxyglucose (2-DG; 
10 mM) ± 3 hours (A) or 24 hours (B) treatment with lipopolysaccharide (LPS; 
0.1 µg/mL) with anti-GAPDH loading control. Top: Densitometric analysis of 
anti-phospho-NF-κB p65 (Ser536) fluorescence normalised to anti-GAPDH 
fluorescence and represented as fold change from mean of vehicle treated 
controls (n=6). Bottom: representative immunoblot of phospho-NF-κB p65 
(Ser536) with GAPDH loading control. One-way ANOVA with post-hoc Tukey, 
ns p>0.05, ** p<0.01, **** p<0.0001. Data are expressed as mean ± standard 
error of the mean. 
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Figure 3.3.16.2: 2-DG did not affect total p65 NF-κB expression. Mouse 
primary astrocytes were seeded at a density of 4.5 x 105 cells per dish in 60 
mm dishes prior to treatment or vehicle. Cells were lysed and protein collected 
for immunoblotting.  A-B. Anti-NF-κB p65 immunoblot after 2 hours pre-
treatment with 2-deoxyglucose (2-DG; 10 mM) ± 3 hours (A) or 24 hours (B) 
treatment with lipopolysaccharide (LPS; 0.1 µg/mL) with anti-GAPDH loading 
control. Top: Densitometric analysis of anti-NF-κB p65 fluorescence 
normalised to anti-GAPDH fluorescence and represented as fold change from 
mean of vehicle treated controls (n=6). Bottom: representative immunoblot of 
NF-κB p65 with GAPDH loading control. One-way ANOVA with post-hoc 
Tukey. Data are expressed as mean ± standard error of the mean. 
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3.4 Discussion 
In this chapter I have shown that astrocytes have a dynamic metabolic response 
to inflammation. In support of our hypothesis, I have shown that astrocytes 
increase glycolytic rate in response to LPS, which is necessary for cytokine 
release. However, contrary to the initial hypothesis I have shown that 
mitochondrial metabolism is maintained, or even increased, during a pro-
inflammatory stimulus in astrocytes. 
 
 Table 3.4 Summary of the astrocytic metabolic response to LPS 
Experimental measure 3 hours 24 hours 
G
ly
c
o
ly
s
is
 
Glucose uptake Unchanged Down 
GLUT1 expression Unchanged Down 
Rate Up Unchanged 
Capacity Up Down 
Reserve Unchanged Down 
M
it
o
c
h
o
n
d
ri
a
l 
m
e
ta
b
o
li
s
m
 
Basal respiration Unchanged Up 
Maximal respiration Unchanged Down 
Spare capacity Unchanged Down 
ATP production Unchanged Up 
Proton leak Unchanged Up 
Coupling efficiency Unchanged Unchanged 
Membrane potential Unchanged Unchanged 
Mitochondrial fission Decrease Unchanged 
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3.4.1 Astrocytes release cytokines in response to pro-inflammatory 
signalling 
The data shown in this chapter confirms that in this model LPS induces a pro-
inflammatory state in mouse primary astrocytes, as has been previously 
published, both in vitro and in vivo (Chistyakov et al., 2018; Li et al., 2016; 
Rosciszewski et al., 2018). This includes release of pro-inflammatory cytokines 
TNF-α and IL-6 over a 24 hour time frame. These molecules are transcriptionally 
regulated by NF-κB signalling, and as the research question regarded this 
signalling pathway other pro-inflammatory molecules regulated primarily by other 
pathways were not measured. It is likely that other inflammatory pathways are 
also activated, as the main receptor of LPS, TLR4, also activates MAPK 
signalling.  
 
3.4.2 Astrocytes have a metabolic response to inflammation 
The data presented here indicate that glycolytic metabolism in astrocytes 
increases rapidly after a pro-inflammatory stimulation. Within 40 minutes of LPS 
treatment glycolytic metabolism was significantly increased and 3 hours after pro-
inflammatory stimulation, astrocytes showed an increased rate of glycolysis and 
glycolytic capacity. Due to the speed of this response (<40 minutes; see fig. 
3.3.4.1C), this initial increase in glucose uptake and glycolysis is likely to be 
driven by increased activity of key rate limiting glycolytic enzymes, such as 
hexokinase II. Although no change in total GLUT1 expression was seen at 3 
hours after LPS treatment, our studies did not assess sub-cellular localisation of 
GLUT1; therefore, increased localisation of GLUT1 at the plasma membrane at 
this time point cannot be ruled out. The increase in glycolytic rate observed after 
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3 hours of LPS treatment may be due to NF-κB mediated increase in expression 
of c-Myc – a transcription factor which regulates expression of many glycolytic 
genes (Goetzman & Prochownik, 2018), and increases transcription of 
hexokinase II (Londhe et al., 2018). The use of intracellular glycogen stores may 
also enable the rapid increase in glycolytic rate in the absence of changes in 
glucose uptake, but this would need to be directly measured in order to confirm 
this statement. Astrocyte glycogen depletion has previously been observed 
following cytokine treatment (Gavillet et al., 2008). It is likely that a combination 
of these mechanisms contribute to the increased rate of glycolysis observed. 
 
As OXPHOS is still intact, HIF is unlikely to be regulating glycolysis as HIF-1α 
can be regulated by reverse electron transport through Complex I (Movafagh et 
al., 2015; Wang et al., 2019). However, in this model Complex I still appears to 
be being used for OXPHOS. Motori et al. showed increased mitochondrial 
fragmentation during inflammation in astrocytes (Motori et al., 2013). However, in 
addition to regulating OXPHOS, mitochondrial fragmentation plays an essential 
role in allowing removal of dysfunctional mitochondria through mitophagy. 
Mitophagy in astrocytes is essential during inflammation to maintain mitochondria 
(Huenchuguala et al., 2017). This prevents cytochrome c release from the 
mitochondria, preventing initiation of apoptosis. I have shown that mitochondrial 
number decreases 3 hours after pro-inflammatory stimuli. Taken together with 
the data presented by Motori, mitochondrial fragmentation may be promoting 
mitochondrial health through allowing mitophagy. 
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Chronic LPS exposure (24 hours) resulted in metabolic adaptations in astrocytes, 
probably to maintain ATP production in the face of prolonged insult: glycolytic 
capacity and reserve were reduced but were accompanied by increased 
mitochondrial metabolism. It has previously been shown that astrocytes increase 
TCA cycle rate after 48 hours treatment with IL-1β or TNF-α (Gavillet et al., 2008). 
Therefore, the increase in mitochondrial metabolism was probably driven by 
increased TCA cycling to enable utilisation of alternate fuel sources. This change 
from glycolysis to TCA cycling may suggest that the astrocytes have depleted 
intracellular glycogen stores, so have limited access to substrates for glycolysis. 
This is further supported by the data shown here that expression of the glucose 
transporter GLUT1 is suppressed after 24 hours inflammation, leading to a 
decrease in glucose uptake. Reduced GLUT1 expression may explain the 
attenuated glycolytic capacity and glucose uptake I observed in astrocytes 
exposed to LPS for 24 hours. It is possible that restricting glucose uptake, through 
downregulating GLUT1 expression, may be a mechanism through which 
astrocytes attempt to reduce and/or resolve glycolytic activity to limit the 
inflammatory response. This conclusion is further supported by the increased 
concentrations of the anti-inflammatory cytokine IL-10 measured at 24 hours, 
demonstrating that astrocytes are mitigating the pro-inflammatory environment 
by this time point. 
 
3.4.3 The glycolytic response to LPS is essential for inflammation in 
astrocytes 
Not only is glycolytic rate increased during inflammation, it appears that glycolysis 
is essential for cytokine release from mouse primary astrocytes during LPS 
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stimulation. Blocking glycolytic function with the non-metabolisable glucose 
analogue 2-DG reduced cytokine release and NF-κB phosphorylation, suggesting 
reduced activity of the NF-κB pathway. As NF-κB phosphorylation was still 
evident 3 hours after glycolytic inhibition, this may suggest a role for paracrine 
and autocrine actions of astrocyte-derived cytokines in perpetuating the 
inflammatory response. The initial production of cytokines may be reduced due 
to 2-DG associated suppression of other inflammatory pathways. Glycolytic 
enzyme pyruvate kinase isoenzyme M2 acts as a kinase for STAT3 (Gao et al., 
2012). Reduced glycolytic flux may lead to lower expression of this enzyme, 
reducing STAT3 signalling. This would lead to a reduced inflammatory response. 
Alternatively, the reduced glycolytic rate may prevent the production of carbon 
intermediates required for cytokine production, through limiting the repurposing 
of TCA cycle enzymes (Menk et al., 2018; Williams & O'Neill, 2018). This would 
result in a negative feedback loop reducing the inflammatory response (Caslin et 
al., 2018; McGettrick & O'Neill, 2013). Although 2-DG treatment caused 
statistically significant levels of cell death in the primary astrocytes, this 
represented a less than 2% decrease in cell viability. Therefore, it is unlikely to 
be cell death causing the reductions in cytokine release and NF-κB 
phosphorylation observed. It has been reported that in macrophages 2-DG 
reduces mitochondrial function independently from glycolytic function (Wang et 
al., 2018). However, in our data there was no change in oxidative rate as a result 
of 2-DG treatment. This suggests that the changes in inflammatory state were 
probably a result of glycolytic inhibition rather than mitochondrial modulation. 
However, I did not measure the effect of 2-DG on the cells after 24 hours, 
therefore the suppressed inflammatory response may be driven through limited 
mitochondrial function rather than restricted glycolysis. 
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3.5 Conclusion 
In conclusion, astrocytes have a dynamic metabolic response to pro-
inflammatory stimulation, which is essential for a cellular pro-inflammatory 
response. Inhibition of the early glycolytic response is sufficient to inhibit cytokine 
release and NF-κB mediated signalling in astrocytes. Additionally, glucose 
transporter GLUT1 is downregulated after extended periods of inflammation, 
resulting in reduced glucose uptake and glycolytic capacity. 
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Figure 3.5: Summary of chapter. 3 hours after pro-inflammatory stimulus, 
astrocytes increased their use of glycolytic metabolism to allow synthesis of 
cytokines. 24 hours after pro-inflammatory stimulus, glycolytic rate is reduced 
through downregulation of GLUT1, and oxidative phosphorylation is 
increased. 
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Chapter 4. NF-κB regulates the metabolic 
response to inflammation in mouse primary 
astrocytes 
 
A modified version of this chapter is published as part of: 
The metabolic response to inflammation in astrocytes is regulated by 
nuclear factor-kappa B signalling. 
Josephine L. Robb, Nadia A. Hammad, Paul G. Weightman Potter, John K. 
Chilton, Craig Beall, Kate L.J. Ellacott. Glia. DOI:10.1002/glia.23835. 
 
4.1 Introduction 
During inflammation NF-κB signalling is activated in astrocytes (Lukasiuk et al., 
1995; Migheli et al., 1997). This has been reported in multiple models with NF-κB 
increasing release of IL-6, TNF-α and IL-10, among other immunomodulatory 
agents (Cao et al., 2006; Choi et al., 2014; Collart et al., 1990; Son et al., 2008; 
Sparacio et al., 1992). Preventing inflammation in astrocytes through inhibition of 
the NF-κB signaling pathway can alter the pathophysiological response to 
disease. For example, inhibition of NF-κB activity in glial-fibrillary acidic protein 
(GFAP) expressing astrocytes promotes functional recovery of spinal cord injury 
in mice, resulting in reduced glial scarring and increased locomotor activity 
(Brambilla et al., 2005). It has also been reported that NF-κB signalling in 
astrocytes can regulate systemic energy homeostasis and food intake in mice 
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(Buckman et al., 2014; Douglass et al., 2017). Inhibition of astrocyte NF-κB 
signaling in the mouse hypothalamus, by deleting IKKβ from GFAP expressing 
cells, improves glucose tolerance and reduces obesity by promoting energy 
expenditure (Douglass et al., 2017). These data demonstrate that in astrocytes 
NF-κB signalling plays an integral role in managing energy homeostasis and the 
cellular response to disease.  
 
Multiple PPRs can initiate NF-κB signalling. Whilst astrocytes do express multiple 
PPRs, including TNFR, IL-1 receptor, CD-40L and other TLRs, such as TLR -1, -
2 and -9, only TLR-4 is sensitive to PAMPs from gram-negative bacteria, and thus 
can detect LPS (Kaltschmidt et al., 2005; Kielian, 2006; Lu et al., 2008; 
Rosciszewski et al., 2018). Decreased TLR-4 expression through siRNA or 
activity through anti-TLR-4 antibodies, or loss of the co-receptor CD-14 almost 
completely ablates both human and mouse astrocyte activation and cytokine 
release induced by LPS, suggesting in these cells TLR-4 is the dominant LPS 
sensor (Park et al., 2017; Tarassishin et al., 2014; Li et al., 2016). Therefore, 
whilst other receptors may be capable of activating NF-κB signalling, in response 
to LPS this is predominantly mediated through the TLR-4. 
 
Activation of TLR-4 leads to recruitment of intracellular kinases. These kinases 
initiate multiple intracellular signalling cascades, including canonical NF-κB 
signalling, culminating in increased transcription of many genes associated with 
inflammation (fig. 1.2.5.2) (Gorina et al., 2011; Lu et al., 2008; Rosciszewski et 
al., 2018). Inhibition of TLR4 activation by LPS in astrocytes prevents NF-κB 
signalling. This is neuroprotective, reducing inflammation and improving memory 
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dysfunction in vitro and in vivo (Gong et al., 2014; Li et al., 2018; Muhammad et 
al., 2019; Zhou et al., 2015). This demonstrates that TLR-4 stimulation by LPS is 
an activator of NF-κB in astrocytes and that NF-κB plays a role in pathology. 
 
 In other cell types it has been demonstrated that NF-κB signalling can regulate 
glycolysis during inflammation through multiple mechanisms. These include 
direct regulation of glucose transporter (eg. GLUT1) expression and insertion into 
the membrane, and hexokinase II expression (Kawauchi et al., 2008b; Londhe et 
al., 2018; Sommermann et al., 2011). NF-κB may also indirectly regulate 
glycolysis by impacting the activity of other transcription factors including HIF-1α 
which can regulate expression of glycolytic enzymes (D'Ignazio et al., 2016; van 
Uden et al., 2008). This may suggest that the changes to glycolytic metabolism 
in astrocytes observed in the previous chapter are modulated by NF-κB 
signalling. 
 
Together this evidence may suggest that NF-kB plays a role in driving metabolic 
changes in astrocytes during inflammation.  To our knowledge this mechanism of 
metabolic regulation has not been explored in astrocytes. 
 
4.2 Hypothesis 
In this chapter I hypothesised that the metabolic response to inflammation in 
astrocytes is regulated by NF-κB signalling. 
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4.3 Results 
4.3.1 NF-κB inhibitor TPCA-1 reduced LPS-induced NF-κB Ser536 
phosphorlyation 
TPCA-1 was developed as a specific inhibitor of IKK-β and is used in this study 
to inhibit canonical NF-κB signalling (Podolin et al., 2005). To confirm that the 
concentration of TPCA-1 used was sufficient to inhibit NF-κB activation in mouse 
primary astrocytes, NF-κB phosphorylation (Ser536) was quantified using 
immunoblotting in lysates of cells treated with TPCA-1 and/or LPS for 3 hours 
and 24 hours. NF-κB phosphorylation (Ser536) was significantly increased by 
LPS treatment (3 hours, 71%, p=0.021; 24 hours, 84%, p=0.0208) but attenuated 
by TPCA-1 pre-treatment. This was evident to a greater extent after 24 hours (fig. 
4.3.1.1B; 20% increase from control, p=0.87) than after 3 hours (fig. 4.3.1.1A; 
41% increase from control, p=0.28). Total NF-κB expression was not altered by 
treatments after 3 hours or 24 hours (fig. 4.3.1.2A-B). 
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Figure 4.3.1.1: Pharmacological compound TPCA-1 inhibited NF-κB p65 
phosphorylation by LPS in mouse primary astrocytes. Mouse primary 
astrocytes were seeded at a density of 4.5 x 105 cells per dish in 60 mm dishes 
prior to treatment or vehicle. Cells were lysed and protein collected for 
immunoblotting. A-B. Immunoblot of NF-κB p65 phosphorylation (Ser536) 
with GAPDH loading control after 2 hours pre-treatment with NF-κB inhibitor 
TPCA-1 (1 µM) ± 3 hours (A) or 24 hours (B) treatment with lipopolysaccharide 
(LPS; 0.1 µg/mL). Top: Densitometric analysis of NF-κB p65 phosphorylation 
as a fold change from the mean of vehicle treated controls. Bottom:  
Representative blot. One-way ANOVA with post hoc Tukey, * p<0.05. n=6. 
Data are expressed as mean ± standard error of the mean. 
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Figure 4.3.1.2: TPCA-1 did not modulate NF-κB p65 expression in mouse 
primary astrocytes. Mouse primary astrocytes were seeded at a density of 
4.5 x 105 cells per dish in 60 mm dishes prior to treatment or vehicle. Cells 
were lysed and protein collected for immunoblotting.  A-B. Immunoblot of NF-
κB p65 with GAPDH loading control after 2 hours pre-treatment with NF-κB 
inhibitor TPCA-1 (1 µM) and 3 hours (A) or 24 hours (B) treatment with 
lipopolysaccharide (LPS; 0.1 µg/mL). Top: Densitometric analysis of NF-κB 
p65 as a fold change from the mean of vehicle treated controls. Bottom:  
Representative blot. One-way ANOVA with post hoc Tukey, n=6. Data are 
expressed as mean ± standard error of the mean. 
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4.3.2 TPCA-1 did not reduce cell viability 
At micromolar concentrations TPCA-1 has been reported to decrease cell viability 
in macrophages, dendritic cells and T-cells (Tilstra et al., 2014). To make sure 
inhibition of NF-κB signalling had no effect on cell viability which could affect our 
data, cell viability was measured using propidium iodide exclusion. TPCA-1 
treatment had no impact on cell viability (fig. 4.3.2; p=0.95). This indicates that 
any reduction in reported measures after inhibition with TPCA-1 are not 
attributable to reduced cell viability.   
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Figure 4.3.2: TPCA-1 did not affect cell viability in mouse primary 
astrocytes. Propidium iodide staining and flow cytometry of cells 24 hours 
after treatment. Cells were seeded at a density of 3.5 x 105 cells per well in a 
6 well plate. After treatment with LPS, cells were trypsinised and stained with 
2 µg/mL propidium iodide prior to analysis with the BD Accuri C6 Plus flow 
cytometer. A. 2 hours pre-treatment with NF-κB inhibitor TPCA-1 (1 µM) ± 
lipopolysaccharide (LPS; 0.1 µg/mL; n=3). One-way ANOVA with post hoc 
Tukey. Data are presented as mean ± standard error of the mean. B-E. Gating 
used to define events. Plot 2 region of interest and P1 defined non-viable cells. 
Example collection plots with data from Ctrl (B), LPS (C), TPCA-1 (D) TPCA-
1+LPS treated cells. 
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4.3.3 NF-κB inhibitor TPCA-1 reduced LPS induced cytokine release 
To confirm that NF-κB played a role in inflammatory signalling in mouse primary 
astrocytes, and regulated the cytokines measured in the study, TPCA-1 was used 
to inhibit NF-κB signalling. 2 hours of pre-treatment with TPCA-1 inhibited the 
inflammatory response to LPS after 3 hours and 24 hours of treatment. TNF-α 
and IL-6 release were significantly reduced by TPCA-1 (fig. 4.3.3A-D; p<0.0001).  
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Figure 4.3.3: NF-κB inhibition reduced LPS induced release of pro-
inflammatory cytokines in mouse primary astrocytes. Mouse primary 
astrocytes were seeded at a density of 4.5 x 105 cells per dish in 60 mm dishes 
prior to treatment or vehicle. Conditioned media was collected and used for 
estimation of extracellular cytokine concentrations using DuoSet ELISAs 
(BioTechne, UK). A-B. Extracellular TNF-α concentration after 2 hours pre-
treatment with NF-κB inhibitor TPCA-1 (1 µM) ± 3 hours (A; n=5) or 24 hours 
(B; n=4) lipopolysaccharide (LPS; 0.1 µg/mL) treatment. C-D. Extracellular IL-
6 concentration after 2 hours pre-treatment with TPCA-1 (1 µM) ± 3 hours (C) 
or 24 hours (D) LPS treatment (n=6). One-way ANOVA with post hoc Tukey, 
**** p<0.0001 relative to all other data sets on the graph. Data are expressed 
as mean ± standard error of the mean. 
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4.3.4 NF-κB inhibition reduced baseline glycolytic metabolism and 
prevented LPS induced increases in glycolytic rate 
Previously published work on other cell types has implicated NF-κB signalling in 
the regulation of cellular metabolism (Goetzman & Prochownik, 2018; 
Sommermann et al., 2011). To investigate the effect of inhibiting NF-κB signalling 
on glycolytic metabolism in mouse primary astrocytes during inflammation, 
astrocytes were exposed to TPCA-1 (1 µM) for 2 hours prior to treating with LPS 
for 3 hours, after which a Glycolytic Stress Test was performed. Cells treated with 
TPCA-1 and LPS displayed a 27% reduction in glycolytic rate compared to cells 
treated with LPS alone (fig. 4.3.4A-B; p<0.0001). This suggests that NF-κB 
signalling plays an instrumental role in the glycolytic response to LPS. 
Importantly, treatment with TPCA-1 alone reduced glycolytic rate by 28% 
compared to vehicle treated astrocytes (fig. 4.3.4A-B; p<0.0001). This suggests 
that NF-κB signalling plays an important role in regulating basal metabolism in 
astrocytes independently from pro-inflammatory signalling. Glycolytic capacity 
was also significantly reduced in TPCA-1 groups (in the presence (29%; 
p<0.0001) or absence (36%; p<0.0001) of LPS) compared to controls (fig. 
4.3.4C-D). This resulted in a reduction of glycolytic reserve in TPCA-1 groups of 
45% without LPS (p<0.0001) and 32% with LPS treatment (p<0.0001).  
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Figure 4.3.4: NF-κB inhibition reduced glycolytic metabolism in mouse 
primary astrocytes after 3 hours treatment with LPS. Cells were seeded 
at a density of 4 x 104 cells per well in Seahorse XF96 cell culture microplates. 
Glycolysis, represented as extracellular acidification rate (ECAR) of the cells 
was measured using the Seahorse BioAnalyzer XFe96 in conjunction with a 
Glycolytic Stress Test (Agilent, UK). A. ECAR of mouse primary cortical 
astrocytes during a Glycolytic Stress Test after 2 hour pre-treatment with NF-
κB inhibitor, TPCA-1 (1 µM) ± 3 hours lipopolysaccharide (LPS; 0.1 µg/mL) 
compared with vehicle treated control (0.017 mM fatty acid free bovine serum 
albumin/0.01% v/v DMSO). Glu= 10 mM glucose, Oligo = 1 µM oligomycin, 2-
DG = 10 mM 2-deoxyglucose. B. Glycolytic rate: change in ECAR after Glu 
treatment. C. Glycolytic capacity: change in ECAR after Oligo treatment. D. 
Glycolytic reserve: difference between glycolytic rate and glycolytic capacity. 
One-way ANOVA with post hoc Tukey; ns p>0.05, * p<0.05, ** p<0.01, **** 
p>0.0001; n=32, 2 independent plates. Data are expressed as mean ± 
standard error of the mean. 
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4.3.5 Inhibition of NF-κB did not have a regulatory effect on 
mitochondrial metabolism independently of LPS after 3 hours of 
treatment 
To investigate whether NF-κB signalling plays a role in normal mitochondrial 
function, Mito Stress Tests were conducted on mouse primary astrocytes pre-
treated with TPCA-1 for 2 hours prior to treatment with LPS for 3 hours. TPCA-1 
pre-treatment did not change mitochondrial maximal respiration, proton leak or 
spare capacity with or without treatment with LPS compared to vehicle treated 
controls (fig. 4.3.5.1C, D & F respectively). TPCA-1 pre-treatment prior to LPS 
significantly increased basal respiration by 18% (fig. 4.3.5.1B; p=0.01), 
increasing mitochondrial ATP production by 21% (fig. 4.3.5.1E; p=0.002), due to 
a 2% increase in coupling efficiency (fig. 4.3.5.1G; p=0.028). Despite increased 
mitochondrial ATP production, there was no change in intracellular ATP content 
after TPCA-1 treatment compared to vehicle treated controls (fig. 4.3.5.2). 
 
195 
 
 
 
 
196 
 
 
 
 
 
 
Figure 4.3.5.1: NF-κB inhibition did not alter mitochondrial function in 
astrocytes 3 hours after LPS treatment. Cells were seeded at a density of 
4 x 104 cells per well in Seahorse XF96 cell culture microplates. Oxidative 
phosphorylation, represented as oxygen consumption rate (OCR) of the cells 
was measured using the Seahorse BioAnalyzer XFe96 in conjunction with a 
Mito Stress Test (Agilent, UK). A. OCR of mouse primary cortical astrocytes 
during a Mito Stress Test after 2 hours pre-treatment with NF-κB inhibitor, 
TPCA-1 (1 µM) ± 3 hours lipopolysaccharide (LPS; 0.1 µg/mL) compared with 
vehicle treated control (0.017 mM fatty acid free bovine serum albumin/0.01% 
v/v DMSO). Oligo = 0.5 µM oligomycin, FCCP = 1 µM, R/A = 0.5 µM 
rotenone/antimycin. B. Basal respiration: difference in OCR prior to Oligo 
injection and after R/A injection. C. Maximal respiration: difference in OCR 
after injection of FCCP and after R/A injection. D. Proton leak: difference in 
OCR after Oligo injection and after R/A injection. E. ATP production: difference 
in OCR prior to Oligo injection and after Oligo injection. F. Spare capacity: 
difference in OCR between basal respiration (B) and maximal respiration (C). 
G. Coupling efficiency: percentage of basal respiration (B) used for ATP 
production (E). One-way ANOVA with post-hoc Tukey, * p<0.05, ** p<0.01; 
n=45, 3 independent plates. Data are presented as mean ± standard error of 
the mean. 
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Figure 4.3.5.2: NF-κB inhibition did not affect intracellular ATP in mouse 
primary astrocytes. Mouse primary astrocytes were seeded at a density of 4 
x 103 cells per well in black 96 well plates. Intracellular ATP (iATP) after 
treatment was estimated using the ATPLite TwoStep kit (PerkinElmer, UK). 
iATP represented as a fold change from the mean of vehicle treated controls 
(one-way ANOVA with post-hoc Tukey, p>0.05; n=4). Data are presented as 
mean ± standard error of the mean. 
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4.3.6 Glycolytic consequences of prolonged exposure to LPS were 
abolished through inhibition of NF-κB signalling 
To establish whether the longer-term effects of LPS on metabolism were 
impacted by inhibition of NF-κB, mouse primary astrocytes were cultured with 
TPCA-1 for 2 hours prior to addition of LPS for 24 hours. TPCA-1 treatment did 
not alter the astrocyte glycolytic rate after 24 hours in the presence or absence 
of LPS (fig. 4.3.6A-B). Treatment with TPCA-1 prevented the 24 hour LPS 
induced decrease in glycolytic capacity (fig. 4.3.6C; 37%; p=0.0003) and reserve 
(fig. 4.3.6D; 72% p<0.0001), but TPCA-1 alone did not alter glycolytic capacity 
or reserve when compared to vehicle treated astrocytes. 
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Figure 4.3.6: Inhibition of NF-κB signalling prevented the reduction in 
glycolytic capacity induced by 24 hours LPS treatment in mouse primary 
astrocytes. Cells were seeded at a density of 4 x 104 cells per well in 
Seahorse XF96 cell culture microplates. Glycolysis, represented as 
extracellular acidification rate (ECAR) of the cells was measured using the 
Seahorse BioAnalyzer XFe96 in conjunction with a Glycolytic Stress Test 
(Agilent, UK). A. ECAR of mouse primary cortical astrocytes during a 
Glycolytic Stress Test 24 hours after 2 hour pre-treatment with NF-κB inhibitor, 
TPCA-1 (1 µM) ± lipopolysaccharide (LPS; 0.1 µg/mL) compared with vehicle 
treated control (0.017 mM fatty acid free bovine serum albumin/0.01% v/v 
DMSO). Glu = 10 mM glucose, Oligo = 1 µM oligomycin, 2-DG = 10 mM 2-
deoxyglucose B. Glycolytic rate: change in ECAR after treatment with Glu. C. 
Glycolytic capacity: change in ECAR after treatment with Oligo. D. Glycolytic 
reserve: difference between glycolytic rate and glycolytic capacity. One-way 
ANOVA with post hoc Tukey, *** p<0.001, **** p<0.0001; n=32, 2 independent 
plates. Data are expressed as mean ± standard error of the mean. 
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4.3.7 GLUT1 expression was reduced by 24 hour LPS treatment in 
mouse primary astrocytes through NF-κB signalling 
To determine whether the LPS-induced decrease in GLUT1 was NF-κB 
dependent, lysates from mouse primary astrocytes cultured for 2 hours with 
TCPA-1 prior to treatment with LPS for 24 hours were immunoblotted with anti-
GLUT1. The LPS-induced reduction in GLUT-1 expression (47%; p<0.0001) was 
partially attenuated by TPCA-1 pre-treatment (fig. 4.3.7; p=0.081). 
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Figure 4.3.7: Inhibition of NF-κB prevented the suppression of GLUT1 
expression induced by 24 hours LPS treatment in mouse primary 
astrocytes. Mouse primary astrocytes were seeded at a density of 4.5 x 105 
cells per dish in 60 mm dishes prior to treatment or vehicle. Cells were lysed 
and protein collected for immunoblotting.  A. Representative immunoblot of 
GLUT1 expression with GAPDH loading control after 2 hour pre-treatment 
with NF-κB inhibitor TPCA-1 (1 µM) ± 24 hour treatment with 
lipopolysaccharide (LPS; 0.1 µg/mL). B. Densitometric analysis of A as a fold 
change from means of vehicle treated controls. One-way ANOVA with post 
hoc Tukey, **** p<0.0001, *** p<0.001; n=6. Data are expressed as mean ± 
standard error of the mean. 
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4.3.8 Inhibition of NF-κB altered mitochondrial respiration 
independently from LPS treatment after 24 hours 
To investigate the role of NF-κB in the previously observed mitochondrial 
response to a chronic inflammatory stimulus (fig. 3.3.14), astrocytes were pre-
treated with TPCA-1 for 2 hours prior to treatment for 24 hours with LPS. LPS-
induced increases in basal respiration (65%; p<0.0001), proton leak (84%; 
p<0.0001) and mitochondrial ATP production (61%; p<0.0001) were reduced by 
TPCA-1 pre-treatment (fig. 4.3.8.1A, B, D, & E). Maximal respiration was 
reduced by TPCA-1 pre-treatment with LPS treatment by 35% (p<0.0001). This 
was greater than the reduction induced by LPS-alone (-18%; p=0.013; fig. 
4.3.8.1C). Treatment with TPCA-1 alone reduced basal respiration and ATP 
production by 25% (p=0.013) and 24% (p=0.011) respectively, independently 
from LPS treatment (fig. 4.3.8.1B & F). Despite this change in mitochondrial ATP 
production, intracellular ATP levels were not altered (fig. 4.3.8.2). TPCA-1 
reduced maximal respiration by 33% (fig. 4.3.8.1C; p<0.0001), independently of 
LPS treatment, suggesting that NF-κB signalling may play a role in normal 
mitochondrial metabolism, which was attenuated by TPCA-1. TPCA-1 pre-
treatment attenuated the LPS induced 78% reduction in spare capacity to 55% 
(fig. 4.3.8.1F; p<0.0001). No significant change was seen in coupling efficiency 
after pre-treatment with TPCA-1 (fig. 4.3.8.1G). 
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Figure 4.3.8.1: NF-κB inhibition prevented LPS induced changes to 
mitochondrial metabolism in mouse primary astrocytes 24 hours after 
treatment. Cells were seeded at a density of 4 x 104 cells per well in Seahorse 
XF96 cell culture microplates. Oxidative phosphorylation, represented as 
oxygen consumption rate (OCR) of the cells was measured using the 
Seahorse BioAnalyzer XFe96 in conjunction with a Mito Stress Test (Agilent, 
UK). A. OCR of mouse primary cortical astrocytes during a Mito Stress Test 
24 hours after 2 hour pre-treatment with NF-κB inhibitor, TPCA-1 (1 µM) ± 
lipopolysaccharide (LPS; 0.1 µg/mL) compared with vehicle treated control 
(0.017 mM fatty acid free bovine serum albumin/0.01% v/v DMSO). Oligo = 
0.5 µM oligomycin, FCCP = 1 µM, R/A = 0.5 µM rotenone/antimycin. B. Basal 
respiration: difference in OCR prior to Oligo injection and after R/A injection. 
C. Maximal respiration: difference in OCR after injection of FCCP and after 
R/A injection. D. Proton leak: difference in OCR after Oligo injection and after 
R/A injection. E. ATP production: difference in OCR prior to Oligo injection and 
after Oligo injection. F. Spare capacity: difference in OCR between basal 
respiration (B) and maximal respiration (C). G. Coupling efficiency: 
percentage of basal respiration (B) used for ATP production (E). One-way 
ANOVA with post-hoc Tukey; **** p<0.0001, *** p<0.001, * p<0.05; n=30, 2 
independent plates. Data are presented as mean ± standard error of the 
mean. 
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Figure 4.3.8.2: Inhibition of NF-κB did not alter intracellular energy 
balance after 24 hours in mouse primary astrocytes. Mouse primary 
astrocytes were seeded at a density of 4 x 103 cells per well in black 96 well 
plates. Intracellular ATP (iATP) after treatment was estimated using the 
ATPLite TwoStep kit (PerkinElmer, UK). iATP represented as fold change in 
luminescence from the mean of vehicle treated controls (one-way ANOVA with 
post-hoc Tukey, p>0.05; n=4). Data are presented as mean ± standard error 
of the mean. 
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4.4 Discussion 
In this chapter I have demonstrated that NF-κB signalling regulates metabolism 
in mouse primary astrocytes both during inflammation and independently from a 
pro-inflammatory stimulus. This data supports our hypothesis. 
 
 Table 4.4.1 Summary of the astrocytic metabolic response to 3 
hours LPS treatment after inhibiting NF-κB signalling 
Experimental measure 3 hours 
LPS TPCA-1 + 
LPS 
TPCA-1 
G
ly
c
o
ly
s
is
 Rate Up Restored Down 
Capacity Up Restored Down 
Reserve Unchanged Down Down 
M
it
o
c
h
o
n
d
ri
a
l 
m
e
ta
b
o
li
s
m
 
Basal respiration Unchanged Up Unchanged 
Maximal respiration Unchanged Unchanged Unchanged 
Spare capacity Unchanged Unchanged Unchanged 
ATP production Unchanged Up Unchanged 
Proton leak Unchanged Unchanged Unchanged 
Coupling efficiency Unchanged Up Unchanged 
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 Table 4.4.2 Summary of the astrocytic metabolic response to 24 
hours treatment with LPS after inhibiting NF-κB signalling 
Experimental measure 24 hours  
LPS TPCA-1 + 
LPS 
TPCA-1 
G
ly
c
o
ly
s
is
 
GLUT1 expression Down Restored Unchanged 
Rate Unchanged Unchanged Unchanged 
Capacity Down Restored Unchanged 
Reserve Down Restored Unchanged 
M
it
o
c
h
o
n
d
ri
a
l 
m
e
ta
b
o
li
s
m
 
Basal respiration Up Restored Unchanged 
Maximal respiration Down Down Down 
Spare capacity Down 
Partially 
restored 
Down 
ATP production Up Restored Down 
Proton leak Up Restored Down 
Coupling efficiency Unchanged Unchanged Unchanged 
 
4.4.1 NF-κB signalling regulates release of pro-inflammatory agents in 
astrocytes 
The main receptor for LPS in astrocytes is TLR-4 (Gorina et al., 2011; Lu et al., 
2008). This receptor activates multiple intracellular pro-inflammatory signalling 
pathways, including MAPKs, Akt and NF-κB (Lu et al., 2008). NF-κB is activated 
through multiple mechanisms and an important regulatory mechanism is 
phosphorylation of Ser536 by IKK-β. Once phosphorylated NF-κB can translocate 
into the nucleus where it initiates transcription of target genes. In the model used 
here, the pro-inflammatory state caused by LPS was at least in part contributed 
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to by NF-κB signalling. Phosphorylation of NF-κB was induced by LPS at both 3 
hours and 24 hours. Pharmacological inhibition of IKK-β with TPCA-1 reduced 
both NF-κB phosphorylation and release of TNF-α and IL-6, which are 
transcriptionally regulated by NF-κB (Collart et al., 1990; Son et al., 2008; 
Sparacio et al., 1992). This has previously be demonstrated (Birrell et al., 2005; 
Podolin et al., 2005). However, it is worth noting that TPCA-1 has also been 
shown to inhibit STAT3, a transcription factor expressed in mouse primary 
astrocytes which plays a role in inflammatory signalling in other cell types (Nan 
et al., 2014). Therefore a role for STAT3 in the mechanisms explored here cannot 
be ruled out. Additionally, TLR-4 acts through multiple signalling pathways which 
were not explored in this body of work. These may play an integral role in 
astrocyte immunometabolism, which may be reflected through reduced 
autocrine/paracrine signalling. To investigate the role of these pathways would 
require data that is not currently available. 
 
4.4.2 NF-κB signalling regulates the metabolic response to 
inflammation in astrocytes 
Inhibition of NF-κB signalling abolished the metabolic changes induced by pro-
inflammatory stimuli. NF-κB signalling has been shown to increase translocation 
of GLUT transporters into the plasma membrane (Sommermann et al., 2011). 
GLUT transporters are important regulators of glycolytic rate (Macheda et al., 
2005). As inhibition of NF-κB signalling with TPCA-1 abolished LPS-induced 
increases in glycolytic rate and capacity 3 hours after treatment, NF-κB-regulated 
changes to GLUT localisation may be the mechanism through which mouse 
primary astrocytes increase glycolysis during pro-inflammatory stimulation. To 
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confirm this, further investigation looking at subcellular localisation of GLUT1 and 
other glucose transporters after pro-inflammatory stimulation in these cells is 
required. 
 
24 hours of LPS exposure significantly reduced glycolytic capacity and reserve, 
whilst basal mitochondrial metabolism was increased. These changes were 
attenuated by TPCA-1 pre-treatment, suggesting they were driven by NF-κB 
signalling. In other cell types, NF-κB promotes expression and stabilisation of p53 
(Aleyasin et al., 2004; Fujioka et al., 2004; Mauro et al., 2011). p53 expression 
reduces transcription of the glucose transporter GLUT1 (Johnson & Perkins, 
2012; Mauro et al., 2011; Schwartzenberg-Bar-Yoseph et al., 2004; Wang et al., 
2018). Glucose uptake and GLUT1 expression were significantly reduced by 24 
hours LPS treatment. This reduction in GLUT1 expression was abolished by 
TPCA-1 pre-incubation, suggesting glycolytic rate and capacity is reduced due to 
restricted glucose uptake due to NF-κB signalling increasing p53 activity and the 
subsequent suppression of GLUT1 expression. A restriction in glucose uptake 
through reduced GLUT1 expression may be a mechanism by which astrocytes 
attempt to reduce and/or resolve their inflammatory response via limiting 
glycolytic activity. The restoration of glycolytic capacity and rate after pre-
incubation with TPCA-1 may also be in part due to intracellular glycogen stores 
being maintained as the cells have not experienced a period of increased 
glycolysis.  
 
In the presence of p53, NF-κB promotes mitochondrial metabolism (Mauro et al., 
2011). p53 upregulates cytochrome oxidase II, a subunit of OXPHOS complex IV 
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(Matoba et al., 2006).  As the increase in basal mitochondrial metabolism was 
attenuated by TPCA-1, together these data may suggest that p53 is upregulated 
by NF-κB 24 hours after a pro-inflammatory stimulus. However, I did not directly 
measure p53 expression. This would be an interesting line of investigation to 
follow up, particularly in light of the role of p53 mutations in cancer, a disease 
which is well documented to have immunometabolic changes. 
 
Although the evidence presented in this chapter suggests it is likely that p53 is 
the driving mechanism of the immunometabolic changes reported here, there are 
multiple other pathways by which NF-κB could be acting that should be 
considered. NF-κB has been shown to promote mitochondrial health. The NF-κB 
subunit p62, which has not been investigated in this body of work, mediates 
mitophagy in response to LPS stimulation (Zhong et al., 2016). Mitophagy is the 
removal of damaged mitochondria through autophagy. Damaged mitochondria 
can recruit proteins that initiate apoptosis. Therefore, NF-κB driven mitophagy 
prevents apoptosis in response to mitochondrial damage. The work by Motori et 
al. and our previous data presented in Chapter 3 suggest that mitophagy may be 
important in astrocytes during inflammation (fig 3.3.11) (Motori et al., 2013). NF-
κB can also regulate mitochondrial dynamics in other cell types. Knock out of NF-
κB regulators IKKα, IKKβ and NEMO from a mouse endothelial fibroblast cell line 
significantly reduced expression of OPA1, a major regulator of inner 
mitochondrial membrane fusion. Additionally, TNF receptors were shown to 
maintain mitochondrial fusion through OPA1 driven by NF-κB and STAT3 
signalling in cardiomyocytes (Nan et al., 2017). Together, this suggests that NF-
κB signalling is important for mitochondrial fusion. However, I did not directly 
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explore the role of NF-κB on mitophagy and regulators of mitochondrial dynamics 
in these cells. This would be an interesting avenue for further study. 
 
 Beyond the regulation of mitochondrial dynamics, NF-κB signalling has been 
shown to regulate mitochondrial respiration through altering gene expression 
(Albensi, 2019). NF-κB binds the c-Myc promoter to increase expression of c-Myc 
(Ji et al., 1994). C-myc is an important transcription factor which is essential for 
the expression of mitochondrial proteins such as components of electron transfer 
chain complexes I, II and IV, and therefore normal OXPHOS function (Agarwal et 
al., 2019; Goetzman & Prochownik, 2018; Graves et al., 2012; Li et al., 2005; 
Wang et al., 2015). However, as c-Myc activity and expression was not measured 
in this body of work I cannot confirm the involvement of this transcription factor in 
astrocyte immunometabolism.  
 
4.4.3 NF-κB signalling maintains normal astrocyte metabolism in the 
absence of inflammatory stimulation 
In the absence of a pro-inflammatory stimulus, I demonstrate here that there is 
still a low level of NF-κB p65 phosphorylation in mouse primary astrocytes. 
Although in our model this may be an artefact of low levels of stress induced by 
in vitro culture, there are studies suggesting that there is also a low level of NF-
κB signalling present in astrocytes in vivo (Dresselhaus & Meffert, 2019). 
Interestingly, the data presented in this chapter suggests that NF-κB signalling is 
important for maintenance of normal metabolic function in the absence of a pro-
inflammatory stimulus. TPCA-1 treatment in the absence of a pro-inflammatory 
stimulus reduced glycolytic rate compared to vehicle treated controls. This 
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suggests that NF-κB plays a role in glycolysis during normal metabolic function. 
As this decrease in rate was only evident after the addition of glucose, it may 
indicate that inhibition of NF-κB signalling in astrocytes reduces the ability of the 
cell to take up exogenous glucose, rather than reflecting an altered ability to utilise 
internal glycogen stores. This may suggest that inhibition of NF-κB reduces 
GLUT1, and other glucose transporters, insertion into the cellular membrane. 
This would support the previous speculation that the increase in glycolytic rate 
driven by NF-κB is due to GLUT1 insertion into the membrane. Again, this would 
need to be verified through investigating the subcellular localisation of GLUT 
transporters. However, the decrease in glycolytic rate after NF-κB inhibition is 
transient, as the glycolytic profile is restored to control levels after 24 hours. This 
suggests that astrocytes have compensatory mechanisms to ensure normal 
cellular function can be maintained. Therefore, although NF-κB is important for 
normal glycolytic flux, it does not appear to be essential. 
 
After 24 hours inhibition of NF-κB signalling, mitochondrial metabolism is 
significantly decreased even in the absence of a pro-inflammatory stimulus. 
However, this is not evident 3 hours after NF-κB inhibition. This suggests that the 
role NF-κB plays in the maintenance of normal metabolic metabolism is in 
regulating transcription. Therefore, the absence of NF-κB signalling would not be 
evident until after autophagy of pre-existing proteins. However, the expression of 
many mitochondrial proteins is driven by promoters targeted by the transcription 
factor c-Myc during normal metabolism. As NF-κB promotes c-Myc transcription 
and expression, this may be the mechanism through which NF-κB maintains 
normal mitochondrial function (Ji et al., 1994). No later time points were 
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investigated, so I cannot comment on whether there may be redundancy 
mechanisms for maintaining mitochondrial function, although it is highly probable. 
 
Alternatively to translocating to the nucleus, the p65 NF-κB subunit can localise 
in the mitochondria after pro-inflammatory stimulation in the absence of tumour 
suppressor p53 (Cogswell et al., 2003; Johnson et al., 2011). This suppresses 
the transcription of mitochondrial genes and oxygen consumption through 
decreased cytochrome oxidase III expression. This is therefore a secondary 
mechanism through which NF-κB can regulate OXPHOS. To investigate whether 
this mechanism is playing a role in basal metabolism in these cells, employing 
methods to investigate subcellular localisation of p65 would be informative. 
Together, these data suggest that the low level of NF-κB phosphorylation plays 
a role in normal astrocyte metabolism. 
 
4.5 Conclusion 
This chapter demonstrates that the rapid and flexible glycolytic response to 
inflammatory insults in astrocytes was abolished through inhibition of canonical 
NF-κB signalling using the pharmacological inhibitor TPCA-1, implicating this 
pathway as a major regulator of inflammatory metabolism in astrocytes. 
Furthermore, pharmacological inhibition of NF-κB signalling was sufficient to 
impact basal glycolytic metabolism in astrocytes, independent of inflammation, 
suggesting an integral role for NF-κB in astrocyte resting metabolism. In support 
of the hypothesis, inhibition of glycolysis prevented cytokine release from 
astrocytes, and resulted in inhibition of NF-kB phosphorylation, suggesting that 
glycolysis in astrocytes is essential for maintaining an inflammatory response. 
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Together these data indicate that in astrocytes metabolic adaptations are 
necessary for the full inflammatory response to LPS and, in turn, inhibiting NF-κB 
signalling is sufficient to impact basal metabolism. 
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Figure 4.5: Summary of chapter. 3 hours after pro-inflammatory stimulus, 
astrocytes increase their use of glycolytic metabolism through NF-κB 
mediated mechanisms to allow the synthesis of cytokines. 24 hours after pro-
inflammatory stimulus, NF-κB driven mechanisms decrease glycolytic rate 
through downregulation of GLUT1 expression, and NF-κB signalling increases 
oxidative phosphorylation. 
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Chapter 5. TSPO as a regulator of astrocyte 
metabolism 
 
5.1 Introduction 
Translocator protein 18 kDa (TSPO) is an outer mitochondrial membrane (OMM) 
protein expressed in tissues throughout the body and highly conserved across 
kingdoms and phyla (Fan et al., 2012). In mammals TSPO expression is 
significantly upregulated during pro-inflammatory conditions including within the 
brain, most notably in glial cells, including astrocytes (McNeela et al., 2018).  
TSPO is also upregulated in many cancerous cells, including in gliomas (brain 
tumours) (Galiègue et al., 2004; Janczar et al., 2015; Miyazawa et al., 1998). This 
has led to TSPO being used as a radioligand target for positron emission 
tomography (PET) imaging for neuroinflammatory conditions such as Alzheimer’s 
disease (Edison et al., 2018; Largeau et al., 2017).  
 
Interest in the function of TSPO increased when evidence began to emerge 
demonstrating anti-inflammatory and protective properties of some TSPO 
ligands. This suggested therapeutic potential in targeting TSPO (Arbo et al., 
2015). In cells in culture, TSPO ligands derived from a natural TSPO antagonist 
called quinazoline, such as PK11195, reduce LPS-induced microglial activation, 
reducing release of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6 
(Bae et al., 2014; Biswas et al., 2018). In vivo TSPO agonists have protective 
effects. Etifoxine reduces oedema after intracerebral haemorrhage in rodents, 
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promoting healing and reducing inflammation through an action on microglia, and 
reduces neuronal loss after traumatic brain injury in rats (Li et al., 2017; 
Shehadeh et al., 2019). TSPO agonist XBD-173 (emapunil, AC-5216) protects 
against neurodegeneration in a mouse model of Parkinson’s disease, and retinal 
ischemia (Gong et al., 2019; Mages et al., 2019). Quinazoline-derived tricyclic 
compounds which modulate TSPO have also been reported to have protective 
effects on glioblastoma cells, preventing cell death from glutamate toxicity 
(Vainshtein et al., 2015). Together these data suggest that modulation of TSPO 
activity is protective in neurological disease or after CNS injury. 
 
For many years the primary function of TSPO was thought to be as a regulator of 
steroidogenesis due to its proposed role in transporting cholesterol into 
mitochondria (Papadopoulos et al., 2018). As such, the CNS protective effects of 
TSPO ligands have been partially attributed to increased neurosteroid production 
(Dhir & Rogawski, 2012). However, recently the importance of TSPO in 
steroidogenesis in vivo has been called into question because, on the cellular 
and whole organism level, steroid production is maintained even in the absence 
of TSPO (Tu et al., 2014). This suggests that the role of TSPO in regulating 
inflammation is probably partially independent of any contribution to 
steroidogenesis. 
 
Emerging evidence from multiple independent research teams suggests that 
TSPO plays a role in regulating mitochondrial metabolism. For example, deletion 
of TSPO from MA-10 steroidogenic cells increases fatty acid oxidation (FAO) and 
the expression of genes associated with its regulation, including carnitine 
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palmitoyl transferase 1A (CPT-1A), the rate-limiting enzyme in this process (Tu 
et al., 2016). Additionally, complementary independent data shows that systemic 
treatment with the TSPO antagonist PK11195 increases gene expression of 
CPT-1A in mice and zebrafish (Gut et al., 2013). CPT-1A, like TSPO, is localised 
to the outer mitochondrial membrane where it is critical for mediating the transport 
of fatty acids into the mitochondrion for oxidation. As yet, the regulatory role of 
TSPO in astrocyte metabolism is unclear. 
 
As further support of a potential role in regulating cellular metabolism, TSPO 
expression is upregulated in cancerous cells. In many cancers, cells undergo a 
metabolic shift termed the ‘Warburg effect’ characterised by increased aerobic 
glycolysis and lactate production, and a decrease in mitochondrial respiration 
(Vander Heiden et al., 2009). I postulate that in this context the decrease in 
mitochondrial respiration may potentially be modulated through increased 
expression of TSPO.  
 
Taken together these studies support an important regulatory role for TSPO in 
suppressing fatty acid metabolism potentially by regulating CPT-1A activity. 
These data may suggest that the anti-inflammatory and protective action of TSPO 
ligands observed by others may be driven through TSPO-mediated regulation of 
cellular metabolism, which may be a promising therapeutic target for reducing 
inflammation in astrocytes. 
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5.2 Hypothesis 
I hypothesise that the anti-inflammatory actions of TSPO ligands are driven by 
modulation of cellular metabolism via an interaction with CPT-1A. By 
understanding the role of TSPO in astrocyte metabolism I hope to further 
development of therapies for CNS disease. 
 
5.3 Results 
5.3.1 TSPO expression was upregulated after 24 hours in LPS treated 
mouse primary astrocytes 
TSPO expression has been reported to be upregulated in response to 
inflammation in many cell types, both in vivo and in vitro (McNeela et al., 2018). 
To confirm that TSPO expression was regulated during inflammation in mouse 
primary astrocytes, the cells were exposed to LPS for 3 hours or 24 hours, and 
protein lysates were immunoblotted to quantify relative expression of TSPO. 3 
hours after LPS treatment there was no significant change in TSPO expression 
compared with vehicle treated cells (fig. 5.3.1A & B). However, TSPO expression 
was significantly increased (40% increase; fig. 5.3.1C & D; p=0.0396) after 24 
hours of exposure to LPS. 
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Figure 5.3.1: TSPO expression in mouse primary astrocytes was 
increased after 24 hours of LPS treatment. Mouse primary astrocytes were 
seeded at a density of 4.5 x 105 cells per dish in 60 mm dishes prior to 
treatment with lipopolysaccharide (LPS; 0.1 µg/mL) or vehicle. Cells were 
lysed and protein collected for immunoblotting. A. Representative immunoblot 
of TSPO expression with GAPDH loading control after 3 hours treatment with 
LPS. B.  Densitometric analysis of A as fold change from mean of vehicle 
treated controls. C. Representative immunoblot of TSPO expression with 
GAPDH loading control after 24 hours LPS treatment. D. Densitometric 
analysis of C as fold change from mean of vehicle treated controls. Unpaired 
t-test, * p>0.05; n=12. Data are expressed as mean ± standard error of the 
mean. 
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5.3.2 TSPO expression in mouse primary astrocytes was decreased 
following inhibition of glycolysis with 2-DG 
As demonstrated in Chapters 3 and 4 of this thesis, mouse primary astrocytes 
have a metabolic response to LPS-induced inflammation. As TSPO is regulated 
during inflammation, I investigated whether TSPO expression could be regulated 
by metabolic fluctuations independent of inflammatory activation. After 24 hours 
of treatment, TSPO expression was decreased significantly by the glycolytic 
inhibitor 2-DG (50% reduction; p=0.0016), but was not modulated by the AMP 
kinase (AMPK) activator AICAR (fig. 5.3.2). Treatment with 0.1 µg/mL LPS was 
used as a positive control (50% increase; p=0.0013).  
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Figure 5.3.2: TSPO expression was reduced following inhibition of 
glycolysis with 2-DG but unchanged by activation of the major metabolic 
regulator AMPK. Mouse primary astrocytes were seeded at a density of 4.5 
x 105 cells per dish in 60 mm dishes prior to treatment or vehicle. Cells were 
lysed and protein collected for immunoblotting.  A. Representative immunoblot 
of TSPO expression with GAPDH loading control after 24 hours treatment with 
lipopolysaccharide (LPS; 0.1 µg/mL), 2-deoxyglucose (2-DG; 10 mM), or 
AMPK activator AICAR (1 µM). B. Densitometric analysis of A as fold change 
from mean of vehicle treated controls. One-way ANOVA with post-hoc Tukey, 
** p<0.01; n=11. Data are expressed as mean ± standard error of the mean. 
224 
 
5.3.3 TSPO ligands did not cause cell death after 24 hours 
To ensure the concentrations of TSPO ligands used in the forthcoming studies 
were not causing cell death, cell viability was measured after 24 hours of 
treatment by measuring propridium iodide exclusion using flow cytometry. The 
TSPO antagonist PK11195 (fig. 5.3.3.1; 50 nM) did not cause significant cell 
death. The TSPO agonist XBD-173 (fig. 5.3.3.2; 50 µM) decreased cell viability 
by 3.4% after 24 hours of treatment compared to DMSO vehicle treated controls 
(p=0.02). However, while statistically significant, this low percentage of cell death 
is unlikely to be responsible for the magnitude of change seen in other 
experiments using this ligand.  
 
Further studies in this chapter used 25 nM PK11195, as the KD (equilibrium 
dissociation constant) of the compound is reported as 7.4 ± 3 nM, reported as 
and concentrations greater than 1 µM of PK11195 are reported to have off-target 
effects, including inhibiting ATP synthesis (Hatty et al., 2014; Cleary et al., 2007; 
James et al., 2006; Kita et al., 2004; Lacapère et al., 2001). Although the Ki 
(inhibitory constant) of XBD-173 is reported as 0.297 ± 0.009 nM (when 
displacing [3H]-PK11195), XBD-173 was used at 25 µM to enable comparison 
with previously published literature while minimising cell death (Biswas et al., 
2018; Karlstetter et al., 2014; Kita et al., 2004; Ravikumar et al., 2016).  
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Figure 5.3.3.1: The TSPO ligand PK11195 did not decrease viability of 
mouse primary astrocytes after 24 hours of treatment. Cells were seeded 
at a density of 3.5 x 105 cells per well in a 6 well plate. After treatment with 
LPS, cells were dissociated and stained with 2 µg/mL propidium iodide prior 
to analysis with the BD Accuri C6 Plus flow cytometer. A. Percentage of cells 
excluding propidium iodide 24 hours after treatment with PK11195 (50 nM). 
Unpaired t-test; n=3. Data are expressed as mean ± standard error of the 
mean. B-C. Gating used to define events. Plot 2 region of interest P2 defined 
non-viable cells from plot 1 region of interest P1. Example collection plots 
contain data from control (B) and PK11195 (C; 50 nM) treated cells. 
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Figure 5.3.3.2: The TSPO ligand XBD-173 did not have a major impact on 
viability of mouse primary astrocytes after 24 hours of treatment. Cells 
were seeded at a density of 3.5 x 105 cells per well in a 6 well plate. After 
treatment with LPS, cells were dissociated and stained with 2 µg/mL 
propidium iodide prior to analysis with the BD Accuri C6 Plus flow cytometer. 
A. Percentage of cells excluding propidium iodide 24 hours after treatment 
with XBD-173 (50 µM). Unpaired t-test, * p<0.05; n=3. Data are expressed as 
mean ± standard error of the mean. B-C. Gating used to define events. Plot 2 
region of interest P2 defined non-viable cells from plot 1 region of interest P1. 
Example collection plots contain data from control (B) and XBD-173 (C; 50 
µM) treated cells. 
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5.3.4 TSPO ligands did not reduce inflammation in mouse primary 
astrocytes 
There have been several reports from in vivo models that TSPO ligands reduce 
inflammation, including in the CNS (Bae et al., 2014; Biswas et al., 2018; 
Daugherty et al., 2013). ELISAs against TNF-α and IL-10 were used to measure 
cytokine release from astrocytes after LPS treatment in the presence or absence 
of TSPO ligands. LPS increased astrocyte TNF-α release after 3 hours 
(p<0.0001). However, neither PK11195 (fig. 5.3.4.1A; 25 nM) nor XBD-173 (fig. 
5.3.4.1B; 25 µM) reduced this LPS-induced TNF-α release. LPS increased IL-10 
release after 24 hours (p<0.0001). While PK11195 had no impact (fig. 5.3.4.2A), 
XBD-173 significantly reduced LPS-induced IL-10 from astrocytes by 85.3% (fig. 
5.3.4.2B; p<0.0001). 
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Figure 5.3.4.1: TSPO ligands did not change LPS-induced TNF-α release 
from mouse primary astrocytes. Mouse primary astrocytes were seeded at 
a density of 4.5 x 105 cells per dish in 60 mm dishes prior to treatment or 
vehicle. Conditioned media was collected and used for estimation of 
extracellular cytokine concentrations using DuoSet ELISAs (BioTechne, UK). 
A. TNF-α release from mouse primary astrocytes after 1 hour PK11195 (25 
nM) pre-treatment and 3 hours lipopolysaccharide (LPS; 0.1 µg/mL) treatment 
(n=6). B. TNF-α release from mouse primary astrocytes after 1 hour XBD-173 
(25 µM) pre-treatment and 3 hours LPS treatment (n=6). One-way ANOVA 
with post-hoc Tukey, *** p<0.001, ns p>0.05. Data are presented as mean ± 
standard error of the mean. 
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Figure 5.3.4.2: TSPO ligands had differential effects on LPS-induced IL-
10 release from mouse primary astrocytes. Mouse primary astrocytes 
were seeded at a density of 4.5 x 105 cells per dish in 60 mm dishes prior to 
treatment or vehicle. Conditioned media was collected and used for 
estimation of extracellular cytokine concentrations using DuoSet ELISAs 
(BioTechne, UK). A. IL-10 release from mouse primary astrocytes after 1 hour 
PK11195 (25 nM) pre-treatment and 24 hours lipopolysaccharide (LPS; 0.1 
µg/mL) treatment (n=6). B. IL-10 release from mouse primary astrocytes after 
1 hour XBD-173 (25 µM) pre-treatment and 24 hours LPS treatment (n=5). 
One-way ANOVA with post-hoc Tukey, **** p<0.0001, ns p>0.05. Data are 
presented as mean ± standard error of the mean. 
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5.3.5 TSPO ligands altered basal metabolism in mouse primary 
astrocytes 
Mouse primary astrocytes were treated with TSPO ligands for 1 hour prior to 
measuring basal extracellular acidification rate (ECAR) as a measure of 
glycolysis and basal oxygen consumption rate (OCR) as a measure of 
mitochondrial metabolic function. TSPO antagonist PK11195 (25 nM) 
significantly increased ECAR by 52% (fig. 5.3.5.1C-D; p=0.0052), and OCR by 
62% (fig. 5.3.5.1A-B; p=0.0133). Conversely TSPO agonist XBD-173 (50 µM) 
significantly decreased ECAR by 35% (fig. 5.3.5.2C-D; p=0.001). XBD-173 (50 
µM) significantly reduced OCR by 57% compared to control (fig. 5.3.5.2A-B; 
p=0.0001). However, lower concentrations of XBD-173 (25 µM) did not alter 
either OCR or ECAR after 1 hour of treatment (fig. 5.3.5.2C-D).  Although basal 
metabolism was altered within an hour, mitochondrial membrane potential, 
measured by TMRE uptake, was not altered 1 hour after treatment with TSPO 
ligands (fig. 5.3.5.3), in contrast to the positive control FCCP which caused a 
71% reduction (P<0.0001). Glucose uptake was also unaltered 1 hour after 
treatment with TSPO ligands (fig. 5.3.5.4). 
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Figure 5.3.5.1: TSPO ligands altered basal metabolic rate in mouse 
primary astrocytes. Cells were seeded at a density of 4 x 104 cells per well 
in Seahorse XF96 cell culture microplates. After 1 hour pre-treatment, 
oxidative phosphorylation rate, represented as oxygen consumption rate 
(OCR) and glycolysis represented as extracellular acidification rate (ECAR) of 
the cells were measured using the Seahorse BioAnalyzer XFe96.  A. OCR 
after 1 hour pre-treatment with PK11195 (n=14-16). B. Area under the curve 
(AUC) of A. C. ECAR after 1 hour pre-treatment with PK11195 (n=14-16). D. 
AUC of C. One-way ANOVA with post-hoc Tukey, ** p<0.01, * p<0.05. Data 
are presented as mean ± standard error of the mean. 
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Figure 5.3.5.2: TSPO ligands altered basal metabolic rate in mouse 
primary astrocytes. Cells were seeded at a density of 4 x 104 cells per well 
in Seahorse XF96 cell culture microplates. After 1 hour pre-treatment, 
oxidative phosphorylation rate, represented as oxygen consumption rate 
(OCR) and glycolysis represented as extracellular acidification rate (ECAR) of 
the cells were measured using the Seahorse BioAnalyzer XFe96. A.  
Mitochondrial metabolic rate represented by oxygen consumption rate (OCR) 
after 1 hour pre-treatment with XBD-173 (n=16-18). B. Area under the curve 
(AUC) of A. C. Glycolytic rate represented by the extracellular acidification rate 
(ECAR) after 1 hour pre-treatment with XBD-173 (n=16-18). D. AUC of C. 
One-way ANOVA with post-hoc Tukey, *** p<0.001, ** p<0.01. Data are 
presented as mean ± standard error of the mean. 
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Figure 5.3.5.3: TSPO ligands did not alter mitochondrial membrane 
potential. TMRE uptake by mouse primary astrocytes after 1 hour incubation 
with PK11195 (25 nM) or XBD-173 (25 µM), relative to DMSO vehicle treated 
control. FCCP (1 µM) used as positive depolarisation control. Cells were 
seeded at a density of 3.5 x 105 cells per well in a 6 well plate. After treatment 
with LPS, cells were dissociated and incubated with FCCP prior to incubation 
with TMRE (100 nM) and analysis with the BD Accuri C6 Plus flow cytometer. 
One-way ANOVA with post hoc Tukey, **** p<0.0001; n=4. Data are 
presented as mean ± standard error of the mean.  
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Figure 5.3.5.4: TSPO ligands did not alter glucose uptake rate. Mouse 
primary astrocytes were seeded at a density of 4 x 104 cells per well in 96 well 
plates. Glucose uptake rate after treatment with lipopolysaccharide (LPS) was 
estimated using the Glucose Uptake-Glo kit (Promega, UK). Glucose uptake 
by mouse primary astrocytes was represented as fold change 2-
deoxyglucose-6-phosphate (2DG6P) luminescence after 1 hour incubation 
with PK11195 (25 nM) or XBD-173 (25 µM), relative to mean of 
contemporaneous DMSO vehicle treated controls. One-way ANOVA with post 
hoc Tukey; n=6. Data are presented as mean ± standard error of the mean.  
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5.3.6 The TSPO ligand XBD-173 increased fatty acid oxidation 
Modulation of TSPO activity impacts fatty acid metabolism in other cell types (Gut 
et al., 2013; Kim et al., 2019; Tu et al., 2016). To explore this in astrocytes, mouse 
primary astrocytes treated for 1 hour with TSPO ligands were evaluated in the 
Seahorse bioanalyser using a fatty acid oxidation (FAO) Mito Stress Test, as 
described in the methods. By limiting access to glucose and pyruvate overnight, 
and providing carnitine and exogenous fatty acids in the form of palmitate (C16), 
the cells decrease glucose metabolism and increase dependency on fatty acid 
metabolism. By blocking fatty acid transport into the mitochondria in some of the 
cells using CPT-1 inhibitor etomoxir (40 µM), this assay allows quantification of 
oxygen consumption specifically attributable to oxidation of fatty acids (see fig. 
2.2.12.4). Treatment with PK11195 did not alter the basal or maximal rate of FAO 
compared to vehicle treated controls (fig. 5.3.6A, C & D). However, treatment 
with XBD-173 increased basal FAO rate by 219.6% (fig. 5.3.6B & C; p=0.005) 
and maximal respiration by 152.8% (fig. 5.3.6B & D; p=0.0019) compared to 
vehicle treated controls. 
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Figure 5.3.6: TSPO ligand XBD-173 increased fatty acid oxidation rate in 
mouse primary astrocytes. Cells were seeded at a density of 4 x 104 cells 
per well in Seahorse XF96 cell culture microplates. Oxidative phosphorylation, 
represented as oxygen consumption rate (OCR) of the cells was measured 
using the Seahorse BioAnalyzer XFe96 in conjunction with a fatty acid 
oxidation (FAO) Mito Stress Test (Agilent, UK). A. Time course of FAO Mito 
Stress test in PK11195 treated mouse primary astrocytes. B. Time course of 
FAO Mito Stress test in XBD-173 treated mouse primary astrocytes. Ligands 
[PK11195 (25 nM) or XBD-173 (25 µM)], oligomycin (oligo; 0.5 µM), FCCP (1 
µM), and rotenone/antimycin (R/A; 0.5 µM) were added as indicated by 
vertical dotted lines. Palmitate (200µM; C16) was added at time = 0. C. Basal 
FAO rate calculated as the difference in OCR between etomoxir treated 
negative controls (eto; 40 µM) and the comparable treatment group 
immediately prior to addition of oligo. D. Maximal FAO rate calculated as the 
difference in OCR between etomoxir treated negative controls (eto; 4 µM) and 
the comparable treatment group after addition of FCCP. One-way ANOVA 
with post hoc Tukey, ** p<0.01. n=19-21. Data are presented as mean ± 
standard error of the mean. 
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5.3.7 TSPO knock out astrocytes did not express TSPO 
Due to concerns about potential off-target effects of TSPO ligands, TSPO knock 
out models were employed to further explore the role of the protein in cellular 
metabolism and verify the specificity of the TSPO ligands (Bader et al., 2019; 
Cleary et al., 2007). Two different models were used: primary astrocytes derived 
from mice with germline knock out of TSPO (TSPO-/-) and a CRISPR/Cas9 gene 
edited TSPO-deficient human astroglioma cell line (U373). 
 
Mouse TSPO-/- astrocytes were used to more directly compare with the data 
collected in mouse primary astrocytes using ligands. These cells were 
untransformed so were less likely to display phenotypic drift than frequently 
passaged immortalised cell lines. This means the cells may behave more closely 
to how they would behave in vivo. Additionally, to complement the data collected 
with mouse primary astrocytes and TSPO ligands it was important to use 
astrocytes from the same species, particularly as has been shown that human 
astrocytes behave differently to mouse astrocytes (Oberheim et al., 2009). The 
transformed U373 cell line was also used as there is evidence in the literature 
that TSPO is highly expressed in cancer cells, such as astrogliomas. Therefore, 
studying the function of TSPO in the human astroglioma U373 cell line was an 
interesting model for studying TSPO in the context of a cancer cell. 
 
Germline heterozygous (TSPO+/-) mice were imported from MRC Harwell from 
mice re-derived from sperm obtained from the Infrafrontier European Mutant 
Mouse Archive and used to establish a breeding colony in Exeter. Astrocytes 
from TSPO-/- animals of both sex were used and compared to wild-type (TSPO+/+) 
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littermates. TSPO expression was verified in TSPO+/+ and TSPO-/- mouse primary 
astrocytes using immunoblotting (fig. 5.3.7A). GFAP expression was used to 
confirm the lysates were from astrocytes (fig. 5.3.7B).  
 
The U373 CRISPR/Cas9 TSPO deficient cell line was created by Daisy Stewart 
as part of her professional training year project in the Ellacott lab under the 
guidance of Dr Rosie Bamford and Dr Asami Oguro-Ando. TSPO expression was 
verified in the unmodified control (WT), empty vector (EV) and TSPO deficient 
(KO) cells using immunoblotting by Daisy Stewart under my guidance (fig. 
5.3.7C). 
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Figure 5.3.7: The genetically modified cells used did not express TSPO 
Mouse primary astrocytes or U373 astroglioma cells were seeded at a density 
of 4.5 x 105 cells per dish in 60 mm dishes prior to lysis. Protein collected for 
immunoblotting. A. Immunoblot of TSPO expression in mouse primary 
astrocytes from TSPO+/+ and TSPO-/- mice. GAPDH was used as a loading 
control. B. Immunoblot of GFAP expression in mouse primary astrocytes from 
TSPO+/+ and TSPO-/- mice. GAPDH was used as a loading control. Columns 
(1-3) indicate independent samples from different animals (same samples 
used in panels A and B). C. Immunoblot of TSPO expression in U373 lysates 
from untransfected cells (WT), cells transfected with an empty CRISPR/Cas9 
vector (EV), and transfected with a CRISPR/Cas9 vector containing guide 
RNA (KO). GAPDH was used as a loading control. 
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5.3.8 TSPO expression was higher in U373 astrocytoma cells than in 
mouse primary astrocytes 
To assess baseline differences between the two models used, TSPO expression 
was compared in 10 µg of lysate from a number of different glial cell types in 
culture. Subjectively, TSPO expression appeared to be higher in U373 
astroglioma cells compared to mouse primary astrocytes (CRT). Although equal 
quantities of protein were loaded TSPO expression could not be accurately 
quantified due to the significant variation in GAPDH expression between cell 
types (fig. 5.3.8; immunoblot performed by Daisy Stewart under my supervision). 
Whilst this difference in TSPO expression is interesting, and something to bear 
in mind when considering the other data sets collected in these cell types this 
experiment would need further repeats, including an appropriate loading control 
of total protein to be able to draw conclusions from it. Out of interest, human 
primary astrocytes (HPA) and mouse microglia (BV-2) cell lines were also 
compared, and found to express TSPO; however, these are not explored further 
in this thesis. 
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Figure 5.3.8: TSPO was differentially expressed in different glial cell 
types. Immunoblot of TSPO expression in 10 µg protein lysate from human 
astroglioma (U373), mouse microglia (BV-2), mouse primary astrocytes 
(CRT), and human primary astrocytes (HPA). GAPDH was used as a loading 
control. Cells were seeded at a density of 4.5 x 105 cells per dish in 60 mm 
dishes prior to lysis and protein collection for immunoblotting. 
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5.3.9 Basal metabolic parameters were different in U373 and mouse 
primary astrocytes 
To assess whether U373 human astrocytoma and mouse primary astrocytes had 
different basal metabolic phenotypes they were directly compared using the 
Seahorse metabolic analyser by Daisy Stewart under my supervision. Compared 
with mouse primary astrocytes, U373 cells had 40.7% lower mitochondrial 
respiration (fig. 5.3.9A; p<0.0001) but 56.3% higher glycolytic rate (fig. 5.3.9B; 
p=0.0003). This suggests that in line with what is reported in many cancer cell 
types, U373 cells are more reliant on glycolysis than mouse primary astrocytes, 
which showed comparatively higher OXPHOS (DeBerardinis & Chandel, 2016). 
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Figure 5.3.9: U373 astroglioma cells and mouse primary astrocytes had 
different metabolic phenotypes. Cells were seeded at a density of 4 x 104 
cells per well in Seahorse XF96 cell culture microplates. Oxidative 
phosphorylation rate, represented as oxygen consumption rate (OCR) and 
glycolysis represented as extracellular acidification rate (ECAR) of the cells 
were measured using the Seahorse BioAnalyzer XFe96.  A. OCR in U373 and 
mouse primary astrocytes. B. ECAR in U373 and mouse primary astrocytes. 
C. OCR compared to ECAR of mouse primary astrocytes and U373 cells. 
Unpaired t-test, **** p<0.0001, *** p<0.001; n=22-24. Data are presented as 
mean ± standard error of the mean. 
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5.3.10 Metabolic effects of TSPO ligands were absent in TSPO-KO 
U373 astroglioma cells 
To verify that PK11195 did not have off-target effects at the concentrations used 
in these studies, TSPO-KO U373 cells were treated with PK11195 (25 nM) and 
XBD-173 (25 µM) for 1 hour prior to metabolic analysis. Whilst PK11195 
increased ECAR by 63% in WT U373 cells (fig. 5.3.10B; p<0.0001), this effect 
was completely attenuated by loss of TSPO (p=0.95). XBD-173 did not alter 
ECAR or OCR after 1 hour treatment in WT or TSPO-KO U373 cells (fig. 5.3.10A 
& B); however, based on the earlier studies with mouse primary astrocytes (fig. 
5.3.5) this was not unexpected at the concentration used in this experiment. 
Contrary to studies in mouse primary astrocytes (fig. 5.3.5.1) OCR was not 
significantly increased after treatment with PK11195 (fig. 5.3.10A). Interestingly, 
loss of TSPO in U373 cells reduced basal OCR by 24% (fig. 5.3.10A; p=0.0131) 
and ECAR by 47% (fig. 5.3.10B; p=0.0052) compared to WT controls. This is 
further evidence that TSPO modulates astrocyte metabolism. 
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Figure 5.3.10: Loss of TSPO prevented TSPO ligand induced changes to 
U373 astroglioma metabolism. Cells were seeded at a density of 4 x 104 
cells per well in Seahorse XF96 cell culture microplates. After 1 hour pre-
treatment, oxidative phosphorylation rate, represented as oxygen 
consumption rate (OCR) and glycolysis represented as extracellular 
acidification rate (ECAR) of the cells were measured using the Seahorse 
BioAnalyzer XFe96. A. Area under the curve (AUC) of the OCR of U373 cells 
expressing TSPO (WT) or not expressing TSPO (KO) 1 hour after treatment 
with PK11195 (25 nM) or XBD-173 (25 µM). Two-way ANOVA: Genotype 
p=0.0002, F(1,134)=14.39; Ligand p=0.044, F(2,134)=3.19; Interaction p=0.22, 
F(2,134)=1.53 B. AUC of the ECAR of TSPO-WT or TSPO-KO 1 hour after 
treatment with PK11195 or XBD-173. Two-way ANOVA: Genotype, 
p<0.0001, F(1,134)=194.0; Ligand, p<0.0001, F(2,134)=58.51; Interaction, 
p<0.0001, F(2,134)=56.95.  Multiple comparisons by post-hoc Tukey’s, * 
p<0.05, ** p<0.01, **** p<0.0001; n=22-26. Data are presented as mean ± 
standard error of the mean. 
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5.3.11 Loss of TSPO reduced mitochondrial respiration in mouse 
primary astrocytes 
Metabolism in TSPO-deficient mouse primary astrocytes was measured using a 
Mito Stress Test in the Seahorse bioanalyser. TSPO-/- astrocytes had 37.1% 
reduction in basal mitochondrial metabolism compared to TSPO+/+ astrocytes 
(fig. 5.3.11.1A & B; p=0.0006). Loss of TSPO also reduced maximal 
mitochondrial metabolism by 40.2% (fig. 5.3.11.1A & C; p=0.0012). Proton leak 
and ATP production were also reduced in TSPO-/- in astrocytes by 46% and 
35.8% respectively (fig. 5.3.11.1D, p<0.0001; fig. 5.3.11.1E, p=0.0009). 
However, spare capacity and coupling efficiency were unaltered (fig. 5.3.11.1F 
& G). ECAR prior to addition of oligomycin was reduced by 52.6% in TSPO-/- cells 
(fig. 5.3.11.2; p=0.0001). This suggests TSPO-/- reduced glycolytic rate in mouse 
primary astrocytes. 
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Figure 5.3.11.1: Loss of TSPO reduced mitochondrial metabolism in 
mouse primary astrocytes. Cells were seeded at a density of 4 x 104 cells 
per well in Seahorse XF96 cell culture microplates. Oxidative phosphorylation, 
represented as oxygen consumption rate (OCR) of the cells was measured 
using the Seahorse BioAnalyzer XFe96 in conjunction with a Mito Stress Test 
(Agilent, UK). A. OCR of mouse primary cortical astrocytes during a Mito 
Stress Test expressing (+/+) and not expressing TSPO (-/-). Oligomycin 
(Oligo; 0.5 µM), FCCP (1 µM), and rotenone/antimycin (R/A; 0.5 µM) were 
added as indicated by vertical dotted line. B. Basal mitochondrial respiration 
in TSPO +/+ and -/- mouse primary astrocytes, calculated as the difference in 
OCR before addition of Oligo and after addition of R/A. C. Maximal 
mitochondrial respiration, calculated as the difference in OCR after addition of 
FCCP and after addition of R/A. D. Proton leak, calculated as the difference 
between OCR after Oligo addition and after addition of R/A. E. Mitochondrial 
ATP production, calculated as the difference in OCR before and after addition 
of Oligo. F. Spare capacity, calculated as the difference in OCR between basal 
and maximal mitochondrial metabolism. G. Coupling efficiency, the 
percentage of basal metabolism used for ATP production. Unpaired t-test, **** 
p<0.0001, *** p<0.001, ** p<0.01. n=22-24. Data are presented as mean ± 
standard error of the mean. 
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Figure 5.3.11.2: Loss of TSPO reduced glycolytic metabolism in mouse 
primary astrocytes. Extracellular acidification rate (ECAR) data from Mito 
Stress Test in fig. 5.3.11.1 prior to injection of oligomycin (0.5 µM) in mouse 
primary astrocytes expression (+/+) and not expressing TSPO (-/-). Unpaired 
t-test, *** p<0.001. n=22-24. Data are presented as mean ± standard error of 
the mean. 
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5.3.12 Loss of TSPO from U373 astroglioma cells decreased 
mitochondrial function 
To investigate whether loss of TSPO from human astroglioma cells resulted in a 
similar response as was seen in mouse primary astrocytes, TSPO-KO U373 cells 
were subjected to a Mito Stress Test (fig. 5.3.12.1A). Basal respiration was 
reduced in cells not expressing TSPO by 26% (fig. 5.3.12.1B; p<0.0002), leading 
to a 26% reduction in mitochondrial ATP production (fig. 5.3.12.1E; p<0.0004) 
compared to empty vector controls (EV). Maximal respiration was reduced by 
27% (fig. 5.3.12.1C; p<0.001). Proton leak was reduced by 19% (fig. 5.3.12.1D; 
p<0.0011). Spare capacity was reduced by 27% (fig. 5.3.12.1F; p<0.0025). 
However, coupling efficiency was unchanged (fig. 5.3.12.1G). ECAR was also 
significantly reduced by 46% (fig. 5.3.12.2; p<0.0001). 
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Figure 5.3.12.1: Loss of TSPO reduced mitochondrial metabolism in 
U373 astroglioma cells. Cells were seeded at a density of 4 x 104 cells per 
well in Seahorse XF96 cell culture microplates. Oxidative phosphorylation, 
represented as oxygen consumption rate (OCR) of the cells was measured 
using the Seahorse BioAnalyzer XFe96 in conjunction with a Mito Stress Test 
(Agilent, UK). A. OCR of U373 cells during a Mito Stress Test expressing (EV) 
and not expressing (KO) TSPO. Oligomycin (Oligo; 0.5 µM), FCCP (1 µM), 
and rotenone/antimycin (R/A; 0.5 µM) were added as indicated by the vertical 
dotted line. B. Basal mitochondrial respiration in TSPO EV and KO U373 cells, 
calculated as the difference in OCR before addition of Oligo and after addition 
of R/A. C. Maximal mitochondrial respiration, calculated as the difference in 
OCR after addition of FCCP and after addition of R/A. D. Proton leak, 
calculated as the difference between OCR after Oligo addition and after 
addition of R/A. E. Mitochondrial ATP production, calculated as the difference 
in OCR before and after addition of Oligo. F. Spare capacity, calculated as the 
difference in OCR between basal and maximal mitochondrial metabolism. G. 
Coupling efficiency, the percentage of basal metabolism used for ATP 
production. Unpaired t-test, *** p<0.001, ** p<0.01; n=22-24. Data are 
presented as mean ± standard error of the mean. 
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Figure 5.3.12.2: Loss of TSPO reduced glycolytic metabolism in U373 
astroglioma cells. Extracellular acidification rate (ECAR) data from Mito 
Stress Test (fig. 5.3.12.1) of human U373 astroglioma cells expressing (EV) 
and not expressing (KO) TSPO prior to injection of oligomycin. Unpaired t-
test, **** p<0.001; n=22-24. Data are presented as mean ± standard error of 
the mean. 
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5.3.13 Loss of TSPO from U373 astroglioma cells increased fatty acid 
oxidation 
To investigate the role of TSPO in U373 metabolism, the FAO Mito Stress Test 
was used (as described above in section 5.3.6). In U373 cells, loss of TSPO 
increased maximal rate of FAO by 145.5% compared to EV controls (fig 5.3.13C; 
p=0.0025). However, basal FAO was not altered in TSPO-KO cells compared to 
EV controls (fig 5.3.13B). 
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Figure 5.3.13: Loss of TSPO increased rate of fatty acid oxidation in 
human U373 astroglioma cells. Cells were seeded at a density of 4 x 104 
cells per well in Seahorse XF96 cell culture microplates. Oxidative 
phosphorylation, represented as oxygen consumption rate (OCR) of the cells 
was measured using the Seahorse BioAnalyzer XFe96 in conjunction with a 
fatty acid oxidation (FAO) Mito Stress Test (Agilent, UK). A. Time course of 
FAO Mito Stress Test in U373 astroglioma cells expressing (EV) and not 
expressing (KO) TSPO. Oligomycin (Oligo; 0.5 µM), FCCP (1 µM), and 
rotenone/antimycin (R/A; 0.5 µM) were added as indicated by vertical dotted 
lines. Palmitate (200 µM; C16) was provided as a substrate. B. Basal FAO 
rate calculated as the difference in oxygen consumption rate (OCR) between 
etomoxir treated negative controls (eto; 40 µM) and the comparable treatment 
group immediately prior to addition of Oligo. C. Maximal FAO rate calculated 
as the difference in OCR between etomoxir-treated negative controls and the 
comparable treatment group after addition of FCCP. One-way ANOVA with 
post hoc Tukey, ** p<0.01. n=16-20. Data are presented as mean ± standard 
error of the mean. 
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5.3.14 Loss of TSPO did not alter intracellular energy balance in U373 
astroglioma cells 
Although loss of TSPO increased FAO in U373 cells, TSPO-KO cells did not have 
altered mitochondrial membrane potential compared to EV controls (fig 5.3.14.1). 
TSPO-KO cells also maintained intracellular ATP levels (iATP) compared to EV 
controls (fig 5.3.14.2). Although glucose uptake rate was reduced by 25.3%, this 
decrease was not statistically significant (fig 5.3.14.3; p=0.11). 
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Figure 5.3.14.1: Mitochondrial membrane potential was not altered by 
loss of TSPO in human astroglioma cells. TMRE uptake by U373 
astroglioma cells not expressing TSPO (KO), relative to mean of TSPO 
expressing U373 empty vector (EV) controls. FCCP (1 µM) was used as 
positive depolarisation control. Cells were seeded at a density of 3.5 x 105 
cells per well in a 6 well plate. After treatment with LPS, cells were dissociated 
and incubated with FCCP prior to incubation with TMRE (100 nM) and 
analysis with the BD Accuri C6 Plus flow cytometer. One-way ANOVA with 
post hoc Tukey, *** p<0.001, ** p<0.01; n=3. Data are expressed as mean ± 
standard error of the mean. 
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Figure 5.3.14.2: Intracellular ATP levels were not altered by loss of TSPO 
in human astroglioma cells. Intracellular ATP (iATP) measurement in U373 
astroglioma cells not expressing TSPO (KO), relative to mean of TSPO 
expressing U373 empty vector (EV) controls. U373 cells were seeded at a 
density of 4 x 103 cells per well in black 96 well plates. iATP after loss of 
TSPO was estimated using the ATPLite TwoStep kit (PerkinElmer, UK). 
Unpaired t-test, n=6. Data are represented as mean ± standard error of the 
mean. 
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Figure 5.3.14.3: Glucose uptake rate was not altered by TSPO KO in 
human astroglioma cells. U373 cells were seeded at a density of 4 x 104 
cells per well in 96 well plates. Glucose uptake rate after loss of TSPO was 
estimated using the Glucose Uptake-Glo kit (Promega, UK). Glucose uptake 
was represented as fold change in 2-deoxyglucose-6-phosphate (2DG6P) 
luminescence by U373 astroglioma cells not expressing TSPO (KO), relative 
to mean of TSPO expressing U373 empty vector (EV) controls. Unpaired t-
test, n=6. Data are represented as mean ± standard error of the mean. 
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5.3.15 TSPO is part of a protein complex with CPT1a 
To investigate how TSPO may be regulating FAO in these cells, I explored 
possible protein-protein interactions. TSPO has been shown to interact with many 
mitochondrial proteins, both directly, and indirectly through forming complexes 
(Ilkan & Akar, 2018; Milenkovic et al., 2015; Shoshan-Barmatz et al., 2019). 
Carnitine palmitoyl transferase-1A (CPT-1A) is the rate-limiting step of fatty acid 
oxidation. Co-immunoprecipitation was used to investigate a possible interaction 
between CPT-1A and TSPO in human astroglioma cells. Antibodies were used 
to pull down TSPO (and any associated proteins) from U373 lysate. Non-specific 
IgG antibodies were used as negative controls in the pull down. Immunoblotting 
was then used to confirm that CPT-1A was present in the protein pulled down 
using the anti-TSPO antibody (fig 5.3.15.1). This demonstrated the TSPO was in 
a protein complex with CPT-1A in these cells. In a separate confirmatory 
experiment, an antibody was used to pull down CPT-1A and any associated 
proteins. Immunoblotting was used to detect TSPO in the protein pulled down 
with this antibody, and negative controls confirmed that the CPT-1A antibody was 
specific for CPT-1A in these cells (fig 5.3.15.2). The antibodies used to 
immunoprecipitate and immunoblot for proteins were raised in different species 
to reduce cross-reactivity and increase specificity (TSPO: rabbit, goat; CPT-1A: 
mouse, rabbit respectively). A second band ~65-70 kDa in size was detected in 
the non-immunoprecipitated lysate lanes after CPT-1A immunoblotting. This may 
be a fragment of CPT-1A or a non-specific band. However, it did not appear in 
either the CPT-1A immunoprecipitate or the TSPO immunoprecipitate. As the 
higher band, closer to 88 kDa in size was detected by both CPT-1A antibodies, 
this was taken to be the CPT-1A band. 
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Figure 5.3.15.1: CPT-1A is in a protein complex with TSPO in U373 
astrocytoma cells. Immunoblot against CPT-1A of total protein lysates (lys) 
and immunoprecipitated protein (Elu). U373 cells were seeded at a density of 
3 x 106 cells per plate in a 150 mm plate prior to lysis and protein 
quantification. Immunoprecipitations were performed with Protein G 
Dynabeads (Invitrogen, UK), and CPT-1A was detected in the lysate at the 
expected weight of 88 kDa using immunoblotting. Goat IgG used as a 
negative control for TSPO immunoprecipitation. Goat anti-TSPO used to co-
immunoprecipitate TSPO and interacting proteins. Mouse IgG used as 
negative control for CPT-1A immunoprecipitation. Mouse anti-CPT-1A used 
as positive control for CPT-1A antibody and immunoprecipitation technique. 
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Figure 5.3.15.2: TSPO is in a protein complex with CPT-1A in U373 
astrocytoma cells. Immunoblot against TSPO (antibody raised in rabbit) of 
total protein lysates (lys) and immunoprecipitated protein (Elu). U373 cells 
were seeded at a density of 3 x 106 cells per plate in a 150 mm plate prior to 
lysis and protein quantification. Immunoprecipitations were performed with 
Protein G Dynabeads (Invitrogen, UK), and TSPO was detected in the lysate 
at the expected weight of 18 kDa using immunoblotting. Goat anti-TSPO used 
as positive control for TSPO antibody and immunoprecipitation technique. 
Goat IgG used as a negative control for TSPO immunoprecipitation. Mouse 
anti-CPT-1A to co-immunoprecipitate CPT-1A and interacting proteins. 
Mouse IgG used as negative control for CPT-1A immunoprecipitation. Whole 
cell lysate used as positive control for TSPO expression in these cells. 
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5.4 Discussion 
I have shown here that loss of TSPO increases FAO in astrocytes, whilst 
decreasing overall OXPHOS and glycolysis. Furthermore, TSPO was found to be 
in a protein complex with CPT-1A, the rate-limiting step of fatty acid oxidation. 
This may represent a functional mechanism by which TSPO impacts fatty acid 
metabolism. 
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5.4.1 TSPO may be regulated by OXPHOS 
As has been previously shown in other cell types and in vivo, I have demonstrated 
that TSPO is upregulated in astrocytes in response to pro-inflammatory 
stimulation with LPS (Beckers et al., 2018; Bonsack & Sukumari-Ramesh, 2018; 
Lavisse et al., 2012). This increase was only seen after 24 hours, not after 3 
hours, of LPS treatment. At the 24 hour time point I previously observed 
adaptations in both mitochondrial and glycolytic metabolism in mouse primary 
astrocytes in response to inflammatory stimulation (Chapter 3). However, as I 
saw no change in TSPO expression after 3 hours of LPS treatment, when 
astrocytes show changes in ECAR but not OCR (Chapter 3), this may suggest 
that TSPO is upregulated during increased OXPHOS as opposed to being 
regulated by changes in glycolysis. 
 
To explore this further I treated cells with the glycolysis inhibitor 2-DG for 24 
hours. In contrast to upregulation by LPS, TSPO expression was downregulated 
by 2-DG. Data shown in Chapter 3 suggests that 2-DG does not regulate 
OXPHOS within the first hour of treatment in mouse primary astrocytes. However, 
I did not examine whether any adaptation in cellular metabolism occurred after 
24 hours treatment with 2-DG and published data from macrophages suggests 
that treatment with 2-DG decreases both glycolysis and OXPHOS after 1 hour of 
treatment (Wang et al., 2018). If 2-DG induces a similar decrease in OXPHOS in 
astrocytes, as is seen in macrophages, this would support the supposition that 
TSPO is regulated by OXPHOS, with increased TSPO expression during states 
of increased OXPHOS and decreased TSPO expression during low OXPHOS 
states. To support this, future studies measuring cellular metabolism after 24 
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hours of 2-DG treatment would be important. Additionally, measuring TSPO 
expression after systematically modulating different aspects of cellular 
metabolism could be informative: directly inhibiting OXPHOS using rotenone or 
oligomycin to inhibit the ETC; using etomoxir to inhibit FAO; and treating with 
UK5099 to inhibit the TCA cycle (O'Neill et al., 2016). These experiments may 
shed more light on the regulation of TSPO levels by metabolic function. 
 
5.4.2 Treatment with an AMPK activator does not regulate TSPO 
expression 
Although it appears that metabolic cues such as increased OXPHOS may play a 
role in regulating TSPO expression, in our study TSPO was not regulated by 
pharmacological activation of the major metabolic regulator AMPK. It is well 
established that AMPK increases OXPHOS through promoting glucose transport 
into the cell and fatty acid transport into the mitochondria by CPT-1A; thus 
increasing both glucose metabolism and FAO (Herzig & Shaw, 2018; Long & 
Zierath, 2006). Therefore, if TSPO expression is regulated by overall 
mitochondrial metabolism it is somewhat surprising that TSPO expression was 
not regulated following pharmacological AMPK activation with AICAR. This may 
suggest that TSPO is upstream of AMPK, and not directly regulated by AMPK 
activity. 
 
This conclusion is supported by recently published data. It has been 
demonstrated that PK11195 treatment and loss of TSPO in a glial cell type called 
tanycytes leads to phosphorylation of AMPK through Ca2+ signalling (Kim et al., 
2019). TSPO has been shown to interact with VDAC, a major Ca2+ channel in the 
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OMM. Disruption of this interaction through loss or modulation of TSPO may 
increase Ca2+ signalling, promoting AMPK activation through calcium-
calmodulin-dependent protein kinase kinase (CaMKK). In work from a separate 
group, loss of TSPO increases expression of the AMPKα subunit in glioma cells 
(Fu et al., 2019). These data suggest TSPO can regulate AMPK activity, rather 
than AMPK activity regulating TSPO. 
 
However, AMPK is activated by low cellular energy state, and as I have shown 
that modulation or loss of TSPO alters metabolic function in the cell the changes 
to AMPK activation may be a response to these changes to maintain metabolic 
homeostasis rather than through direct regulation by TSPO. However, our data 
shows that iATP levels are not decreased by modulation of TSPO expression or 
activity, so are unlikely to be activating AMPK. Important experiments are needed 
to further investigate this data. It would be important to measure metabolic 
changes and AMPK phosphorylation by AICAR at 24 hours in mouse primary 
astrocytes, to ensure the AICAR was active. Additionally, to more rigorously 
investigate the mechanism through which AMPK activation is related to TSPO 
modulation, measurements of AMPK phosphorylation and ADP:ATP ratios in the 
cell after loss or pharmaceutical modulation of TSPO in our model would be 
needed.  
 
5.4.3 Pharmacological modulation of TSPO did not alter pro-
inflammatory cytokine release 
Contrary to published data from in vivo models and microglia in culture indicating 
anti-inflammatory actions, treatment with TSPO ligands did not alter the profile of 
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LPS-induced astrocyte pro-inflammatory cytokine release measured in this study 
(Azrad et al., 2019; Mages et al., 2019). However, this is not completely 
unprecedented, as Klee et al. showed in a recent study that loss of TSPO did not 
alter microglial activation and retinal degradation after light damage (Klee et al., 
2019). While it is feasible that TSPO ligands had no anti-inflammatory effect, this 
is not certain as only limited cytokines and time points were measured. Therefore, 
use of a cytokine array, or RT-qPCR at multiple time points may reveal changes 
in the inflammatory profile that were not evident in this study. 
 
Interestingly, after 24 hours a decrease in LPS-induced IL-10 release was 
observed after treatment with XBD-173, but not PK11195. This may suggest that 
XBD-173 acts through a different mechanism to PK11195, and this is supported 
by the finding that the drugs have different effects on steroidogenesis (Selvaraj & 
Tu, 2016). It is important to reiterate that TSPO ligands are classified as agonists 
based on their ability to displace PK11195 or their activity in promoting steroid 
production, a function of TSPO that has recently become controversial (Selvaraj 
& Tu, 2016; Zhang et al., 2007). Therefore their nomenclature as agonists or 
antagonists may not accurately reflect their action on TSPO as an inflammatory 
or metabolic mediator. Considering the differential effects of the two ligands used 
in this study, and the uncertainty regarding their effect on TSPO activity, it would 
be pertinent to also examine inflammation in TSPO-deficient astrocytes after 
treatment with LPS. 
 
As the metabolic effect of TSPO ligands were measured an hour after treatment, 
whereas inflammation was measured after 24 hours, I do not know if the 
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metabolic changes persisted. Therefore I cannot comment on the effect of the 
metabolic change on inflammation in these cells. It would be appropriate to 
investigate the metabolic function of these cells at 24 hours after ligand exposure 
to investigate the anti-inflammatory response of these cells, or alternatively, in a 
more clinically relevant study to expose cells to LPS for 3 and 24 hours prior to a 
1 hour treatment with TSPO ligands to mimic treatment with TSPO ligands after 
the onset of an inflammatory disease. 
 
5.4.4 Modulation of TSPO signalling impacts astrocyte metabolism 
Glucose metabolism 
Studies have suggested that TSPO regulates glucose metabolism, as increased 
TSPO expression correlates with increased glucose metabolism in many cell 
types (Ferrarese et al., 1994). Consistent with this evidence, U373 astroglioma 
cells — which expressed higher levels of TSPO — had higher rates of glycolysis, 
but reduced OCR and FAO rate compared to mouse primary astrocytes. Our data 
showed loss of TSPO from mouse primary astrocytes and U373 astroglioma cells 
decreased glycolysis (ECAR) in both cell types. However, whilst glucose uptake 
was reduced after loss of TSPO from human astroglioma cells, this was not 
statistically significant.  
 
Recent published work shows that in glioblastoma cells loss of TSPO increases 
aerobic glycolysis (Fu et al., 2019). This may well be driven by an increase in 
expression of genes associated with aerobic glycolysis. Proteins upregulated 
include GLUT1, hexokinase II and lactate dehydrogenase (LDH), suggesting a 
shift towards aerobic glycolysis after loss of TSPO (Fu et al., 2019). This is 
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contrary to our data presented here. It is possible that TSPO promotes glycolysis 
coupled to oxidative metabolism and restrains aerobic glycolysis. This would limit 
total glycolytic rate to that needed for supplying the TCA cycle and OXPHOS. 
Loss of TSPO would therefore increase aerobic glycolysis if the enzymes 
required for aerobic glycolysis were present. Radio isotope labelling of glucose 
and mass spectrometry in combination with TSPO ligands or loss of TSPO may 
be used to assess this change in glucose fate. However, it is important to note 
that our evidence comparing mouse primary astrocytes to U373 cells is 
circumstantial, and as U373 cells are derived from a malignant astrocytoma 
glioblastoma the increased glycolytic rate may be attributable in part to aerobic 
glycolysis and not be a result of increased TSPO expression. 
 
In line with the findings in this study, adipocytes have been shown to increase 
glucose uptake after treatment with TSPO ligands including PK11195 (Li & 
Papadopoulos, 2015). Our data shows that PK11195 increased glycolysis within 
1 hour of treatment. However, the increase in glucose uptake seen after treatment 
with PK11195 was not statistically significant. XBD-173 did not alter glycolytic 
rate or glucose uptake. PK11195 reduces glucose metabolism in activated 
microglia, and as our data was not statistically significant, I cannot confidently 
draw conclusions (Amitani et al., 2008). Additionally, this appears to be 
contradictory to our own data which has shown that TSPO modulation or loss 
decreases glycolysis. This again may suggest that PK11195 is acting through a 
different mechanism to loss of TSPO and XBD-173. To investigate this more 
robustly, a Glycolytic Stress Test could be used after treatment with PK11195 to 
show whether the changes in glucose uptake and ECAR changes are directly 
driven by glycolytic rate.  
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Importantly, the TSPO ligands used had no effects on metabolism in the TSPO-
deficient U373 cells at the concentrations used, thus confirming the specificity of 
their effects. For consistency and increased robustness, these studies should be 
repeated in the primary astrocytes from TSPO-deficient mice, particularly as 
PK11195 did not induce the same increase in OCR in U373 cells as was 
observed in mouse primary astrocytes. 
 
OXPHOS 
Recent publications have shown that loss of TSPO from human primary 
microglia, mouse microglia, mouse GL261 glioma cells, and glioblastoma cells 
reduces OXPHOS, whilst over-expression of TSPO in T-cells (Jurkat) which 
normally do not express TSPO at all increases expression of genes related to 
OXPHOS (Banati et al., 2014; Fu et al., 2019; Milenkovic et al., 2018). TSPO 
ligands PK11195 and Ro5-4864 also suppress mitochondrial metabolism in 
GL251 glioma cells (Fu et al., 2019). In agreement with this, our data shows that 
astrocytes cultured from mice with germline deletion of TSPO and U373 
astroglioma cells lacking TSPO have significantly decreased OXPHOS rates 
compared to TSPO-expressing controls.  
 
Previously published work suggests that this decrease in OXPHOS may be driven 
by mitochondrial dysfunction through increased mitochondrial fragmentation (Fu 
et al., 2019). However, in our studies no decrease in mitochondrial coupling 
efficiency or change in mitochondrial membrane potential was observed following 
loss of TSPO. I would have expected both of these parameters to have been 
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decreased if the mitochondria were dysfunctional, fragmenting and/or undergoing 
mitophagy (Twig & Shirihai, 2011). This may instead suggest that OXPHOS is 
limited by substrate supply in the absence of TSPO, rather than mitochondrial 
dysfunction, and may imply that the decrease in glycolytic flux and the decrease 
in OXPHOS after loss of TSPO are linked.  
 
FAO 
I have presented data here showing that FAO was significantly increased by loss 
of TSPO from U373 human astroglioma cells. FAO was also similarly increased 
following treatment with the TSPO ligand XBD-173. This suggests XBD-173, 
which has previously been classified as a TSPO agonist based on is activity in 
PK11195 displacement and steroidogenesis assays, impacts FAO in a similar 
manner to loss of TSPO (Selvaraj & Tu, 2016). The findings in the TSPO-deficient 
U373 cells are supported by multiple published studies in other cell types. Work 
presented by Tu et al. using the mouse testicular Leydig cell line MA-10 shows 
that TSPO deficiency increases FAO and expression of related proteins including 
CPT-1A (Tu et al., 2016). Additionally, in vivo the TSPO agonist etifoxine reduces 
intracellular lipid accumulation in hepatocellular carcinoma cells, whilst in mouse 
tanycytes in vitro both PK11195 and loss of TSPO also reduce intracellular lipid 
accumulation (Kim et al., 2019; Lin et al., 2019). This is attributed by the authors 
to increased lipophagy, which could provide substrate for increased FAO 
(Schulze et al., 2017). Together, these data suggest that treatment with TSPO 
ligands or loss of TSPO increase FAO.  
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In our studies the TSPO ligand PK11195 did not alter FAO in mouse primary 
astrocytes. This is surprising as published data from other groups show that 
PK11195 upregulates the expression of mRNA of proteins associated with FAO, 
including CPT-1A in zebra fish, and increases lipophagy (Gut et al., 2013; Kim et 
al., 2019). This is consistent with the change in CPT-1A protein expression seen 
after loss of TSPO from Leydig cells (Tu et al., 2016). This may suggest that 
TSPO has multiple functions relating to increasing lipid mobilisation and PK11195 
increases these genes independently from the role of TSPO in regulating FAO. 
CPT1-A gene expression and lipophagy are known to be regulated by activation 
of AMPK and this may be the mechanism through which PK11195 is acting: 
PK11195 and loss of TSPO have previously been demonstrated to activate 
AMPK (Kim et al., 2011; Kim et al., 2019; Krämer et al., 2007). To further explore 
this, data on AMPK expression and phosphorylation after treatment with TSPO 
ligands or loss of TSPO would be important. 
 
5.4.5 TSPO as a metabolic substrate integrator and switch 
Together data from the literature and metabolic data presented in this chapter 
suggest that increased TSPO expression decreases FAO but promotes overall 
OXPHOS during inflammation through increasing glucose metabolism. This 
suggests that TSPO may play a role in regulating the substrate switching during 
metabolism. I have demonstrated a novel interaction between CPT-1A and 
TSPO, shown for the first time here. This is supported by evidence in the literature 
that VDAC and CPT-1A are found in a protein complex (Gatliff et al., 2014; 
Papadopoulos et al., 1994). This interaction between TSPO and CPT-1A may be 
part of the molecular mechanism by which TSPO regulates FAO.  
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The reported interaction between TSPO and VDAC may mediate the increase in 
glycolysis and OXPHOS attributed to TSPO (Milenkovic et al., 2015; Veenman et 
al., 2008). VDAC has previously been shown to couple the glycolytic regulator 
hexokinase II with the mitochondria to increase glycolytic rate (Camara et al., 
2017; McEnery et al., 1993; Pastorino & Hoek, 2008). This is facilitated through 
an interaction between VDAC and adenosine nucleotide transporter (ANT) 
(Camara et al., 2017; Pastorino & Hoek, 2008). When hexokinase II is coupled to 
the mitochondria, glycolytic rate increases due to increased provision of ATP 
through the VDAC-ANT complex, allowing faster phosphorylation of glucose into 
glucose-6-phosphate (Colombini, 2012; John et al., 2011; Mathupala et al., 2006; 
Rostovtseva & Colombini, 1996). This increases production of pyruvate, allowing 
increased transport and metabolism of pyruvate within the mitochondria.  
 
Hexokinase targeting to the mitochondria also increases ADP turnover and return 
to the ETC through the VDAC-ANT complex for re-phosphorylation into ATP, 
allowing maintenance of OXPHOS (Gumaa & McLean, 1969; Robey & Hay, 
2006; Wilson, 2003). Additionally, it has been reported that VDAC imports 
pyruvate into the mitochondrial intermembrane space, prior to transport into the 
mitochondrial matrix by pyruvate translocase for further metabolism, and this 
appears to be generally accepted (Fang & Maldonado, 2018; Lee, 2014). 
However, to our knowledge there is no data available that directly demonstrates 
this role of VDAC. Therefore, whilst there is strong evidence that VDAC links 
glycolytic rate and OXPHOS, whether pyruvate trafficking by VDAC plays a role 
in this must be regarded with caution without further investigation. An interaction 
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between TSPO and VDAC in this complex may explain why rates of OXPHOS 
and glycolysis both appear to be regulated by modulation of TSPO activity. Taken 
together these data suggest that TSPO may form a complex with CPT-1A, VDAC, 
and hexokinase II enabling it to increase glycolysis and OXPHOS through 
promoting glucose phosphorylation by hexokinase II, and possibly pyruvate 
trafficking into the mitochondria by VDAC, while potentially inhibiting supply of 
acyl-coA to the β-oxidation cycle through reducing CPT-1A activity (see fig. 
5.5.1). 
 
This potential model must be approached with caution at this stage as CPT-1A, 
VDAC and TSPO existing in a complex together at the same time has not yet 
been demonstrated. This could be investigated using immunoprecipitation, mass 
spectrometry and immunoblotting techniques. Additionally, whilst existence of 
this complex would be interesting, the functional relevance of the complex would 
need to be verified by using CPT-1A and hexokinase activity assays to directly 
evaluate the activity of these enzymes following modulation of TSPO activity with 
ligands and/or genetic manipulation.   
 
In our studies I did not observe any alterations in iATP, suggesting that astrocytes 
are capable of defending ATP levels in the absence of TSPO. This indicates that 
although TSPO appears to play a role in fuel selection during metabolism, it does 
not maintain energy supply or regulate demand. However other groups have 
shown that over-expression of TSPO in T-cells increases iATP after addition of 
ADP (Liu et al., 2017b). This suggests that TSPO acts to ensure ATP is rapidly 
produced during perceived energy deficit, making cells preferentially use glucose 
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to produce energy. Interestingly, TSPO ligand Ro5-4864 prevents astrocyte cell 
death during glucose deprivation, suggesting that astrocytes can make use of an 
alternative fuel source when TSPO is modulated (Baez et al., 2017). As 
modulation or loss of TSPO has been shown to increase AMPK phosphorylation, 
I suggest that this is potentially through increased AMPK activity and increased 
FAO capability (Kim et al., 2019).  
 
5.5 Conclusion 
In conclusion, I have shown in this chapter that loss of TSPO increases FAO but 
decreases overall oxidative metabolism. This suggests that TSPO expression 
restricts FAO in astrocytes. This suppression of FAO could potentially be 
mediated through the interaction between TSPO and CPT-1A shown here. 
Additionally, TSPO expression appears to promote mitochondrial metabolism of 
substrates other that fatty acids. This may indicate that TSPO plays a role in 
regulating substrate use through promoting glucose use and pyruvate trafficking 
into the mitochondria, and restricting FAO to allow inflammation. 
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Figure 5.5.1: Hypothetical model by which TSPO regulates metabolism. 
Translocator protein 18 kDa (TSPO) interacts with carnitine palmitoyl 
transferase 1A (CPT-1A) to inhibit fatty acid transport into the mitochondria. 
Voltage dependent anion channel (VDAC) associated with hexokinase II binds 
the TSPO/CPT-1A complex to ‘dock’ to mitochondria and adenosine 
nucleotide transporter (ANT). This increases ATP/ADP exchange between the 
mitochondrial matrix and hexokinase II, increases calcium (Ca2+) transport 
into the mitochondria, and possibly pyruvate transport. This increases 
OXPHOS rate and decreases cytoplasmic Ca2+, restricting Ca2+ mediated 
activation of AMP activated protein kinase (AMPK). 
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Chapter 6. Discussion and Limitations 
 
This chapter will summarise the key findings of this body of work and bring 
together the themes covered. It will also highlight limitations of the studies 
imposed by the methods used and propose further studies which would help 
address any questions raised by this thesis. 
 
6.1 Summary of findings 
6.1.1 NF-κB regulates astrocyte immunometabolism 
This thesis aimed to characterise immunometabolic behaviour in astrocytes and 
examine the role of NF-κB in this phenomenon. Whilst this had been investigated 
to some extent in immune responsive cells such as microglia, macrophages and 
lymphocytes, it had not been directly investigated in astrocytes (Hotamisligil, 
2017; O'Neill et al., 2016; Robb et al., 2019; Van den Bossche et al., 2017). 
 
Work presented in Chapter 3 and Chapter 4 established that immunometabolic 
responses are present in astrocytes and that NF-κB signalling was important in 
this response. Previous work by Gavillet et al. and Belenger et al. shows that pro-
inflammatory cytokines increase CO2 production and glucose uptake while 
decreasing glycogen stores in astrocytes after 48 hours, suggesting an increased 
use of the PPP and TCA cycle (Bélanger et al., 2011b; Gavillet et al., 2008). 
However, beyond this the role of cellular metabolism in astrocyte inflammation 
was relatively unexplored. Our data indicating that NF-κB signalling increased 
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glycolytic rate after 3 hours of treatment with LPS, and that limiting glycolysis with 
2-DG decreased inflammatory outputs (pro-inflammatory cytokine production and 
NF-κB signalling) offers a significant contribution to this emerging field of study 
by demonstrating that intact glycolysis is necessary for the full acute inflammatory 
response of astrocytes following LPS stimulation.  
 
After 24 hours treatment with LPS, astrocytes underwent a further metabolic 
adaptation: decreased glycolytic capacity and increased OXPHOS. The decrease 
in glycolytic capacity was likely to have been driven by the decrease in GLUT1 
expression observed, which was dependent on intact NF-κB signalling. This 
decrease in GLUT1 expression was possibly a mechanism to restrict the ability 
of astrocytes to use glycolysis (Freemerman et al., 2014). In macrophages and 
lymphocytes it has been shown that decreased GLUT1 expression reduces 
inflammation through suppressing glycolysis (Freemerman et al., 2014; Siska et 
al., 2016). As Chapter 3 demonstrated, use of glycolysis was essential to 
maintain a pro-inflammatory response in astrocytes, the downregulation of 
GLUT1 and increased use of OXPHOS could be an anti-inflammatory 
mechanism, contributing to resolution of the pro-inflammatory response. 
 
Together these data give strong evidence that astrocytes have dynamic 
immunometabolic responses, in part orchestrated by NF-κB signalling, as has 
been shown in other cell types (O'Neill et al., 2016; Russell et al., 2019). This 
finding is novel in astrocytes. I propose that these functions are mediated through 
an interaction between p53 and NF-κB, based on previous work by Mauro et al. 
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in fibroblasts (Mauro et al., 2011), but further work would be necessary to 
specifically address this. 
 
6.1.2 Therapeutic targeting of immunometabolism through NF-κB 
inhibition in astrocytes 
As inflammation in astrocytes has been implicated in increasing the severity of 
some diseases, such as Alzheimer’s disease, understanding the resolution of 
inflammation in astrocytes is important to enable development of new therapies 
to restrict chronic inflammation (Chun & Lee, 2018; Liu et al., 2014a). The data 
presented in this thesis may suggest that NF-κB signalling is an appropriate target 
for therapeutically regulating glycolysis in pathologies such as highly glycolytic 
cancers. Supporting this, NF-κB is upregulated in glioblastomas, inhibition of 
which reduces human glioblastoma cell growth in vitro and tumour volume in mice 
in vivo, suggesting it is a suitable target (Puliyappadamba et al., 2014; Robe et 
al., 2004; Waters et al., 2019). However, further studies (as described in the 
discussion of Chapters 3 and 4) would be needed to explore this new hypothesis. 
 
A secondary finding presented in this body of work was that inhibition of NF-κB 
signalling reduced both glycolysis and OXPHOS independently of inflammation. 
This demonstrates that, in agreement with data from fibroblasts (Mauro et al., 
2011), NF-κB supports basal metabolic function in astrocytes in the absence of a 
pro-inflammatory stimulus (Chapter 4). Again, in astrocytes this finding is novel 
and may suggest that basal NF-κB signalling is important for normal astrocyte 
function. Supporting this, loss of NF-κB signalling in vivo reduces GLT-1 
expression and glutamate cycling, which could result in excitotoxicity and 
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neuronal death (Ghosh et al., 2011). Together these data suggest that normal 
astrocyte function relies on NF-κB signalling to maintain the CNS 
microenvironment. This highlights the need to be cautious with application of this 
as a therapy without further study, as inappropriate use could lead to significant 
consequences. 
 
Although immunometabolism is an attractive therapeutic target due to the 
opportunity to re-purpose pre-existing drugs in new contexts, it is important to 
note that caution should be used with this approach. Inflammation is primarily a 
protective response, and inhibition of this may lead to increased disease 
pathology if not properly understood. Additionally, inappropriate inhibition of 
cellular metabolism could result in cellular energy deficits and premature cell 
death. With this is mind, it is important that further research is carried out to 
increase the current understanding of immunometabolism in astrocytes, to 
ensure these therapies can be applied appropriately and safely. 
 
6.1.3 TSPO regulates cellular metabolism in astrocytes 
In a related study I aimed to investigate translocator protein 18 kDa (TSPO) as a 
potential novel regulator of immunometabolism in astrocytes. TSPO is a 
promising therapeutic target for inflammatory disease in the CNS as it is not found 
in neurons (so targeting its activity would have less of an impact on these cells), 
and TSPO ligands have already been approved for use in humans (Li et al., 2017; 
Ravikumar et al., 2016). In this thesis, modulation of TSPO through 
pharmacological manipulation and genetic loss of expression altered cellular 
metabolism, increasing FAO and decreasing the use of glucose derivatives to 
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fuel the TCA cycle (Chapter 5). These findings are supported by an increasing 
body of published work (Gut et al., 2013; Kim et al., 2019; Li & Papadopoulos, 
2015; Lin et al., 2019; Tu et al., 2016). Thus, the changes in TSPO expression in 
astrocytes during inflammation and diseases such as cancers and Alzheimer’s 
disease may be driving the changes to cellular metabolism associated with these 
diseases.  
 
As was expected from previously published data, TSPO was upregulated in 
astrocytes by 24 hours exposure to LPS (Chapter 5), possibly due to the 
metabolic changes reported in Chapter 3 (Azrad et al., 2019; Horiguchi et al., 
2019; Santoro et al., 2016). This was supported by data showing that the 
glycolytic inhibitor 2-DG reduced TSPO expression, although further studies as 
described in Chapter 5 would be important to more fully investigate the role of 
metabolism in TSPO regulation. This reiterates the involvement of cellular 
metabolism in inflammation in astrocytes. Interpreting this with our metabolic 
analysis, the increase in TSPO expression may be expected to decrease FAO 
and increase glycolysis and OXPHOS, as I have reported in Chapter 3. This 
metabolic reprogramming could support neuronal function during periods of 
stress as aerobic glycolysis and OXPHOS have been demonstrated to be 
essential for maintaining normal brain function (Dienel, 2019). 
 
Pathways that regulate TSPO expression also regulate GLUT1 expression, which 
I have demonstrated to be an important regulator of glycolysis in astrocyte 
inflammation. For example, in Chapter 3 and Chapter 4 I found that GLUT1 
expression was downregulated by prolonged NF-κB signalling. NF-κB is 
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downstream of the PI3K/Akt pathway (Dan et al., 2008; Lawrence, 2009). In 
human retinal epithelial cells GLUT1 is downregulated by PI3K/Akt signalling 
(Kim et al., 2007a). PI3K signalling also activates AP-1 which promotes TSPO 
expression, suggesting that the downregulation of GLUT1 and upregulation of 
TSPO may be linked during a pro-inflammatory stimulus (Rashid et al., 2018; 
Shimoyama et al., 2019). This is supported by our data demonstrating that these 
changes in expression both occur 24 hours after exposure to LPS. However, this 
is circumstantial evidence, so further studies are needed to directly confirm this 
hypothesis. Together these data provide further evidence that PI3K signalling 
integrates inflammatory and metabolic signalling through the downstream 
proteins it activates (Hawkins & Stephens, 2015). 
 
While I discovered a novel interaction between TSPO and CPT-1A, the function 
of this interaction was not explored in this body of work. I propose that TSPO and 
CPT-1A interact in a larger complex including VDAC and hexokinase II, which 
have been previously reported to interact with TSPO (Arzoine et al., 2009; 
Camara et al., 2017; Pastorino & Hoek, 2008). I further hypothesise that this 
complex functions to integrate mitochondrial and glycolytic metabolism, based on 
the known functions of the proteins and data shown in this work. If this is 
demonstrated to be true, it may have implications for the possible application of 
TSPO ligands as therapeutics for metabolic diseases, as VDAC and hexokinase 
II are already being investigated in this role in peripheral tissues (Camara et al., 
2017; Roberts & Miyamoto, 2015). However further work is needed to explore 
this new hypothesis, as is detailed in Chapter 5.  
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6.1.4 TSPO as a potential novel regulator of immunometabolism 
Although I have shown that metabolism and inflammation in astrocytes are 
intrinsically linked, metabolism appeared to change independently of 
inflammation when TSPO was manipulated within the time range studied, 
resulting in no change to the concentrations of the cytokines measured (Chapter 
5). However, this was contrary to many published studies (Azrad et al., 2019; 
Horiguchi et al., 2019; Santoro et al., 2016). I suggested that TSPO is a direct 
modulator of cellular metabolism, but not necessarily inflammation. However, due 
to conflicting evidence in the literature and the limited time points measured in 
the studies presented here, I cannot make strong conclusions around this 
hypothesis. 
 
Further to this, I suggested that, unlike in macrophages and other cells in which 
TSPO is anti-inflammatory, FAO is not a regulator of immunometabolism in 
astrocytes, hence why I saw no change in cytokine release (Van den Bossche et 
al., 2017). However, as I did not look at cytokine release or inflammatory 
signalling pathways at later time points I cannot comment on whether FAO affects 
inflammation later in the immunometabolic response. Significant further studies 
as described in Chapter 5 would be necessary to strengthen these conclusions. 
 
However, even though modulation of TSPO does not appear to affect the 
inflammatory profile of astrocytes at the time point examined thus far, many 
astrocyte functions are regulated by cellular metabolism, including those that 
support neuronal function, such as the synthesis of gliotransmitters and the 
recycling of neurotransmitters. Therefore, further studies into the impact that 
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modulation of TSPO may have on the wider CNS microenvironment, including 
gliotransmission and maintenance of the synaptic environment, may reveal more 
about the role of TSPO in astrocytes. 
 
6.2 Limitations 
Specific limitations of each study have been discussed within the relevant 
chapters. This section will detail the overarching limitations of the thesis as a 
whole. 
 
6.2.1 Dependence on in vitro models  
A major limitation of the studies presented was the sole use of in vitro models. 
These inherently take astrocytes out of the wider context of the diverse 
multicellular environment in vivo. The lack of neurotransmitters, cell-cell 
interactions, glial-derived factors, 3D morphology and hormones, among other 
factors, is likely to result in profound changes to astrocyte behaviour. However, 
for the exploratory research conducted in this study in vitro models were an 
appropriate starting point for our investigations and establish proof of principle 
prior to progressing to multicellular in vitro systems and the more complex in vivo 
environment. To take this study further, use of in vivo models would be necessary 
to study the effect of modulating astrocyte immunometabolism on neuronal 
function and whole-body physiology. 
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6.2.2 Limited range of inflammatory pathways studied 
These studies used a reductionist approach, with no study of inflammatory 
pathways other than NF-κB. It is highly unlikely that NF-κB is the only pathway 
playing a role in astrocyte immunometabolism. For example, in many 
inflammatory diseases STAT3 has been shown to play a critical role in cytokine 
release and metabolic reprogramming (Demaria et al., 2014; Kasembeli et al., 
2018; Kurdi et al., 2018; Poli & Camporeale, 2015). Additionally, STAT3 is 
overexpressed in many cancers, including glioblastomas which I have previously 
mentioned to have metabolic perturbations and pro-inflammatory phenotypes 
(Demaria et al., 2014; Yang Sheng et al., 2019). Alternatively, MAPKs, which can 
be activated by inflammatory stimuli, have been shown to play a role in metabolic 
disorders (Papa et al., 2019). Therefore, investigating the effect of other key 
signalling pathways on metabolism during inflammation, in particular STAT3, 
would be both interesting and relevant to explore in further studies. 
 
6.2.3 No direct study of FAO in immunometabolism 
Although suggestions were made that FAO does not play a role in inflammation 
in astrocytes, FAO in mouse primary astrocytes after treatment with LPS, or 
inflammatory outputs after modulating FAO function were not directly measured. 
Therefore, I cannot yet confidently comment on the importance of FAO to the 
inflammatory response in astrocytes. This would be an important study to follow 
up on, especially considering the apparent role of TSPO in modulating this 
metabolic pathway. Initial studies of the astrocyte FAO immunometabolic 
response to LPS using the Seahorse metabolic analyser, combining the study 
design from Chapter 3 with the FAO Mito Stress Test used in Chapter 5, would 
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provide initial information to inform further studies. Results from this experiment 
would inform further experiments blocking FAO with etomoxir and/or promoting 
FAO through activating peroxisome proliferator activating protein activator, or 
another mechanism, and measuring inflammation to directly assess the effect of 
FAO metabolism on inflammation.  
 
6.3 Outstanding questions and future directions 
6.3.1 What is the effect of astrocyte glycolysis on the CNS 
microenvironment during inflammation? 
One important question which requires addressing is the effect of blocking 
glycolysis in astrocytes on the wider CNS environment. As discussed in the 
introduction, astrocytes play an important role in maintaining CNS physiology and 
neuronal health. To answer this question, specifically blocking glycolysis in 
astrocytes during inflammation in vivo would be important. A targeted approach 
using genetic manipulation to restrict GLUT1 expression in astrocytes, or activity 
of glycolytic enzymes such as hexokinase II, and measuring end points such as 
circulating and cerebrospinal fluid cytokines, astrocyte ramification, astrocytic 
expression of glutamate and K+ transporters, neuronal activity with 
electrophysiology and cFos expression, amongst others. This genetic 
modification would have to be inducible as long-term inhibition of astrocyte 
glycolysis is likely to have severely detrimental effects. 
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6.3.2 What is the effect of metabolic intermediates and products from 
astrocytes on the inflammatory response in the CNS? 
Increasing evidence suggests that metabolic intermediates and products 
including succinate, citrate and lactate, are important inflammatory mediators 
(Murphy & O'Neill, 2018; Nolt et al., 2018; Pucino et al., 2019; Williams & O'Neill, 
2018). Investigation into the production and role of these during inflammation in 
the CNS would be interesting. Of interest would be the impact of these molecules 
on the behaviour of other cells in the CNS. Lactate is known to be a 
gliotransmitter, but there is little exploration into the roles of other metabolic 
intermediates in modulating CNS neurotransmission and other functions 
(Gundersen et al., 2015). Investigation of other metabolic intermediates as 
potential novel gliotransmitters may shed light on the control of astrocyte function 
during inflammation in the wider CNS network. 
 
6.3.3 Does FAO play a role in the regulation of inflammation in 
astrocytes? 
To explore the role of TSPO in inflammation further it would be important to 
measure FAO rate after treatment with LPS, and to investigate the importance of 
FAO in inflammation, as described above. This would go some way to exploring 
whether TSPO is directly involved in an immunometabolic regulatory response, 
or whether it just regulates metabolism in astrocytes. It would also be important 
to carry out the studies described in Chapter 5. 
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6.3.4 Does modulation of TSPO activity in astrocytes improve CNS 
health after an inflammatory stimulus? 
As previously mentioned, a major limitation of this study was that astrocytes were 
investigated independently of other cell types. As astrocytes play an important 
role in regulating the CNS environment, the changes in metabolism caused by 
modulation or loss of TSPO may have an impact on the other cell types astrocytes 
interact with. To investigate this, in vivo work in animals with astrocyte-specific 
loss of TSPO challenged with LPS as an inflammatory stimulus followed by 
investigation of inflammatory markers, metabolic markers and neuronal function 
would be interesting. 
 
6.4 Key conclusions arising from this thesis (fig. 6.4) 
 Astrocyte metabolism is intrinsically linked to their inflammatory response, 
giving them ‘immunometabolic’ responses to inflammation. 
 Astrocyte immunometabolism is regulated in part by NF-κB signalling. 
 NF-κB signalling supports basal metabolism in astrocytes in the absence 
of a pro-inflammatory stimulus. 
 TSPO expression promotes cellular glycolysis and OXPHOS in astrocytes. 
 TSPO expression inhibits FAO in astrocytes. 
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Appendices 
Appendix 1: Full representative immunoblots 
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Appendix 1.1: Full representative immunoblots probed with anti-
phospho-NF-κB p65 (Ser536). Immunoblots of treated mouse primary 
astrocyte (CRTAS) lysates. Bands of protein detected by anti-phospho-NF-κB 
(Ser536; Cell Signalling Technologies) were seen at the expected size of ~60 
kDa. Anti-GAPDH (Protein Tech) loading control was used on all blots, and 
detected at the expected size of ~37 kDa. Boxes indicate cropped area for 
use in figures. A. CRTAS treated with 0.1 µg/mL lipopolysaccharide (LPS) for 
3 hours. B. CRTAS treated with 0.1 µg/mL LPS for 24 hours. C. CRTAS pre-
treated with 1 µM TPCA-1 for 2 hours ± 0.1 µg/mL LPS for 3 hours. D. CRTAS 
pre-treated with 1 µM TPCA-1 for 2 hours ± 0.1 µg/mL LPS for 24 hours. E. 
CRTAS pre-treated with 10 mM 2-deoxyglucose (2-DG) for 2 hours ± 0.1 
µg/mL LPS for 3 hours. F. CRTAS pre-treated with 10 mM 2-deoxyglucose (2-
DG) for 2 hours ± 0.1 µg/mL LPS for 24 hours. 
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Appendix 1.2: Full representative immunoblots probed with anti-NF-κB 
p65. Immunoblots of treated mouse primary astrocyte (CRTAS) lysates. 
Bands of protein detected by anti-NF-κB (Cell Signalling Technologies) were 
seen at the expected size of ~60 kDa. Anti-GAPDH (Protein Tech) loading 
control was used on all blots, and detected at the expected size of ~37 kDa. 
Boxes indicate cropped area for use in figures. A. CRTAS treated with 0.1 
µg/mL lipopolysaccharide (LPS) for 3 hours. B. CRTAS treated with 0.1 µg/mL 
LPS for 24 hours. C. CRTAS pre-treated with 1 µM TPCA-1 for 2 hours ± 0.1 
µg/mL LPS for 3 hours. D. CRTAS pre-treated with 1 µM TPCA-1 for 2 hours 
± 0.1 µg/mL LPS for 24 hours. E. CRTAS pre-treated with 10 mM 2-
deoxyglucose (2-DG) for 2 hours ± 0.1 µg/mL LPS for 3 hours. F. CRTAS pre-
treated with 10 mM 2-deoxyglucose (2-DG) for 2 hours ± 0.1 µg/mL LPS for 
24 hours. 
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Appendix 1.3: Full representative immunoblots probed with anti-GLUT1. 
Immunoblots of treated mouse primary astrocyte (CRTAS) lysates. Bands of 
protein detected by anti-GLUT1 (Millipore) were seen at the expected size of 
~50 kDa. Anti-GAPDH (Protein Tech) loading control was used on all blots, 
and detected at the expected size of ~37 kDa. Boxes indicate cropped area 
for use in figures. A. CRTAS treated with 0.1 µg/mL lipopolysaccharide (LPS) 
for 3 hours. B. CRTAS treated with 0.1 µg/mL LPS for 24 hours. C. CRTAS 
pre-treated with 1 µM TPCA-1 for 2 hours ± 0.1 µg/mL LPS for 24 hours. 
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Appendix 1.4: Full representative immunoblots probed with anti-TSPO. 
Immunoblots of mouse primary astrocyte (CRTAS) or human astroglioma 
(U373) lysates. Bands of protein detected by anti-TSPO (Cell Signalling 
Technologies) were seen at the expected size of ~18 kDa. Bands of protein 
detected by anti-GFAP (Millipore) were seen at the expected size of ~50 kDa. 
Anti-GAPDH (Protein Tech) loading control was used on all blots, and 
detected at the expected size of ~37 kDa. Boxes indicate cropped area for 
use in figures. A. CRTAS treated with 0.1 µg/mL lipopolysaccharide (LPS) for 
3 hours. B. CRTAS treated with 0.1 µg/mL LPS for 24 hours. C. CRTAS 
treated with 0.1 µg/mL LPS, 2-deoxyglucose (2-DG; 10 mM), or AMPK 
activator AICAR (1 µM) for 24 hours. D. U373 untransfected cells (WT), cells 
transfected with an empty CRISPR/Cas9 vector (EV), and transfected with a 
CRISPR/Cas9 vector containing guide RNA (KO). E. CRTAS from TSPO+/+ 
and TSPO-/- mice. F. GFAP expression in CRTAS from TSPO+/+ and TSPO-/- 
mice (same samples used in panels E and F). 
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Appendix 2: Annotated MatLab script for mitochondrial 
network analysis 
 
%pixelSizes is a cell array with one cell for each image 
pixelSizes=cell(60,1); 
%Loop through each image in turn 
for i=61:63 
%Read in image 
imgin=sprintf('%d.tif',i); 
img=imread(imgin); 
%filtersize sets up parameters for local threshold filter 
filtersizeX=round(((size(img,1))/200)^2); 
filtersizeY=filtersizeX; 
offset=20; 
%minsize is cut-off size for small noisy objects 
minsize=round(((size(img,1))/350)^2); 
%Select red channel (change this if mitochondrial stain is in a different 
%channel 
imgR=img(:,:,1); 
%Apply local threshold filter to the image 
imgF=imfilter(imgR,fspecial('average',[filtersizeX,filtersizeY]),'replicate'); 
%Subtract filtered image from original 
img2=imgR-(imgF+offset); 
%Select all positive pixels 
imgbw=im2bw(img2,0); 
%Remove noise 
imgbw2=bwareaopen(imgbw,minsize); 
%Save output image 
imgout=sprintf('%d_out.png',i); 
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imwrite(imgbw2,imgout); 
%Create Otsu global threshold for comparison 
imgT=im2bw(imgR,graythresh(imgR)); 
%Display results 
subplot(2,2,1);imshow(imgR); title('Original'); 
subplot(2,2,2);imshow(imgF); title('Global threshold'); 
subplot(2,2,3);imshow(imgbw); title('Local threshold'); 
subplot(2,2,4);imshow(imgbw2); title('Noise removed'); 
%Save displayed results 
saveas(gcf(),sprintf('%d_results.jpeg',i)); 
%Calculate object sizes 
CC=bwconncomp(imgbw2); 
%numPix is a vector containing the number of pixels in each object in the 
%current image 
numPix=cellfun(@numel,CC.PixelIdxList); 
%number of objects in numPix 
objects=length(numPix); 
%mean number of pixels in each object in current image 
pixMean=mean(numPix); 
%median number of pixels in each object in current images 
pixMedian=median(numPix); 
%Object number, Mean value and Median value is copied into the appropriate 
%cell for that image 
pixelSizes{1,1}='ImageNumber'; 
pixelSizes{1,2}='No.Objects'; 
pixelSizes{1,3}='MeanPixels'; 
pixelSizes{1,4}='MedianPixels'; 
pixelSizes{i-59,1}=i; 
pixelSizes{i-59,2}=objects; 
pixelSizes{i-59,3}=pixMean; 
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pixelSizes{i-59,4}=pixMedian; 
%Loop ends, go back and open next image... 
end 
%Export pixelSizes as .csv (Excel) file 
xlswrite('MitoData.xls',pixelSizes); 
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Appendix 3: Immunometabolic Changes in Glia – A Potential 
Role in the Pathophysiology of Obesity and Diabetes 
Josephine L. Robb, Nicole A. Morrissey, Paul G. Weightman Potter, Hannah E. 
Smithers, Craig Beall, Kate L.J. Ellacott. Neuroscience. (2019) 
DOI: 10.1016/j.neuroscience.2019.10.021 
 
Abstract: Chronic low-grade inflammation is a feature of the pathophysiology of 
obesity and diabetes in the CNS as well as peripheral tissues. Glial cells are 
critical mediators of the response to inflammation in the brain. Key features of glia 
include their metabolic flexibility, sensitivity to changes in the CNS 
microenvironment, and ability to rapidly adapt their function accordingly. They are 
specialised cells which cooperate to promote and preserve neuronal health, 
playing important roles in regulating the activity of neuronal networks across the 
brain during different life stages. Increasing evidence points to a role of glia, most 
notably astrocytes and microglia, in the systemic regulation of energy and 
glucose homeostasis in the course of normal physiological control and during 
disease. Inflammation is an energetically expensive process that requires 
adaptive changes in cellular metabolism and, in turn, metabolic intermediates can 
also have immunomodulatory actions. Such “immunometabolic” changes in 
peripheral immune cells have been implicated in contributing to disease 
pathology in obesity and diabetes. This review will discuss the evidence for a role 
of immunometabolic changes in glial cells in the systemic regulation of energy 
and glucose homeostasis, and how this changes in the context of obesity and 
diabetes. 
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Appendix 4: The metabolic response to inflammation in 
astrocytes is regulated by nuclear factor-kappa B signaling. 
Josephine L. Robb, Nadia A. Hammad, Paul G. Weightman Potter, John K. 
Chilton, Craig Beall, Kate L.J. Ellacott. Glia. (2020) 
DOI: 10.1002/glia.23835 
 
Abstract: Inflammation and metabolism are intrinsically linked with inflammatory 
stimuli inducing metabolic changes in cells and, in turn, metabolic capacity 
determining cellular inflammatory responses. Although well characterized in 
peripheral immune cells there is comparatively less known about these 
“immunometabolic” responses in astrocytes. In this study we tested the 
hypothesis that the astrocytic inflammatory response driven by nuclear factor-
kappa B (NF-κB) signaling is dependent on glycolytic metabolism. Using mouse 
primary cortical astrocyte cultures we assessed changes in cellular metabolism 
after exposure to lipopolysaccharide (LPS), with cytokine ELISAs and 
immunoblotting being used to measure inflammatory responses. Results indicate 
temporally distinct metabolic adaptations to proinflammatory stimulation in 
astrocytes: 3 hour LPS treatment increased glycolysis but did not alter 
mitochondrial metabolism, while following 24 hours of LPS treatment we 
observed increased oxidative phosphorylation, and decreased glycolytic capacity 
and glucose uptake partly due to reduced glucose transporter 1 (GLUT1) 
expression. Inhibition of NF-κB signaling with the IKK-beta inhibitor TPCA-1 
prevented the LPS induced changes to glycolysis and oxidative phosphorylation. 
Furthermore, TPCA-1 treatment altered both glycolysis and oxidative 
phosphorylation independently from inflammatory stimulation, indicating a role for 
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NF-κB signaling in regulation of basal metabolism in astrocytes.  Inhibition of 
glycolysis with 2-deoxyglucose significantly attenuated LPS-induced cytokine 
release and NF-κB phosphorylation, indicating that intact glycolysis is required 
for the full inflammatory response to LPS. Together our data indicate that 
astrocytes display immunometabolic responses to acute LPS-stimulation which 
may represent a potential therapeutic target for neuroinflammatory disorders. 
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Appendix 5: Example flow cytometry gating data from TMRE 
uptake assay (Fig. 3.3.10) 
 
 
  
Appendix 5. Representative data plots from TMRE dye uptake assays. 
Cells were plated at a density of 3.5 x105 cells in 6 well dishes. After treatment 
with vehicle or lipopolysaccharide (0.1 µg/mL; LPS) cells were dissociated 
and incubated with FCCP (1 µM) or vehicle for 15 minutes prior to 30 minutes 
incubation with TMRE dye (100 nM) or vehicle and data collection on the BD 
Accuri C6 plus flow cytometer. Data from gate P1 Plot 1 was shown on Plot 
2. Gate M1 Plot 2 was determined using the no TMRE stained control (FMO; 
A). Gate M2 started from the point gate M1 finished, and was used to 
determine stained cells. The mean of data in M2 was used as the TMRE dye 
uptake for the group. A. No TMRE stained control. B. vehicle treated control. 
C. 24 hour LPS treatment. D. FCCP treated depolarisation control. 
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